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Abstract 
Among keratinocyte-derived squamous cell carcinoma (SCC), cutaneous SCC (CSCC) is the 
second most common cutaneous cancer type and the most common of the potentially fatal 
skin cancers. Approximately 90% of head and neck cancers are SCC (HNSCC) and HNSCC 
worldwide is the sixth most common cancer type afflicting mankind. While resectable 
disease may be treated by surgery with radiation or chemoradiation, there are still no curative 
options for advanced, unresectable disease. However, chemotherapy alone may offer a hope 
for unresectable, disseminated SCC, where 50-60% of patients have disease recurrence 
within 2 years and approximately 30% of these develop metastatic disease. The mainstay of 
chemotherapeutic treatment in SCC is the platinum-based drug, cisplatin, 5-fluorouracil (5-
FU), taxanes, and anti-EGFR monoclonal antibody such as Cetuximab. Nonetheless, despite 
advances in treatment techniques, the 5-year survival rate still remains at around 55%. 
Therefore, there remains a lack of options for recurrent or metastatic disease.    
 
The E2F family of transcription factors has emerged as key regulators of proliferation, 
differentiation and response to stress and apoptotic stimuli in keratinocytes. Consistent with 
these roles, dysregulation of E2F expression/activity is a common occurrence in cancer and 
SCC in particular. Thus, better understanding of the E2F family of proteins is essential to 
establish how these processes are disrupted during SCC genesis. The E2F network exists as a 
complex map of interacting pathways, and the complete understanding of the E2F family will 
not be possible until physiological functions of newly identified inhibitory E2F proteins, 
E2F7 and E2F8, are fully revealed. I provide strong evidence, from in vitro experiments, that 
E2F7 plays a unique and non-redundant role in modulating UV- or chemotherapy-induced 
cytotoxicity whereas E2F8 has a unique and non-redundant capacity to regulate squamous 
differentiation. In addition, I report on a unique feedback loop between E2F1, E2F7 and 
E2F8 that highlights a previously unreported interdependent axis.  
 
With respect to E2F7-specific functions, my work characterised two previously unidentified 
pathways as therapeutic targets, E2F7/Sphk1/S1P/AKT and E2F7/RacGAP1/AKT, by which 
the transcription factor E2F7 suppresses doxorubicin specific sensitivity in SCC cells. 
Targeting these pathways has the potential to expand the clinical activity of existing 
chemotherapeutics. I provide, in vitro, in vivo and patient data in this study that shows that 
E2F7-dependent repression of doxorubicin sensitivity is mediated via the induction of  
Sphingosine kinase 1 (Sphk1) and Rac GTPase activating protein 1 (RacGAP1). These are 
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both novel findings and have significant implications for drug resistant SCC. Specifically, I 
showed that (i) E2F7 is overexpressed in patient SCCs and inhibits sensitivity to doxorubicin, 
(ii) that E2F7-dependent doxorubicin resistance is mediated via E2F-dependent induction of 
Sphk1 leading to overproduction of Sphingosine-1-phosphate (S1P) which in turn activates 
AKT, (iii) that pharmacological inhibition of Sphk1 or AKT sensitizes SCC cells to the 
cytotoxic actions of doxorubicin in in vivo models of SCC resulting in profound tumour 
regression, iv) that induction RacGAP1 in SCC cells increases their sensitivity to doxorubicin 
and overexpression of RacGAP1 is linked to poor outcomes in SCC patients and v) that 
E2F7-dependent doxorubicin resistance is mediated via induction of RacGAP1 which in turn 
activates AKT-dependent pathways in vitro and in vivo. Since dysregulation of the E2F 
family of transcription factors is one of the most frequent targets in oncogenesis, it is likely 
that our findings will be relevant to many other cancer types. Moreover, our findings provide 
proof of concept for immediate translation to initiate a clinical trial using combinations of 
clinically available agents such as doxorubicin + AKT inhibitor or doxorubicin + an SK1 
inhibitor.  
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1 Introduction 
Excerpts of this introductory chapter were published as an invited review in the International 
Journal of Molecular Sciences in a specialist volume entitled UV Induced Cell Death. “The 
role of the E2F Transcription factor family in UV-induced apoptosis” (Hazar-Rethinam, 
Endo-Munoz et al. 2011).  
 
1.1 Foreword 
Squamous cell carcinoma (SCC) is a common life threatening malignancy in humans and is 
associated with significant mortality in the advanced disease setting (Clayman, Lee et al. 
2005). Among SCC, approximately, 95% of head and neck cancers are SCC and in the 
developed world approximately 40% of patients with head and neck squamous cell carcinoma 
will die because of their disease (Clayman, Lee et al. 2005). Whilst surgery and radiation 
therapy are curative in early or localised disease, advanced disseminated disease is generally 
considered incurable and current systemic therapies are palliative in nature (Cranmer, 
Engelhardt et al. 2010). For this reason there is considerable need for new and selective 
agents to treat SCCs. However, development of new treatment strategies for SCC will require 
knowledge of keratinocyte (KC) biology and the underlying pathology of how SCCs form.  
 
Although epigenetics and post-translational processes play a role in KC functions, the major 
regulators remain the transcription factors. Many transcription factors have been reported to 
play a role in the control of squamous differentiation and carcinogenesis. Of these, the E2F 
family of transcription factors has emerged as key regulators of many functions of KCs 
(Endo-Munoz, Dahler et al. 2009). This family of master proteins are key regulators of 
proliferation, differentiation and responses to stressors such as ultra violet (UV) radiation, 
oxidative stress and cytotoxic agents. 
 
We, and others, have previously shown that SCC of the skin and mucosae are characterised 
by the overexpression and dysregulation of the transcription factor, E2F1 (Jones, Dicker et al. 
1997; Dicker, Popa et al. 2000; Wong, Barnes et al. 2003). This results in the deregulation of 
proliferation, suppression of differentiation and deregulation of apoptotic responses in human 
KCs (Jones, Dicker et al. 1997; Pierce, Gimenez-Conti et al. 1998; Pierce, Schneider-
Broussard et al. 1999; Dicker, Popa et al. 2000). Furthermore, my laboratory has recently 
shown that the E2F inhibitor, E2F7, is also overexpressed in human SCC (Endo-Munoz, 
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Dahler et al. 2009). Thus, E2F7, and presumably other inhibitory E2Fs such as E2F8, are able 
to antagonize the pro-apoptotic effects of E2F1 (Endo-Munoz, Dahler et al. 2009). Moreover, 
it was previously shown that inhibiting E2F1 or E2F7 is able to reinstate many properties 
relating to differentiation and growth inhibition (Wong, Barnes et al. 2003). The opposing 
action of E2F members is predicted to determine proliferation, differentiation and apoptosis 
in KCs in response to normal endogenous and exogenous stimuli (eg: mitogens or UV).   
 
I will now introduce some of the concepts and molecular data relating to the control of 
squamous differentiation and the mediation of responses to various cytotoxic stimuli such as 
UV and chemotherapeutics. Finally, I will focus on the role and contribution of newly 
identified, inhibitory E2F proteins, E2F7 and E2F8 in modulating many of these functions in 
KCs. 
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1.2 Skin in general 
The skin is the largest organ in the body and provides a protective barrier against 
environmental insults (Eckert 1989). The structure of skin can broadly be divided into two 
compartments: an epidermal layer of keratinising stratified squamous epithelial cells and the 
dermal layer which provides nutrients, insulation and structural support for the epidermis 
(Eckert 1989). The epidermis is a self-renewing tissue consisting of many different cell types 
including Langerhan’s cells, Merkel’s cells, melanocytes and KCs. KCs are the predominant 
cells in keratinising stratified squamous epithelium (Fuchs and Raghavan 2002; Gambardella 
and Barrandon 2003). Therefore, understanding KC biology will provide knowledge about 
the key mechanisms controlling the integrity of the skin, and events that lead to cutaneous 
neoplasia.    
 
1.3 Neoplastic development of the skin and squamous cell carcinoma  
Skin cancers are frequently divided into melanoma and non-melanoma skin cancers (NMSC). 
Melanoma is a common and aggressive tumour type derived from melanocytes. NMSC are 
neoplasms of epithelial origin and include basal cell carcinoma (BCC) and squamous cell 
carcinoma (SCC) (Conney, Kramata et al. 2008). In a recent study, Trakatelli et al. 
(Trakatelli, C et al. 2007) showed that NMSC had significantly increased in incidence in 
Caucasians in the last decade. The frequency of NMSC in Europe is 300 out of 100,000 per 
year for BCC, and 150 out of 100,000 per year for SCC. In fact, KC-derived skin cancers are 
the most common neoplasm in Caucasian populations with a risk of 70% in a 70 years old 
Australian male (Staples, Elwood et al. 2006). Common risk factors for NMSC are UV 
radiation, compromised immune system, age, tobacco use and arsenic. Accordingly, NMSC 
are commonly found on sun-exposed areas such as the face, head and neck, and the dorsum 
of hands (Erb, Ji et al. 2005). Human papillomavirus infection has also been associated with 
NMSCC and virally-associated NMSC often has an earlier onset than NMSC caused by 
ultraviolet radiation, tobacco and alcohol use (Harwood, Surentheran et al. 2000; Nindl, 
Gottschling et al. 2007). Inherited factors such as polymorphism in glutathione S-transferases 
are also considered as risk factors (Copper, Jovanovic et al. 1995; Ramsay, Harden et al. 
2001).  
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Figure 1.1 Hematoxylin and Eosin stained sections of normal (A) and neoplastic skin 
(B). The arrow indicates keratin pearls.   
 
Among SCC, cutaneous squamous cell carcinoma (CSCC) is the second most common 
cutaneous cancer type and the most common of the potentially fatal skin cancers. Excessive 
UV exposure is the most common causative agent for CSCCs (Walshe, Serewko-Auret et al. 
2007). Approximately 90% of head and neck cancers are squamous cell carcinomas 
(HNSCC) (Sankaranarayanan, Masuyer et al. 1998; Chin, Boyle et al. 2006), and HNSCC 
worldwide is the sixth most common cancer type afflicting mankind (Chin, Boyle et al. 
2006). SCCs most frequently arise from stratified squamous epithelia such as the epidermis 
or the mucosae of the head and neck, oesophagus or cervix. SCC generally arises due to 
malignant transformation of the predominant cells in keratinising stratified squamous 
epithelium. Histological examination of SCC demonstrates the presence of distinctive keratin 
pearls which are bundles of keratin filaments (Figure 1.1). SCCs have the ability of 
metastasize locally, regionally and to distant sites (Erb, Ji et al. 2005).  SCC is staged 
according to the Tumour Nodes Metastases (TNM) classification system developed by the 
American Joint Committee on Cancer (AJCC) (Edge and Compton 2010). In the TNM 
classification, T refers to size of the primary tumour, N refers to the levels of nodal 
involvement and M describes whether distant metastasis is detectable. By the use of this 
classification, four stages of disease were defined, from I to IV. These numbers reflect 
increasing disease progression; the more advanced the disease stage, the poorer the prognosis 
for the SCC patient. SCC follows a pattern of lymph node metastasis dependent on tumour 
location, such as the tongue and floor of the mouth having greater tendency for lymphatic 
spread because of the volume of lymphatics in these areas (Chin, Boyle et al. 2006). 
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Advanced disease that has spread regionally or to distant sites is associated with a poor 
survival rate of 50% (Veness, Porceddu et al. 2007; Marur and Forastiere 2008).  
 
Generally surgery and/or radiation therapy are the principle treatment option in early stages 
of SCC (Stage I and II) and for local disease control. While resectable stage III and IV 
disease may be treated by surgery with radiation or chemoradiation (Chin, Boyle et al. 2006), 
there are still no curative options for advanced, unresectable Stage III and IV disease (Watt, 
Pourreyron et al. 2011). However, chemotherapy alone may offer a hope palliatively for 
unresectable, disseminated SCC, where 50-60% of patients have disease recurrence within 2 
years and approximately 30% of these develop metastatic disease (Posner 2005). The 
mainstay of chemotherapeutic treatment in SCC is the platinum-based drug, cisplatin, 5-
fluorouracil (5-FU), taxanes, and anti-EGFR monoclonal antibody such as Cetuximab 
(Posner 2005; Bernier and Vrieling 2008; Panikkar, Astsaturov et al. 2008; Specenier and 
Vermorken 2009). Nonetheless, despite advances in treatment techniques, the 5-year survival 
rate still remains at around 55%. Therefore, treatment is always required for SCC with a lack 
of options for recurrent or metastatic disease.    
 
CSCCs are typically thought to originate from premalignant precursor lesions such as actinic 
keratoses and Bowen’s Diseases (Diepgen and Mahler 2002) whilst premalignant forms of 
HNSCC are referred to as leukoplakias or erythroplasias. Multi-step accumulation of genetic 
alterations including inactivation of tumour suppressor genes such as p16 and p53 and 
activation of oncogenes such as Cyclin D1 and Epidermal Growth Factor Receptor (EGFR) 
in these premalignant progenitor cells contributes to neoplastic transformation.  In fact, 
EGFR signalling promotes survival of SCC cells via activation of several downstream 
signalling molecules such as ERK, AKT and STAT3 and STAT5 (Kalyankrishna and 
Grandis 2006). Almost 50% of genes that are altered in neoplastic epithelial cells are already 
altered in these precursor lesions (Serewko, Popa et al. 2002; Perez-Ordoñez, Beauchemin et 
al. 2006). As a consequence, SCC cells exhibit defects in cell cycle regulatory machinery 
(Shintani, Mihara et al. 2002; Le and Giaccia 2003), differentiation markers (Sugiyama, 
Speight et al. 1993; Gasparoni, Fonzi et al. 2004), and many other regulatory molecular 
pathways including apoptotic machinery (Serewko, Popa et al. 2002; Ye, Yu et al. 2008). 
One of the hallmarks of squamous cell carcinoma is aberrant/dysregulated control of 
differentiation and response to DNA damage mediated by UV radiation.  
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1.3.1 Dysregulated Differentiation Program 
One well documented cause of SCC transformation is dysregulated differentiation. As 
mentioned above, SCCs arise from precursor lesions (e.g.: actinic keratoses for CSCC or 
leukoplakia or erythroplasia for HNSCC). Early lesional events transform normal cells into 
premalignant cells with greater proliferation potential and defects in their differentiation 
program. This is evidenced by their compromised ability to commit to an irreversible 
terminal differentiation program compared to non-malignant KCs (Dicker, Serewko et al. 
2000). There is a need to elucidate the mechanisms at a molecular and cellular level, which 
regulate these early transforming events. Notably, our earlier studies have shown that these 
early transformed cells retain an ability to respond to a normal differentiation stimuli and 
initiate a squamous differentiation program, but there is a block in the pathways that prevents 
them from doing so (Wong, Barnes et al. 2003; Wong, Barnes et al. 2004). Thus, identifying 
the nature of this block may provide a mechanism by which we could intervene to reinstate 
differentiation in early or advanced SCC.  
 
1.3.2 UV in skin malignancies 
Regardless of classification, the main contributory factor in the development of cutaneous 
malignancies, in humans, is ultraviolet (UV) exposure (Black, deGruijl et al. 1997). Although 
this link was first reported in 1875, it took over one hundred years to accumulate evidence for 
the causative nature of UV in CSCC formation (Boukamp 2005). For example, i) 
epidemiological studies have shown a strong link between UV exposure and SCC incidence 
(Young 2009), ii) use of UV-blocking sunscreens reduces SCC incidence (Ulrich, Jürgensen 
et al. 2009), iii) UV radiation causes SCC in experimental animal systems (Holmberg, Helin 
et al. 1998; Pierce, Schneider-Broussard et al. 1999), iv) SCCs acquire a mutation signature 
that is diagnostic of UV exposure (Nishigori 2006) and v) various molecules such as p53 
have been shown to be mutated and causative in the formation of UV-induced SCC 
(Boukamp 2005). As mentioned in the above section, the incidence rates of skin cancers are 
rising and their incidence reflects the potent carcinogenic activity of UV radiation (Clayman, 
Lee et al. 2005). UV-induced SCC formation is associated with dysregulation of the control 
of proliferation, differentiation and apoptosis (de Gruijl, van Kranen et al. 2001; Ichihashi, 
Ueda et al. 2003; Erb, Ji et al. 2005; Walshe, Serewko-Auret et al. 2007; Endo-Munoz, 
Dahler et al. 2009). In particular, apoptotic controls related to sensitivity and response to UV-
induced damage are a key target during SCC transformation (Qin, Chaturvedi et al. 2002). 
Consequently, the major safeguard mechanism, sunburn cell formation, is compromised in 
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KCs following mutational/carcinogenic doses of UV (Wrone-Smith, Bergstrom et al. 1999). 
However, the exact mechanisms by which UV-induced mutational damage contributes to the 
biological events controlling KC transformation and SCC progression remain unclear.   
 
After addressing the above two dysregulated processes during neoplastic transformation, now 
I will focus on these programs in the context of the epidermis.  
 
1.4 The Epidermis and Squamous Differentiation 
The integrity of the epidermis is maintained by the KCs undergoing a tightly regulated 
program of squamous differentiation. The differentiated KCs establish and maintain a tight 
barrier to serve as a defence against environmental insults and to prevent the loss of fluids 
(Fuchs and Raghavan 2002). Complete differentiation is a slow and coordinated program 
which usually takes 2 weeks to complete. It occurs sequentially through the different layers 
of the epidermis (Fuchs and Raghavan 2002). The KCs undergo morphological, nuclear, 
cytoskeletal and biochemical alterations, eventually giving rise to specialized and distinct 
layers of epidermis. These layers include the basal layer, spinous layer, granular layer, 
transition zone and cornified layer (Figure 1.2).  
 
The basal layer of the epidermis comprises mitotically active and undifferentiated KCs that 
are attached to the basement membrane of the epidermis (Lippens, Denecker et al. 2005) 
(Figure 1.2). This layer also contains the stem cell population (Alonso and Fuchs 2003). The 
stem cells give rise to a continuous supply of transit amplifying cells (TA) that eventually 
undergo terminal differentiation and renew the epidermis (Li, Simmons et al. 1998). Upon 
receiving the growth arrest signal, TA cells irreversibly withdraw from the cell cycle, detach 
and move into the spinous layer. This is the layer where differentiation starts to take place. As 
a result the cells become larger and flatter in appearance. Thus, orchestrated cytoskeletal 
reorganization takes place by the replacement of cytokeratin types present in this layer 
(Eckert 1989; Lippens, Denecker et al. 2005). The functional consequence of this 
rearrangement of keratins is the formation of cytoskelatal filaments that contribute to the 
integrity and rigidity of the epidermis. Cells of the spinous layer continue to move to the 
external surface of the epidermis and differentiate forming the granular layer (Figure 1.2). 
The granular layer is characterised by the presence of keratohyalin granules (Eckert 1989). 
The cells in this layer are still alive and metabolically active (Wolff-Schreiner 1977). The 
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outermost layer of the epidermis is the cornified layer where generation of corneocytes takes 
place. Corneocytes are characterised by a network of keratin filaments accounting for 80% of 
the cornified cell (Eckert 1989). Cells of the granular layer lose their organelles and nucleic 
acids by enzymatic digestion, and final assembly of the cornified envelope takes place (Fuchs 
1990). The corneocytes are embedded in, and integrated within, a tough horny layer of 
crosslinked proteins known as the cross linked envelope. Cross linking of proteins via -
glutamyl Ɛ-lysine bonds is catalysed by the actions of transglutaminase type I (Byrne, 
Tainsky et al. 1994; Eckert, Sturniolo et al. 2005).     
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Figure 1.2 The morphology of epidermis during squamous differentiation. Adapted 
from Eckert et al., 1997 (Eckert, Crish et al. 1997). 
 
The progress through the differentiation program is controlled primarily by transcription 
factors and hence differentiation status is marked by the expression/downregulation of 
specific suites of genes (Harvat, Wang et al. 1998; Sark, Fischer et al. 1998; Ito, Udaka et al. 
2000; D'Souza, Pajak et al. 2001). Significantly, the differentiation program in vitro and in 
vivo is almost identical and consequently the culture of KCs represents an excellent model to 
study KC differentiation and responses (Jones, Dicker et al. 1997; Dahler, Jones et al. 1998; 
Dicker, Serewko et al. 2000; Serewko, Popa et al. 2002). The primary keratins expressed in 
the basal layer are keratin 5 and keratin 14 (Alonso and Fuchs 2003). Besides the expression 
of these specific keratins, cells of this layer also express genes involved in proliferation, such 
as cdc2 (or cdk1) and E2F1 (Dahler, Jones et al. 1998; Dicker, Popa et al. 2000). When the 
cells are stimulated to differentiate the expression of these proliferation specific genes, 
including keratin 5 and 14, is terminated and the expression of differentiation-specific genes 
is induced. These early differentiation specific genes include glutamine-lysine rich proteins 
such as, involucrin and the calcium dependent enzyme, transglutaminase type 1 (TG1) 
(Banks-Schlegel and Green 1981; Watt and Green 1982; Simon and Green 1984). Involucrin 
is expressed early in the transition into the spinous layer. It is an important protein for 
squamous differentiation as involucrin with TG1 protein will form the primary component of 
the cross linked cornified envelope. The other characteristic proteins expressed from the cells 
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of spinous layer are keratin 1 and keratin 10, where they contribute to the cytoskeletal 
network for KCs (Eichner, Sun et al. 1986; Eckert 1989). The transcription of these 
cytokeratins is terminated as cells pass into the granular layer. Their transcription is 
superceded by the transcription of precursors of the cornified envelope including: loricrin, 
filaggrin and cornifin (Fleckman, Dale et al. 1985; Magnaldo, Pommes et al. 1990; Marvin, 
George et al. 1992). Many of these proteins are included in the formation of the cross-linked 
envelope and their crosslinking is catalysed by TG1 (Dlugosz and Yuspa 1993).  Once cells 
are incorporated into the cornified layer they will ultimately be shed and replaced by cells 
beneath them (Eckert 1989). Thus, the differentiation program involves proliferation, growth 
arrest, differentiation, apoptosis and shedding of KCs. All these processes are tightly co-
ordinated by a combination of key regulatory transcription factors.  
   
1.5 Molecular Regulation of Squamous Differentiation 
The regulation of gene expression that accompanies, and drives, the differentiation process is 
complex and involves transcriptional regulation, mRNA stability, microRNA and epigenetic 
regulation. However, transcription factor-mediated regulation of gene expression is by far the 
most important of these mechanisms.   
 
1.5.1 Transcriptional Control of Squamous Differentiation 
Transcription, the synthesis of RNA from a DNA template, is governed by several regulators 
that either modulate the basal transcription rate or modulate transcription in response to 
stimuli (Eckert, Crish et al. 1997). One of the major groups of regulators consists of 
transcription factors. Transcription factors regulate the transcription of genes in a tissue-
specific manner in response to physiological and/or environmental stimuli (Martinez 2002). 
They bind to cis-acting DNA sequences in the promoter or enhancer region of genes and 
determine the function of those genes, allowing for either the activation of suppression of 
transcription (Kadonaga, Carner et al. 1987; Kornberg 1999).  
 
The squamous differentiation program is primarily managed at the transcriptional level by 
several well characterized regulatory transcription factors as described above. Some of the 
well characterized differentiation specific genes and the transcription factors that have been 
shown to regulate them are summarized in Table 1.1. Sp1 also known as specificity protein 1 
was the first mammalian transcription factor cloned (Kadonaga, Carner et al. 1987). It is 
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involved in tissue-specific transcriptional control as evidenced from the presence of 
functional Sp1 sites in several tissue-specific promoters (Blake, Jambou et al. 1990). 
Functional Sp1 sites are present in the promoters of squamous differentiation-specific genes 
where Sp1 is responsible for the differentiation-specific induction of gene expression (Won, 
Yim et al. 2002). Sp1 acts cooperatively with other transcription factors in the regulation of 
the differentiation program. One example of this partnership is the cooperative role of Sp1 
and the activator protein-1 (AP1) which is another important transcription factor that plays a 
role in the activation of keratin 1 and profilaggrin (Huff, Yuspa et al. 1993; Jang, Steinert et 
al. 1996). Sp1 and AP1 act together to co-ordinate the induction of differentiation genes such 
as involucrin, which is required for cornified envelope formation (Jang and Steinert 2002). 
AP1 regulates the expression of most of the keratins such as keratin 1, 5 and 14 and 
comprises functional hetero and homodimers of jun and fos family of proteins (Ohtsuki, 
Tomic-Canic et al. 1992; Sinha, Degenstein et al. 2000). AP1 has also been shown to 
modulate the protein kinase C pathway which gets activated during differentiation (Karin 
1995). Moreover, AP1 also regulates the activation of late differentiation genes such as TG1, 
loricrin and involucrin (Saunders, Bernacki et al. 1993; Welter, Gali et al. 1996; Jang and 
Steinert 2002). POU domain proteins have been shown to negatively regulate differentiation 
specific genes like keratin 5, keratin 14 and involucrin (Welter, Gali et al. 1996; Sugihara, 
Kudryavtseva et al. 2001). Ets group of proteins plays a role in differentiation through the 
interactions with other key transcription factors like Sp1 (Eckert, Crish et al. 1997). 
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Table 1.1 Summary of transcription factors involved in the regulation of differentiation 
specific genes. 
Genes Transcription Factor Refs 
cdc2 E2F1 (Dicker, Popa et al. 2000) 
E2F1 E2F7, E2F8  (de Bruin, Maiti et al. 2003; 
Di Stefano, Jensen et al. 2003; 
Logan, Delavaine et al. 2004; 
Hallstrom, Mori et al. 2008; 
Panagiotis Zalmas, Zhao et al. 
2008; Endo-Munoz, Dahler et 
al. 2009) 
Keratin 5 NF-КB, Sp1, AP1, POU factor (Ohtsuki, Tomic-Canic et al. 
1992; Sugihara, 
Kudryavtseva et al. 2001) 
Keratin 14 NF-КB, POU factor, AP1, AP2, 
Ets, CBP/p300, E2F1 
(Rossi, Jang et al. 1998; 
Dicker, Popa et al. 2000; 
Sugihara, Kudryavtseva et al. 
2001; Paramio and 
Blumenberg 2006) 
Involucrin p63, AP1, Sp1, POU factor, Whn, 
RBP-J 
(Welter, Crish et al. 1995; 
Welter, Gali et al. 1996; 
Rangarajan, Talora et al. 
2001; Baxter and Brissette 
2002; Jang and Steinert 2002) 
TG-1 AP1, p63, E2F1 (Saunders, Bernacki et al. 
1993; Dicker, Popa et al. 
2000) 
Keratin 1 AP1, p63, C/EBP, RBP-J, Whn (Huff, Yuspa et al. 1993; Zhu, 
Oh et al. 1999; Rangarajan, 
Talora et al. 2001; Baxter and 
Brissette 2002) 
Keratin 10 C/EBP, RBP-J, AP2, E2F1 (Maytin, Lin et al. 1999; Zhu, 
Oh et al. 1999; Dicker, Popa 
et al. 2000; Rangarajan, 
Talora et al. 2001) 
Loricrin Sp1, c-jun, p300/CREB, AP1, 
RBP-J, Whn 
(Zhu, Oh et al. 1999; 
Rangarajan, Talora et al. 
2001; Baxter and Brissette 
2002; Jang and Steinert 2002) 
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filaggrin AP1, RBP-J, Whn (Jang, Steinert et al. 1996; 
Rangarajan, Talora et al. 
2001; Baxter and Brissette 
2002) 
TG-3 Sp1, Ets (Lee, Jang et al. 1996) 
Sp1 E2F7 (Hazar-Rethinam, Cameron 
et al. 2011) 
 
RBP-J is highly expressed in the skin, and its role is implicated in the regulation of early 
differentiation markers, whilst repressing the late differentiation ones (Rangarajan, Talora et 
al. 2001). C/EBP proteins get activated upon the initiation of differentiation and regulate the 
expression of keratin 1 and 10 (Zhu, Oh et al. 1999). Nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-КB) negatively regulates the promoters of keratin 4 and 15. 
Moreover, they interact with AP1 proteins and contribute to the regulation of differentiation 
specific genes (Rossi, Jang et al. 1998; Paramio and Blumenberg 2006). Opposing action of 
p63 was proposed, and it was reported that p63 is required for both the proliferative and 
differentiation potential of developmentally mature KCs (Truong, Kretz et al. 2006; Senoo, 
Pinto et al. 2007). The pleiotropic E2F family of proteins is also considered to be an 
important family of transcription factors to regulate squamous differentiation (Dicker, Popa et 
al. 2000).  Their role is complex and will be discussed later in this review. However, as seen 
from the above discussion, multiple transcription factors are involved in the regulation of 
differentiation genes and the co-ordination of the complete differentiation program 
undoubtedly involves the co-ordinated action of multiple transcription factors acting together.  
 
1.6 The Epidermis and UV (Sunburn Cells) 
One of the major insults that challenges the skin is UV. The UV radiation spectrum is 
grouped into three bands based on wavelength including UVA, UVB and UVC. Although 
only 10% of UVB (280-320 nm) radiation penetrates the atmosphere, the ability of UVB 
radiation to damage DNA, to disrupt pro-apoptotic signalling pathways and to suppress 
immune responses makes it the most carcinogenic wavelength in the terrestrial environment 
(Nickoloff, Qin et al. 2002). Despite the more potent carcinogenic activity of UVB, it is only 
capable of penetrating the more superficial epidermal layers whereas UVA can penetrate 
deeper into the dermis (Maverakis, Miyamura et al. 2010). Following UVB exposure, KCs of 
the epidermis will follow one of two fates. They either undergo growth arrest accompanied 
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by the mobilisation and activation of the nucleotide excision repair system (NER) to repair 
the damaged DNA (mutations/DNA lesions). Alternatively, if the DNA damage is perceived 
to be too great and the cells lack the capacity to repair the damage then the cells will be 
induced to apoptose (Chaturvedi, Qin et al. 1999; Qin, Chaturvedi et al. 2002). Apoptosis is a 
safeguard mechanism that prevents cells from passing on mutated DNA to their progeny. 
Thus, the apoptotic machinery provides a means by which mutated, potentially premalignant 
cells, are able to be eliminated (Rodust, Stockfleth et al. 2009). UV-induced apoptosis results 
in the formation of so-called “sunburn cells” or apoptotic KCs. Sunburn cells are easily 
identified by the presence of photo lesions, pyknotic nuclei and cytoplasmic shrinkage 
characteristic of apoptotic cells (Laethem, Claerhout et al. 2005). 
 
1.7 Transcriptional Control of UV-induced Responses 
When KCs are exposed to UV, especially UVB radiation, specific transcription factors get 
activated. This results in the expression of “UV response genes”. Two well characterized 
transcription factors activated upon UV exposure are AP1 and NF-КB (López-Camarillo, 
Aréchaga Ocampo et al. 2011). NF-КB has also been shown to play important role in the 
transcriptional response to cytotoxic agents like chemotherapeutic drugs (López-Camarillo, 
Aréchaga Ocampo et al. 2011). Crosstalk between these two transcription factors and 
signalling pathways exists and has been studied extensively (Zenz and Wagner 2006; Cooper 
and Bowden 2007). MAPK pathway is one of these pathways, which includes JNKs, ERKs 
and p38 MAP kinases (Assefa, Garmyn et al. 1997; Muthusamy and Piva 2010). Other 
transcription factors characteristic of the UV response are JUNB, JUND, c-FOS, ETR101, 
EGR1, HRY and XBP-1 and E2F family of transcription factors (Li, Turi et al. 2001; Hazar-
Rethinam, Endo-Munoz et al. 2011; López-Camarillo, Aréchaga Ocampo et al. 2011). 
Exposure to UV radiation is thought to activate the Retinoblastoma/E2F axis (Rb/E2F). 
Moreover, the disruption of the Rb/E2F axis, caused by UV exposure, results in elevated 
levels of E2F proteins (Endo-Munoz, Dahler et al. 2009). This indicates that E2F proteins are 
involved in the cellular response to UV irradiation.  
 
1.8 The E2F Family of Transcription Factors 
The E2F transcription factor family plays a major role in a number of KC functions such as 
proliferation, differentiation and response to stress or apoptotic signals. Consistent with these 
roles, dysregulation of E2F is a common occurrence in human cancer and SCC in particular 
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(Jones, Dicker et al. 1997; Dicker, Popa et al. 2000; Wong, Barnes et al. 2003).  Specifically, 
the E2F family of transcription factors has emerged as pleiotropic regulators, directly 
controlling i) cell proliferation, ii) apoptosis, iii) differentiation, iv) DNA-damage response 
and DNA repair, v) development, vi) senescence, vii) autophagy, viii) mammalian endocycle, 
ix) mammalian polyploidisation and x) tumour angiogenesis and metastasis (Helin, Lees et al. 
1992; Trimarchi and Lees 2002; Ichihashi, Ueda et al. 2003; Stevens and La Thangue 2004; 
Erb, Ji et al. 2005; Moon and Dyson 2008; Panagiotis Zalmas, Zhao et al. 2008; Polager, Ofir 
et al. 2008; Chen, Ouseph et al. 2012; Pandit, Westendorp et al. 2012; Schaal, Pillai et al. 
2014), despite the fact that E2F target genes were initially implicated in the regulation of the 
G1/S phase transition of the cell cycle and in DNA replication (Rowland and Bernards 2006). 
Moreover, E2Fs are also indirectly involved in modulating the activity of important cellular 
signalling pathways such as MAPK, p38 and PI3K/AKT through transcriptional regulation of 
upstream pathway components (Chaussepied and Ginsberg 2005; Bashari, Hacohen et al. 
2011). 
 
E2F was first discovered as a cellular factor required for the activation of the E2 viral 
promoter (Nevins 1998; Erb, Ji et al. 2005), and then identified as the essential downstream 
target of Rb (Rowland and Bernards 2006). This factor was later cloned and named E2F1 
(Helin, Lees et al. 1992; Kaelin, Krek et al. 1992; Shan, Zhu et al. 1992). However, it was 
quickly recognised that E2F1 was just one member of, what is now a family of 8 members. 
E2Fs 1-8 code for 10 different E2F forms (Dimova and Dyson 2005) (Figure 1.3).  
 
The E2F family can be broadly classified as typical E2Fs (E2F1-6) and atypical E2Fs (E2F7-
E2F8). All typical E2Fs carry one N-terminally located, evolutionary conserved, DNA-
binding domain (DBD) (Figure 1.3). The DBD is followed by a dimerisation partner (DP) 
binding domain (Lammens, Li et al. 2009) (Figure 1.3). There are two members of DP family 
proteins, DP1 and DP2 that interact with E2F isoforms through the conserved DP binding 
domain (Ichihashi, Ueda et al. 2003) (Figure 1.3). In mammalian cells, most E2F DNA-
binding takes place once E2F-DP heterodimers form to exert their function (Stevens and La 
Thangue 2003). 
 
E2Fs are most frequently classified based on their transcriptional activity (Figure 1.3). For 
example, the E2F family is generally divided into three subclasses: activator E2Fs (E2F1-
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E2F3a), repressor E2Fs (E2F3b-6) and inhibitory E2Fs (E2F7, E2F8). The activator subclass 
of E2Fs can drive quiescent cells into S phase of the cell cycle by binding to their target 
genes and inducing gene expression. The combined deletion of the three activator E2Fs in 
mouse embryo fibroblast results in the complete inhibition of proliferation (Wu, Timmers et 
al. 2001). The expression of activator E2Fs varies during the cell cycle reaching a peak of 
activity, bound to target gene promoters via E2F response elements, during late G1/S phase. 
In this context, they are key factors controlling the expression of genes and activities required 
for DNA synthesis (Cam and Dynlacht 2003; Dimova and Dyson 2005; Li, Ran et al. 2008). 
The expression and activity of the repressor E2Fs (E2F3b, E2F4, E2F5 and E2F6) remain 
relatively constant throughout the cell cycle (Dimova and Dyson 2005). E2F4 and E2F5 bind 
target gene promoters during G0 with E2F inhibitory pocket proteins coupled with repressive 
histone deacetylases (HDACs) (Takahashi, Rayman et al. 2000; Sherr and McCormick 2002) 
and prevent promiscuous transcription of proliferation genes (Attwooll, Denchi et al. 2004; 
Berton, Mitchell et al. 2005; Dimova and Dyson 2005). The so-called repressor E2Fs get 
their name due to their ability to actively recruit transcriptional inhibitors such as HDAC1 
(e.g. E2F4 and E2F5) or PRC2 (E2F6) to the E2F sites resulting in transcriptional repression 
(Leone, DeGregori et al. 1998; Berton, Mitchell et al. 2005). Indeed, Gaubatz and his 
colleagues showed that ablation of two repressor E2Fs together, E2F4 and E2F5, in mouse 
embryonic fibroblasts (MEFs), causes reduction in their responsiveness to growth inhibitory 
signals and fail to repress G0-specific genes (Gaubatz, Lees et al. 2001). E2F6 forms a 
multimeric protein complex containing Mga and Max proteins in order to repress target gene 
transcription during G1/S phase in a Rb independent manner (Ogawa, Ishiguro et al. 2002; 
Giangrande, Zhu et al. 2004).    
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Figure 1.3 Domain organisation of activating, repressive or inhibitory E2Fs. Number of 
amino acid is indicated on the right. Same colour boxes indicate homologues regions. 
There are two known E2F7 isoforms; E2F7a and E2F7b which differ only in their C 
termini. Both isoforms of E2F7 are expressed in all cell lines analysed (Zhan, Huang et al. 
2014).  
 
Several studies demonstrate that E2Fs serve critical functions beyond cell-cycle regulation 
(Chen, Tsai et al. 2009; Chong, Wenzel et al. 2009; Wenzel, Chong et al. 2011). Hence, the 
role of the E2Fs is complex. Individual E2F family members can be involved in multiple 
cellular activities. For example, E2F1 is directly involved in the G1/S transition of the cell 
cycle (Johnson, Ohtani et al. 1994), stimulating apoptosis (Trimarchi and Lees 2002; Iaquinta 
and Lees 2007), suppressing differentiation (Wong, Barnes et al. 2003; Wong, Barnes et al. 
2004; DeGregori and Johnson 2006) and acting as a transducer of the DNA damage response 
in KCs (Berton, Mitchell et al. 2005). In addition, multiple E2F family members can play a 
role in the same cellular functions and frequently share the same E2F binding sites in gene 
promoters (consensus E2F binding site is TTTCGCGC) (de Bruin, Maiti et al. 2003; Di 
Stefano, Jensen et al. 2003). For example E2Fs 1, 2 and 3a are all involved in the transition 
through the G1/S phase of the cell cycle (Leone, DeGregori et al. 1998). Finally, there is 
emerging evidence to indicate that E2F isoform specific-sites and functions may also exist. 
For example, in KCs we recently showed that E2F7 could selectively suppress differentiation 
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through the repression of Sp1’s transcription mediated via a selective and novel E2F7-
specific response element (5’-CTCCTTTCCCCCTCCCTCAT-3’) (Hazar-Rethinam, 
Cameron et al. 2011).  Finally, it is important to note that activating and repressive or 
inhibitory E2Fs exist that antagonise one another function either through direct competition 
for binding sites (eg: E2F1 and E2F7 in G1/S phase gene promoters) or indirectly by 
opposing each other’s action (Mariconti, Pellegrini et al. 2002; de Bruin, Maiti et al. 2003; 
Christensen, Cloos et al. 2005). For example E2F1 can suppress differentiation genes whilst 
E2F7 can derepress the same genes but through independent DNA response elements (Hazar-
Rethinam, Cameron et al. 2011). Thus, understanding E2F function requires an understanding 
of the opposing actions of the E2F family members.   
 
1.9 Atypical E2Fs: new players in the E2F family 
Despite around 3500 publications focusing on E2Fs, our knowledge about these master 
regulators is very limited especially when it comes to two most recently identified members 
of the family. These novel, evolutionary conserved, members form a distinct arm of E2F 
family and were first discovered in Arabidopsis thaliana, and named as DP-E2F-Like (DEL1 
to DEL3) through a genome survey in order to find genes containing sequences homologues 
to E2F-DBD (Kosugi and Ohashi 2002; Mariconti, Pellegrini et al. 2002). They have been 
found in numerous organisms so far, and named as EF27 and E2F8 following their discovery 
in mice and human (de Bruin, Maiti et al. 2003; Di Stefano, Jensen et al. 2003; Logan, 
Delavaine et al. 2004; Christensen, Cloos et al. 2005; Logan, Graham et al. 2005; Maiti, Li et 
al. 2005). Their unique structural properties distinguish them from the rest of the family. 
Therefore, they were also termed as “atypical” E2Fs.     
 
1.9.1 Molecular features of atypical E2F proteins 
One of the atypical E2Fs, E2F7, exists as an alternatively spliced form (Figure 1.3). The 
shorter isoform, E2F7a, is 728 amino acid-long. The longer isoform of E2F7, E2F7b, carries 
13 exons, and encodes a protein of 911 amino acids (de Bruin, Maiti et al. 2003). The only 
difference between these two isoforms is the extra exon of E2F7b located in the C-terminal 
tail from amino acid 7143 (Di Stefano, Jensen et al. 2003). Our previous experiments showed 
that E2F7a expression is negligible compared to E2F7b in KCs. Therefore, the future 
reference to E2F7 refers to E2F7b.   
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Although there are numerous structural differences between atypical and canonical E2F 
proteins, DBD is the most notable feature that separates them from each other. In contrast to 
canonical E2Fs, the DBD is duplicated in atypical E2Fs and the integrity between these two 
DBDs is essential for their function (Figure 1.3). It was previously shown that the mutation 
in either of the DBD is able to completely diminish the DNA binding function of these 
proteins (Kosugi and Ohashi 2002; Di Stefano, Jensen et al. 2003; Logan, Delavaine et al. 
2004; Christensen, Cloos et al. 2005; Logan, Graham et al. 2005; Maiti, Li et al. 2005). 
Three-dimensional modelling of E2F7 and E2F8 further demonstrated that duplicated DBD 
of atypical E2Fs is able to mimic the binding between canonical E2F protein and their partner 
protein (Li, Ran et al. 2008).  
 
Atypical E2Fs bind target gene promoters in a DP-independent fashion due to the lack of a 
DP-binding domain (Figure 1.3) (de Bruin, Maiti et al. 2003; Di Stefano, Jensen et al. 2003; 
Ichihashi, Ueda et al. 2003; Logan, Delavaine et al. 2004; Logan, Graham et al. 2005; Maiti, 
Li et al. 2005). Instead, they utilize two tandem DBDs to recognise and bind target sequences 
(Ouseph, Li et al. 2012). Moreover, coimmunoprecipitation studies have shown that the 
atypical E2Fs are able to form homodimers and heterodimers with each other (Di Stefano, 
Jensen et al. 2003; Maiti, Li et al. 2005; Li, Ran et al. 2008). One other important feature of 
atypical E2Fs is the lack of a recognisable transactivation domain (Figure 1.3) (Iaquinta and 
Lees 2007). The lack of functional domains on E2F7 and E2F8 has led to the hypothesis that 
their main mode of action is to compete with canonical E2Fs binding and subsequent 
modulation of response elements.  Indeed, studies have shown that ablation of atypical E2Fs 
can induce the expression of defined subsets of E2F-regulated genes (Li, Ran et al. 2008; 
Panagiotis Zalmas, Zhao et al. 2008). Finally, atypical E2Fs possess motifs known to be 
responsible for ubiquitin-mediated degradation, which is absent in canonical E2Fs 
(Christensen, Cloos et al. 2005). This ties in with the observed instability of atypical E2Fs 
(Christensen, Cloos et al. 2005).  
 
1.9.2 Transcriptional regulation of atypical E2F expression 
The expression of E2F7 and E2F8 is cell-cycle regulated, which distinguishes them from 
repressor E2Fs. Transcription of E2F7 and E2F8 increases towards G1/S transition reaching 
its peak during mid to late S phase as targets of E2F1 (Berton, Mitchell et al. 2005; 
Christensen, Cloos et al. 2005; Lammens, Li et al. 2009; Hazar-Rethinam, Cameron et al. 
2011). Sequence analysis of atypical E2Fs resulted in the identification of consensus E2F-
21 
 
binding sites on their promoters. In particular, the direct association of E2F1, E2F3, E2F4 and 
E2F7 proteins with promoter elements of atypical E2Fs was shown previously (Di Stefano, 
Jensen et al. 2003; Christensen, Cloos et al. 2005). In a separate study, this relationship 
between atypical promoters and other family members was also confirmed demonstrating that 
E2F1 and, to a lesser extent, E2F4 and E2F7 bind the E2F8 promoter (Christensen, Cloos et 
al. 2005), and E2F7 occupies the promoters of E2F1, E2F2, E2F3 and E2F8 as well as its 
own promoter (Westendorp, Mokry et al. 2011). Clearly, atypical E2Fs are targets of E2Fs. 
Indeed, screening for genes regulated by E2F1 independently identified E2F7 as an E2F1-
regulated gene (Di Stefano, Jensen et al. 2003). Of interest, in addition to canonical E2Fs, 
recent work has shown that E2F7 is a direct p53 target gene and is upregulated by p53 in 
mediating response to DNA damage and cellular senescence (Aksoy, Chicas et al. 2012; 
Carvajal, Hamard et al. 2012). E2F7 has a p53-binding site in its promoter, and, interestingly, 
no specific p53 binding sites were detected in any of the other E2F promoters (Aksoy, Chicas 
et al. 2012).     
 
Once expressed, E2F7 and E2F8 bind to the E2F1 promoter via an E2F response element and 
inhibit its expression (de Bruin, Maiti et al. 2003; Di Stefano, Jensen et al. 2003; Logan, 
Delavaine et al. 2004). Hence, there is clear evidence that E2F1 and E2F7 exist in a negative 
feedback loop that modulate both their activity and transcription. Thus, the role of E2F7 and 
E2F8 in cell cycle control appears to tie in with the direct inhibition of the E2F1 activities 
related to cell cycle traverse (Di Stefano, Jensen et al. 2003; Raj, Brash et al. 2006). To date, 
the participation of E2F8 in this feedback loop has not been elucidated. Besides E2F1, E2F2 
and E2F3a have been also reported to induce E2F7 and E2F8 transcription at G1/S phase of 
cell cycle (de Bruin, Maiti et al. 2003; Di Stefano, Jensen et al. 2003; Logan, Delavaine et al. 
2004; Christensen, Cloos et al. 2005; Logan, Graham et al. 2005; Maiti, Li et al. 2005). 
Furthermore, expression profiling and biochemical approaches identified one of the canonical 
E2F activators, E2F3a, as a key E2F family member that antagonizes E2F7/8 functions in 
coordinating cell cycle progression and subsequent placental development (Ouseph, Li et al. 
2012). This suggests that they are required for the balanced and timely regulation of genes 
involved in S-phase via a feed-forward loop, where an activator induces a target gene but at 
the same time also induces a repressor of the very same target limiting the extent of the 
induction, between two arms of the E2F family (Westendorp, Mokry et al. 2011; Aksoy, 
Chicas et al. 2012). In addition to canonical E2Fs, Westendorp et al performed a genome-
wide promoter occupancy analysis and reported that E2F7 binds to multiple G1/S-regulated 
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gene promoters and inhibits their transcription in cell cycle phase-specific context  
(Westendorp, Mokry et al. 2011).  
 
When it comes to the expression patterns of atypical E2Fs, our knowledge is limited as not 
much is known about the tissue-specific expression profiles of these proteins. From the little 
that has been published there appears to be considerable overlap in expression (Maiti, Li et al. 
2005). However, there are observed differences between atypical E2Fs’ expression profiles in 
cell lines. The observation that E2F7 and E2F8 can be expressed in the same tissue begs the 
question of whether they share similar gene targets or whether they perform independent 
roles in these cells.  At present there is no data available on this matter.   
 
1.9.3 Regulation of transcription by atypical E2Fs 
Till now how atypical E2Fs act to repress gene transcription remains to be determined. One 
possibility could be ruled out based on structural differences between canonical and atypical 
E2Fs. It is unlikely that atypical E2Fs act through co-recruitment of Rb family members to 
target promoters which repress gene expression by sequestering activated E2Fs and recruiting 
histone-modifying activities (Morris and Dyson 2001; Nijwening, Geutjes et al. 2011), since 
atypical E2Fs lack pocket protein binding domain. Instead, several studies suggest that 
atypical E2Fs compete with the activating E2Fs for promoter occupancy of E2F target genes 
to prevent transcriptional activation (Li, Ran et al. 2008; Westendorp, Mokry et al. 2011; 
Aksoy, Chicas et al. 2012). Recently, Liu et al unveiled the mechanism by which E2F7 
repress E2F1 gene transcription (Liu, Shats et al. 2013). The authors showed that E2F7 (and 
E2F8) forms an E2F1-E2F7 complex and an E2F7-E2F7 homodimer on adjacent E2F-
binding sites. Upon forming these complexes, E2F7 recruits the co-repressor C-terminal-
binding protein (CtBP), and, significantly, CtBP2 is essential for E2F7-mediated repression 
of E2F1 transcription (Liu, Shats et al. 2013). In the very same paper, the authors also 
hypothesized based on their results that the direct interaction between E2F1 and E2F7 could 
direct E2F7 to the E2F target promoters which are activated by E2F1 (Liu, Shats et al. 2013). 
A recent unbiased proteomics analysis of CtBP2-associated proteins confirmed the findings 
from Liu’s paper and showed that CtBP proteome contains components of the Nucleosome 
Remodelling Deacetylase (NuRD) and E2F7 (Zhao, Subramanian et al. 2014). This study 
further provides insight into binding kinetics between CtBP2 and E2F7, and demonstrates 
that E2F7 interacts with CtBP2 though a canonical CtBP binding motif with the hydrophobic 
cleft region of CtBP2 (Zhao, Subramanian et al. 2014)      
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Despite their classification as transcriptional repressors, intriguingly, several recent studies 
highlighted an unanticipated functional interaction between E2F7/8 and their target genes 
(Deng, Wang et al. 2010; Sirma, Kumar et al. 2011; Weijts, Bakker et al. 2012). E2F7 was 
shown to bind and activate human telomerase reverse transcriptase (TERT) promoter in 
hepatocytes in response to proliferation (Sirma, Kumar et al. 2011), and Collagen and 
Calcium Binding EGF domains 1 protein promoters (Ccbe1) in HeLa cells (Weijts, van Impel 
et al. 2013). However, a molecular mechanism through which E2F7 activates the 
transcription of these promoters was not provided. In the liver, E2F8 was found to bind and 
enhance promoter activity of Cyclin D1 promoter. In the same study, a possible model was 
proposed where E2F8 acts in a dominant negative manner by relocating some E2F 
transrepressors (Deng, Wang et al. 2010). On the other hand, Weijts and his colleagues 
elegantly provided evidence for a molecular mechanism as to how atypical E2Fs enhance 
promoter activity (Weijts, Bakker et al. 2012). This study showed a novel function for E2F7 
and E2F8 in activating the transcription of the vascular endothelial growth factor A (VEGFA) 
and subsequently contributing to proper formation of blood vessels (Weijts, Bakker et al. 
2012). E2F7/8 directly binds and stimulates VEGFA promoter activity independent of 
canonical E2F binding sites; instead they bind to non-canonical E2F binding sites and form a 
transcriptional complex with an transcriptional activator the hypoxia inducible factor 1 alpha 
(HIF1α) for full activation of the VEGFA promoter (Weijts, Bakker et al. 2012).     
  
1.9.4 Atypical E2F proteins and differentiation 
As mentioned previously, squamous differentiation is primarily controlled at the 
transcriptional level by key transcription factors such as the E2F family of proteins. The 
participation of E2Fs in differentiation was first observed in myogenic differentiation where 
ectopic expression of one of the typical E2Fs, E2F1, suppressed terminal differentiation 
(Wang, Helin et al. 1995). Similarly, an essential prerequisite to initiate differentiation is the 
downregulation of activating E2Fs, such as E2F1 (Figure 1.4). Our laboratory recently 
showed that one of the inhibitory E2Fs, E2F7, was highly expressed in proliferating KCs and 
could inhibit proliferation-specific markers and sensitise KCs to differentiation stimuli 
(Endo-Munoz, Dahler et al. 2009). It was shown that E2F7 was capable of repressing the 
activity of one of the established differentiation activators, Sp1 (Figure 1.4) (Hazar-
Rethinam, Cameron et al. 2011). The loss of E2F7 leads to derepression of Sp1 protein, and 
subsequent transcription of differentiation specific genes, such as TG-1. Furthermore, we 
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recently showed that E2F7 could selectively suppress differentiation through the repression 
of Sp1 transcription mediated via a selective and novel E2F7-specific response element  
(Hazar-Rethinam, Cameron et al. 2011). In agreement with these studies, E2F7 as a novel 
target of miR-26a was shown to play an important role in monocytic differentiation of acute 
myeloid leukemia cells where ablation of E2F7 was sufficient to commit 
monocytic/macrophage cells to differentiate and increased E2F7 levels counteracted 
monocytic differentiation (Salvatori, Iosue et al. 2012).     
 
The published data clearly shows the involvement of E2F1 and E2F7 in the regulation of 
squamous differentiation. However, E2F7 cannot be considered a global regulator of 
differentiation since it interacts with only selective genes in the differentiation program. 
Although E2F8 has previously been shown to promote erythroid terminal differentiation by 
collaborating with Rb protein where Rb binds and sequesters E2F2 and E2F8 competes with 
E2F2 for E2F2-binding sites on target gene promoters (Ghazaryan, Sy et al. 2014), to our 
knowledge, there is no reported data showing the participation of E2F8 in the differentiation 
program in KCs. Dysregulation of squamous differentiation is a key event in malignant 
conversion of KCs and is evident in early forms of SCC (Sugiyama, Speight et al. 1993; 
Watanabe, Ichikawa et al. 1995; Gasparoni, Fonzi et al. 2004). Significantly, E2Fs are also 
known to be dysregulated in SCC and to contribute to the dysregulation of differentiation 
(Wong, Barnes et al. 2003; Wong, Barnes et al. 2004).  Therefore, understanding both the 
role of individual E2Fs and the interactions between those individual E2Fs is of interest.  
 
 
Figure 1.4 Model of E2F7's role in squamous differentiation. E2F inhibition and Sp1 
activation via downregulation of E2F7 is sufficient to induce markers of squamous 
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differentiation in normal KCs and SCC cells. Figure courtesy of Associate Professor Nicholas 
Saunders and used with permission.   
 
1.9.5 Atypical E2F proteins and DNA damage response 
In vitro and in vivo knockout studies have provided information about atypical E2Fs and their 
biological contribution to DNA damage including UV and chemotherapy mediated responses. 
Reassuringly, E2F7 has been recently identified as a bona fide p53 target gene that is 
activated during DNA damage response and executes its role through transcriptional 
regulation of a subset of indirect p53 target genes (Aksoy, Chicas et al. 2012; Carvajal, 
Hamard et al. 2012). Curiously, only E2F7 expression (in a p53-dependent manner) was 
affected upon DNA damage since the levels of E2F8 remained unchanged (Carvajal, Hamard 
et al. 2012). In addition, in an effort to identify novel E2F7 binding sites in promoters of 
target genes, ChIP-Seq and the global gene expression experiments resulted in a list of E2F7 
target genes (Westendorp, Mokry et al. 2011). DNA repair genes are overrepresented in this 
list, confirming previously publishes studies and providing evidence for an important role for 
E2F7 in DNA damage responses (Westendorp, Mokry et al. 2011).  
 
E2F7 has been shown to bind directly and repress target genes which are important in the 
DNA damage responses such as Rad51, Check1, BRCA1 and BRCA2 by Westendorp and his 
colleagues (Westendorp, Mokry et al. 2011). They further reported that E2F7 overexpression 
alone is sufficient to induce DNA damage by increasing DNA double-strand breaks 
(Westendorp, Mokry et al. 2011). Interestingly, Zalmas and his colleagues examined the 
biological role of E2F7 in DNA damage response and demonstrated that E2F7 contributes to 
DNA damage response not only by regulating transcription of target genes involved in DNA 
damage response, but also by altering the local chromatin environment of the DNA lesion 
(Zalmas, Coutts et al. 2013). Upon DNA damage, E2F7 recognises and binds to damaged 
DNA, recruits CtBP and HDAC to the damaged DNA (Zalmas, Coutts et al. 2013), 
contributing to the DNA damage response through both transcriptional and non-
transcriptional mechanisms.  
 
1.9.5.1 UV-induced responses 
The ability of the different E2Fs to contribute to apoptosis, especially to UVB-mediated 
apoptosis, is contentious. Much of this controversy arises from some seemingly paradoxical 
data relating to the action of E2F1. In response to UVB, E2F1 transcript and protein levels 
26 
 
increase in an ATM/ATR dependent manner and triggers a series of events required for 
apoptosis (Carcagno, Ogara et al. 2009). This suggested that UVB-induced E2F1 mediated 
apoptosis in skin may have tumour suppressive effects. However, studies from Dimova and 
Dyson reported otherwise (Helin, Lees et al. 1992; Dimova and Dyson 2005). Collectively, 
the studies so far suggest that the role of E2F1 in regulating apoptosis may be context-
specific. Moreover, the dose of UVB and the level E2F1 should also be considered in terms 
of apoptotic responses.  
 
Atypical E2Fs bind to, and repress, E2F1-mediated apoptosis via direct inhibition of E2F1 
(Li, Ran et al. 2008; Panagiotis Zalmas, Zhao et al. 2008; Endo-Munoz, Dahler et al. 2009). 
Both E2F7 and E2F8 are expressed in skin (Stevens and La Thangue 2003; Berton, Mitchell 
et al. 2005) and are able to influence the cellular DNA damage response (Panagiotis Zalmas, 
Zhao et al. 2008). In fact, microarray analysis of cells subjected to DNA damage revealed 
that E2F7 and E2F8 could be considered bona fide DNA damage response genes (Li, Ran et 
al. 2008). These studies seem to be relevant to UV responses in skin since we recently 
reported that E2F7 plays a role in regulating proliferation, differentiation and UV-induced 
cytotoxicity in human KCs in vitro (Endo-Munoz, Dahler et al. 2009). Moreover, we reported 
that E2F1 and E2F7 were overexpressed in human SCCs approximately 50-fold and 200-fold 
(Endo-Munoz, Dahler et al. 2009). Such elevations in E2F1 and E2F7 are clearly pathologic 
and the consequences on UV-induced tumour development and progression remain unknown. 
However, given that E2F1 and E2F7 are said to autoregulate the expression of one another 
and given that E2F7 antagonises E2F1-induced apoptosis and UV-induced apoptosis in 
human KCs, it would seem reasonable to speculate that E2F7 may also play a role in UV 
responses in human KCs (Figure 1.5). Thus, apoptotic responses of KCs to UV are likely to 
be dictated by the relative levels of E2F1 and E2F7.   
 
Although the direct relationship between E2F7 proteins and UV-mediated responses has been 
published, the role of E2F8 in UV-mediated DNA damage has not been investigated. 
Therefore, our knowledge about E2F8 is limited in relation to its biological contribution to 
cytotoxic responses caused by UV.  
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Figure 1.5 Schematic showing of how E2F1 and E2F7 contribute to formation of 
cutaneous malignancies due to dysregulated apoptotic control. (Hazar-Rethinam, Endo-
Munoz et al. 2011).  
 
1.9.5.2 Chemotherapy-induced responses 
DNA damage and subsequent stress responses can also be triggered by chemotherapeutic 
agents. Several cell death pathways have been implicated in cisplatin induced cytotoxicity, 
one of which is an E2F1-dependent death pathway (Gordon and Gattone 1986; Ramesh and 
Reeves 2003; Liu and Baliga 2005). Upon cisplatin exposure, E2F1 levels increase and E2F1 
gets stabilized. In this context, E2F1 induction is downstream of cdk2 (Yu, Megyesi et al. 
2007; Yu, Megyesi et al. 2008). This, in turn, induces death signalling via TopBP1 protein 
expression (Liu, Lin et al. 2003). Supporting this, the involvement of E2F1 in cisplatin-
mediated cytotoxicty has been reported in vivo and in vitro (Yu, Megyesi et al. 2007). In 
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addition, to cisplatin-induced cytotoxicity, there are reports on the involvement of E2F1 in 
doxorubicin-mediated stress responses (Dong, Yang et al. 2002; Han, Park et al. 2003; Ianari, 
Gallo et al. 2004). A recent study demonstrated that E2F1 is stabilized following exposure to 
doxorubicin even in the absence of either ATM-dependent phosphorylation or p53 and cAbl, 
which are the two major elements in DNA damage signalling (Ianari, Gallo et al. 2004). 
Moreover, adenovirus mediated E2F1 gene delivery/therapy was able to sensitize melanoma 
cells towards Topoisomerase II inhibitors such as doxorubicin and etoposide in vitro and in 
vivo (Dong, Yang et al. 2002).   
 
Although E2F1 has been shown to play a vital role in the induction of apoptosis caused by 
DNA-damage inducing agents, the fine tuning of E2F1 is required in order to prevent 
aberrant accumulation of E2F1. Accordingly, elevated levels of E2F1 and E2F7 in human 
SCCs have an impact on apoptotic responses and result in chemotherapeutic insensitivity in 
SCC.  
 
As mentioned previously, analysis of cells following DNA damage revealed that E2F7 and 
E2F8 could be considered bona fide DNA damage response genes (Li, Ran et al. 2008). 
Zalmas et al (Panagiotis Zalmas, Zhao et al. 2008) recently showed that DNA damage 
induced by etoposide increased E2F7 and E2F8 expression. Moreover, they demonstrated 
that DNA damage invoked an increase in E2F7 and E2F8 binding to E2F-responsive genes 
such as E2F1 resulting in an inhibition of E2F1-mediated apoptosis (Panagiotis Zalmas, Zhao 
et al. 2008). Li and his group also demonstrated that cells lacking E2F7 and E2F8 were 
hypersensitive to DNA-damage induced apoptosis when treated with camptothecin and 
cisplatin (Li, Ran et al. 2008). Collectively, these findings provide tantalising clues as to the 
relationship between E2Fs and chemotherapeutic responses. Interestingly, in a recent study 
where the authors demonstrated that E2F7 mediates DNA damage-dependent transcriptional 
repression after genotoxic stress, treatment of U2OS cells with a single dose of doxorubicin 
and increasing amounts of etoposide resulted in a time-dependent increase in only E2F7 
mRNA and protein levels whilst E2F8 levels were downregulated (Carvajal, Hamard et al. 
2012). DNA damage-induced transcriptional repression of E2F7 target genes such as E2F1 
was also confirmed in this study demonstrating that E2F7 is recruited to E2F1 promoters after 
treatment with the genotoxic drugs (Carvajal, Hamard et al. 2012). Similar differences in 
E2F8 expression levels were also reported in a recent study where the effects of the 
proteasome inhibitor bortezomib (BZB) on atypical E2Fs was evaluated in hepatocellular 
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carcinoma cells (Baiz, Dapas et al. 2014). BZB treatment of the hepatocyte-like 
hepatocellular carcinoma cells had a significant impact on E2F8 by reducing its levels (Baiz, 
Dapas et al. 2014). Interestingly, BZB treatment had an effect only on E2F8 levels but E2F7 
mRNA levels remained unchanged (Baiz, Dapas et al. 2014), suggesting a chemotherapeutic 
agent-dependent mechanism of action.    
  
1.10 Project aims and hypothesis 
KC-derived SCC of the skin and mucosae are amongst the most common malignancies 
afflicting humans. SCC is characterized by dysregulated proliferation, apoptosis and 
dysregulated differentiation control. Collectively, there is a significant amount of data about 
the importance of E2F family of transcription factors in KC biology. Thus, our previous 
studies with E2F family of transcription factors in the context of KCs have provided 
considerable insight into squamous differentiation and squamous neoplasia. The key findings 
from the work were i) that E2F1, E2F7 and E2F8 are preferentially expressed in proliferating 
human KCs (HEK), ii) that E2F1 is pro-proliferative, a differentiation suppressive and 
proapoptotic, iii) that in contrast, E2F7, and presumably E2F8, are able to antagonize E2F1 
including E2F1-induced apoptosis, iv) that E2F7 is anti-proliferative, a differentiation 
initiator and anti-apoptotic, v) that Sp1 is one of the E2F7-specific genes within KCs playing 
a crucial role in the initiation of differentiation, vi) that E2F8 is anti-proliferative and anti-
apoptotic, however, its contribution toward differentiation has not been elucidated to date and 
vii) that E2F1 and E2F7 are both overexpressed in SCCs by greater than 100-folds. Thus, 
better understanding of the E2F family of proteins is essential to understand how these 
processes are disrupted during SCCgenesis. The E2F network exists as a complex map of 
cross-talking pathways, and the complete understanding of the E2F family will not be 
possible until physiological functions of E2F7/E2F8 and E2F isoform-specific activities and 
gene targets in KCs are fully revealed. Moreover, the knowledge on how E2Fs interact with 
each other will produce a shift in our understanding of the defects underlying SCC formation 
and also provide clear evidence of a potential therapeutic strategy that is SCC-specific. 
Hence, the hypotheses of this project are: 
 
i. That E2F7 and/or E2F8 are key regulators of squamous differentiation. 
ii. That E2F7 and/or E2F8 modulate cytotoxic responses to UV radiation and 
chemotherapeutic agents.  
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iii. That disruption of the E2F1/E2F7/E2F8 axis during SCC formation contributes to the 
development of SCC. 
 
In order to explore these hypotheses, a number of aims were addressed:  
1. Characterise the biological activity of E2F1, E2F7 and E2F8 in murine KC models of 
squamous differentiation, with particular emphasis on E2F8. 
2. Define the molecular basis for E2F1- and E2F7-dependent modulation of 
chemotherapeutic agents including cisplatin, etoposide and anthracyclines sensitivity 
in SCC in vitro and in vivo. 
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CHAPTER TWO 
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2 Material and Methods  
This Chapter will detail general experimental procedures which will be referred to throughout 
the Results Chapters of this thesis. General buffers and media used in this project are 
described in Appendix I.  
 
2.1 Mice 
2.1.1 Mouse strains 
Five different groups of mice were used in this study so far. Control mice were from mix 
background, C57/BL6 and FVB, and did not carry any genetic alterations. Flox mice; E2F7 
and E2F8, were kindly provided by Gustavo Leone (Li, Ran et al. 2008). Specifically, exon 4 
was flanked by LoxP sequences for E2F7 
Flox/Flox
 mice, whereas exon 3 and 4 both were 
flanked for E2F8 
Flox/Flox
 littermates. E2F7/8
Flox/Flox mice 
were generated in house by crossing 
E2F7
 Flox/Flox
 mice with E2F8 
Flox/Flox
 mice. Littermates of floxed mice were from C57/BL6 
background. E2F1 KO mice were generated by inserting a PGK-neo cassette in the DNA 
binding and dimerisation domains of a 7.4 kb fragment of the E2F1 gene, which resulted in 
mutated E2F1 locus that does not encode a functional protein (Field, Tsai et al. 1996). 
E2F1KO mice were also from mixed background. Floxed mice were maintained as 
homozygous population for the E2F floxed allele as well as E2F1KO mice.  
 
2.1.2 Genotyping 
Genotypic analysis of offspring on tail tip DNA was performed by PCR using locus-specific 
primers described in Table 2.2.   
 
2.1.2.1 DNA extraction 
DNA was extracted using the Qiagen DNeasy Blood and Tissue Kit (Qiagen, Chadstone 
Centre, Australia) in accordance with the manufacturer’s instructions.  All reagents in this 
section are provided with the DNeasy Blood and Tissue Kit unless otherwise indicated.  
 
2.1.2.2 PCR 
Where E2F7 and E2F8 genotyping was to performed, 2 µL of extracted DNA was used in a 
PCR reaction consisting of 5µL reaction buffer (Platinum Taq DNA Polymerase Kit, 
Invitrogen, Mt Waverly Australia), 10 µM forward and reverse primers, 40 mM dNTP, 1.5 
µL magnesium chloride (MgCI2), 2.5 µL (5%) dimethyl sulfoxide (DMSO), 34.8 µL water 
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and 0.2 µL Platinum Taq (Invitrogen). E2F7 and E2F8 PCR were run using the same cycling 
conditions: 
 
Temperature and Time  Number of Cycles 
94°C for 2 minutes 1 
94°C for 30 seconds 
55°C for 30 seconds 
72°C for 30 seconds 
 
40 
4°C  Hold 
 
Where E2F1 genotyping was to be performed, two reaction mixes were prepared for each 
DNA sample: Mix “A” and Mix “B”. Mix “A” consisted of 5µL reaction buffer (Platinum 
Taq DNA Polymerase Kit, Invitrogen), 10 µM forward (WT#2) and reverse primers 
(COM#3), 40 mM dNTP, 1.5 µL MgCI2, 38.3 µL water and 0.2 µL Platinum Taq 
(Invitrogen). Mix “B” contained the same ingredients as Mix “A” except the forward primer 
(NEO#1). E2F1 PCR was run using the following conditions: 
 
Temperature and Time  Number of Cycles 
94°C for 2 minutes 1 
94°C for 30 seconds 
56°C for 30 seconds 
72°C for 30 seconds 
 
40 
4°C  Hold 
 
PCR reactions were run in an Eppendorf Gradient Thermal Cycler (Eppendorf, North Ryde, 
Australia). The E2F7 PCR product was electrophoresed on a 3% agarose (Bioline, 
Alexandria, Australia) gel made in TBE (Appendix I) buffer with 0.001% w/v ethidium 
bromide and a DNA ladder (New England Biolabs) to ensure that the PCR product was the 
correct size and visualised under UV light whereas the percentage of agarose/TBE gel for 
E2F8 was 2.5%. E2F1 PCR products from both Mix A and Mix B reactions per sample were 
electrophoresed on a 2% agarose/TBE gel and visualised under UV light.  
 
 
34 
 
2.2 Tissue culture methods 
2.2.1 Mouse epidermal keratinocyte isolation 
Mouse epidermal keratinocytes (MEK) were isolated from newborn mouse pups, 0 to 3 days 
old, in accordance with Institutional Ethics Approval. All procedures were carried out under 
aseptic techniques in a laminar flow hood. Upon transferring pups from animal house (UQ 
Biological Research Facility) to laminar flow hood, pups were sacrificed by decapitation with 
scissors. The body was washed in 70% ethanol for 15 seconds to decontaminate the skin and 
then soaked in phosphate-buffered saline (PBS). Tail tip sample was taken for PCR 
screening. A single incision was made through the skin along the underside of the pup, from 
the neck to the base of the tail. The skin was peeled from the body wall and the carcass was 
discarded. The skin was washed in PBS. The peeled skin was cut into approximately four 
even pieces and tissue pieces were then submerged and incubated overnight at 4°C in filter 
sterilized 5 mg/mL Dispase II (Roche Diagnostics, Castle Hill, Australia) in PBS. The 
Dispase solution was supplemented with 0.1% v/v penicillin/streptomycin (Invitrogen, Mt 
Waverly, Australia), 10 µg/mL gentamycin (Pfizer, West Ryde, Australia) and 0.2 µg/mL 
amphotericin B (Fungizone) (Gibco, Mulgrave, Australia).  
 
Next day, the epidermis (white) was separated from the dermis (jelly) and washed twice in 
PBS to reduce fungal contamination. The epidermal sheet was placed into a 15 mL Falcon 
tube (BD Biosciences, North Ryde, Australia) containing 2 mL of 0.25% w/v trypsin with 
1mM ethylene diamine tetra acetic acid (EDTA) (Invitrogen) and pipetted vigorously for 20 
seconds. 1 mL of 10% v/v foetal bovine serum (FBS) (Bovogen Biologicals, Essendon, 
Australia) in PBS and 5 mL of PBS were added and mixed gently by gentle inversion. Most 
of the skin chunks were removed, and the tube was spun at 200 g for 2 minutes and 
supernatant discarded. The pellet was resuspended in 5 mL of keratinocyte serum-free media 
(KC-SFM) without calcium (Invitrogen) supplemented with 5 µg/mL epidermal growth 
factor (EGF) (Invitrogen), 50 µg bovine pituitary extract per mL (BPE) (Invitrogen), 0.1% 
v/v penicillin/streptomycin (Invitrogen), 1 µg/mL gentamycin (Pfizer) and 0.05 mM calcium 
chloride (CaCl2) (Invitrogen). The resuspended MEKs were seeded in a 25 cm
2 
tissue culture 
flask (Corning Life Sciences, Mount Martha, Australia). MEKs were maintained in culture 
for four to seven days at 37°C, 5% carbon dioxide (CO2) until the keratinocyes approached 
70% confluence and ready to be serially passed.  
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2.2.2 Serial cultivation of mouse epidermal keratinocytes 
When MEKs were ready to passage, media was aspirated and cells were washed twice with 
PBS. 1mL of 0.25% trypsin (Sigma Aldrich, Castle Hill, Australia) supplemented with 1 mM 
EDTA was added to the flask and incubated at 37°C for five minutes in a 5% CO2 incubator. 
Following microscopic observation, when cells had detached from the flask, an equivalent 
volume of 10% v/v FBS (Bovogen Biologicals) in PBS was added to the flask to halt 
trypsinisation. The cells and trypsin solution were transferred into a 15 mL Falcon tube (BD 
Biosciences). The culture vessel was washed with 5 mL of PBS and the PBS wash was added 
to the Falcon tube containing the cells. The tube was centrifuged at 200 g for three minutes. 
The supernatant was discarded and the cell pellet was resuspended in KC-SFM without 
calcium (Invitrogen). MEKs were used at different seeding densities described in the relevant 
materials and method section for the downstream experiments. MEKs were passaged at a 
maximum of three times. 
 
2.2.3 Induction of differentiation 
MEK differentiation was induced in vitro by increasing the concentration of calcium from 
0.05 mM to 1.2 mM in the KC-SFM media. MEKs were cultured with KC-SFK media 
without calcium supplemented with 1.2 mM calcium for the duration of 48 hours. Calcium 
treated MEKs were visualised in a tissue culture vessel on an Olympus CKX41 inverted 
microscope (Olympus), using the Nikon DS-Fi1 camera. Differentiation was also induced by 
growth of cells to confluence.  
 
2.2.4 Human epidermal keratinocytes isolation 
Human epidermal keratinocytes (HEK) were isolated from neonatal foreskins, obtained from 
Dr Terry Russell (Russell Medical Clinic, Mount Gravatt), in accordance with Institutional 
Ethics Approval. All procedures were carried out under aseptic techniques in a laminar flow 
hood. The foreskin was washed twice with 70% ethanol and PBS before removing the excess 
subcutaneous fat layer. The foreskin was cut into small segments and incubated overnight at 
4°C in Dispase II solution as per Section 2.2.1 mouse epidermal keratinocyte isolation.  
Next day, the epidermis (white) was separated from the dermis (jelly) and washed twice in 
PBS. The epidermal sheet was placed into a 15 mL Falcon tube (BD Biosciences) containing 
1 mL of 0.25% w/v trypsin with 1mM ethylene diamine tetra acetic acid (EDTA) (Invitrogen) 
and pipetted vigorously for 3 minutes. 1 mL of 10% v/v FBS (Bovogen Biologicals) in PBS 
and 5 mL of PBS were added and mixed gently by gentle inversion. Most of the skin chunks 
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were removed, and the tube was spun at 200 g for 3 minutes and supernatant discarded. The 
pellet was resuspended in 5 mL of keratinocyte serum-free media (KC-SFM) (Invitrogen) 
supplemented with 5 µg/mL epidermal growth factor (EGF) (Invitrogen), 50 µg bovine 
pituitary extract per mL (BPE) (Invitrogen), 0.1% v/v penicillin/streptomycin (Invitrogen) 
and 1 µg/mL gentamycin (Pfizer). The resuspended HEKs was seeded in a 25 cm
2 
tissue 
culture flask (Corning Life Sciences) and maintained in culture for five to seven days at 
37°C, 5% carbon dioxide (CO2) until the keratinocyes approached 70% confluence and ready 
to be serially passed.  
 
2.2.5 Serial cultivation of human epidermal keratinocytes 
Culturing of human epidermal keratinocytes was carried out as per Section 2.2.2 serial 
cultivation of mouse epidermal keratinocytes. The cell pellet was resuspended in KC-SFM 
media. HEKs were used at different seeding densities described in the relevant materials and 
method section for the downstream experiments. HEKs were passaged at a maximum of four 
times. 
 
2.2.6 Serial cultivation of squamous cell carcinoma (SCC) cell lines 
Several different SCC cell lines were described in the thesis. SCC25 and Detroit562 cell lines 
were obtained from ATCC (ATCC, Cryosite, South Granville, Australia). SCC9, SCC15, 
Cal27, Colo16 and FaDu cell lines were a kind gift from the laboratory of Dr Elizabeth 
Musgrove (Garvan Institute, Sydney, Australia). Short tandem repeats (STR) Genotyping was 
carried out on SCC9, SCC15, Cal27, Colo16 and FaDu cell lines to confirm the genetic 
make-up of these cells. All cells lines were maintained in mycoplasma free conditions and 
routinely tested fro mycoplasma contamination. SCC cells were maintained in SCC media 
(Appendix I) and incubated at 37°C, 5% CO2. Cells were passaged by dissociation as for 
serial cultivation of human epidermal keratinocytes (Section 2.2.5).   
 
2.2.7 Generation of stable cell lines 
In order to generate stable shRNA-expressing SCC cell line (SCC25), SCC cells were 
transfected using Lipofectamine 2000 Transfection Reagent (Invitrogen) as per Section 2.5.2 
SCC cell line transfection. Cells were incubated overnight at 37°C/5% CO2 post transfection 
and the following day cells were trypsinised as per Section 2.2.6 Serial cultivation of 
squamous cell carcinoma cells and plated at a 1:10 dilution into fresh SCC media. Cells were 
allowed to grow overnight and then selection was commenced using 200 µg/mL geneticin 
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selective antibiotic (G418 sulfate) (Gibco), an analog of neomycin sulphate, since shRNA 
plasmids encodes neomycin selection. SCC media supplemented with neomycin were 
replaced every two to three days. Cells were continued to grow under selection for 21 days. 
 
2.2.8 Cryopreservation of cells 
HEKs, MEKs and SCC cell lines were stored in freeze-down media containing specific 
growth media supplemented with 20% FBS (Bovogen Biologicals) and 10% v/v DMSO 
(Sigma Aldrich) in a 1 mL Cryo Vial (Greiner BioOne). A cooling rate of 1°C/minute was 
achieved by using a 5100 Cryo 1° Freezing Container (Nalgene) for minimum of four hours. 
Following this, the cells were transferred to liquid nitrogen for long term storage. To bring 
and repassage cells, the vial was quickly thawed at 37°C and transferred into warmed specific 
media. Following centrifugation (200 g for two minutes), the cell pellet was resuspended in 
media and transferred to a tissue culture vessel.    
 
2.3 Adenovirus protocols 
2.3.1 Pre-packaged adenoviruses 
The following pre-packaged, replication-deficient (E1 and E3 region deleted), human 
serotype 5 adenovirus (Ad) supernatants were obtained from Vector Biolabs (Vector Biolabs, 
Philadelphia, PA, USA): Ad-Cre-GFP which expresses both Cre recombinase and green 
fluorescent protein (GFP) as marker which are driven by two separate promoters, Ad-GFP 
which expresses enhanced GFP (eGFP)  transgene under the control of a CMV promoter and 
Ad-CMV-Null which does not contain any transgene and only carries an empty CMV 
promoter. Viral supernatants were supplied at a titer of 1x10
10
 PFU/mL in a storage buffer 
Dulbecco’s Modified Eagle Medium (DMEM) with 2% bovine serum albumin (BSA), 2.5% 
Glycerol, and upon receipt the supernatants were aliquoted and stored at -80°C.  
 
2.3.2 Adenovirus infection of mouse epidermal keratinocytes 
To infect the isolated MEKs with adenoviruses, 5000 cells/cm
2
 cells were plated in tissue 
culture vessels and grown overnight to be about 50% confluent the next day. The following 
day, the virus supernatant was thawed on ice and a specific multiplicity of Infection (MOI) of 
virus was prepared. MOI refers to the number of virions that are added per cell during 
infection. To figure out the amount of virus needed to add for a certain MOI, the following 
formulas were used: 
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number of cells X desired MOI = total PFU (Plaque Forming Units) 
(total PFU needed) / (PFU/mL) = total mL of virus needed to reach desired dose 
 
Fluorescent images of Ad-GFP infected keratinocytes were visualised on a Widefield 
Fluorescence microscope, using the Zen Software (Carl Zeiss, North Ryde, Australia). The 
required number of virus supernatant was freshly prepared in 150 µL/cm
2
 using the same 
media that the cells are grown in at a various MOI of virus. The media was aspirated and the 
infection media containing virus particles was added to cells. Specific MOI of virus is 
described in the relevant result section, and ranged from MOI of 10 to MOI of 2500. After 
around 16 hours of incubation with virus supernatant at 37ºC/5% CO2, the media was 
replaced with fresh media. Cells were then cultured and harvested after 2 days for analysis 
and/or further treatments.   
   
2.4 General tissue culture methods 
2.4.1 In vitro UVB exposure  
Cells were seeded into a 96-well plate in triplicate at a density of 5000 cells per well and 
allowed to adhere overnight. The following day, media was removed from each well and cells 
were washed once with warmed PBS. Excess PBS was aspirated and 40 µL of warmed PBS 
was added to each well. Cells were exposed to varying doses of UVB radiation (home-made 
irradiator) at various J/cm
2 
delivered as a single exposure while the plate lid removed for the 
indicated doses. UV panel is equipped with two Phillips UVB bulbs (Fisher Biotec, 
Wembley, Australia), which are TL 20W/01RS UV-B Medical bulbs and have the only 
output in the UVB range (280-320 nm). Immediately after UVB exposure, PBS was aspirated 
and 100µL warmed growth media was added to each well. Cells were then cultured further 
24 hours before determining the cell viability.   
 
2.4.2 In vitro drug treatments 
Cells were seeded into a 96-well plate in triplicate at a density of 5000 cells per well and 
allowed to adhere overnight. The following day, cells were treated with doxorubicin (Sigma 
Aldrich), epirubicin (Sigma Aldrich), etoposide (Sigma Aldrich), cisplatin (InterPharma, 
Australia), ZVAD-fmk (Alexis Biochemicals, Sapphire Bioscience, Waterloo, Australia), 
Sphingosine kinase 1 inhibitor (SK1-I) (BML-EI411) (Enzo Life Sciences, Sapphire 
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Bioscience), Sphingosine-1-phosphate (S1P) (Cayman Chemicals, Sapphire Bioscience) and 
BGT226 (Novartis, Basel, Switzerland) at various concentrations delivered as a continuous 
exposure. SK1-I was solubilised in sterile water for in vitro and in vivo experiments. S1P was 
dissolved in 0.3 M NaOH for in vitro experiments. Stocks of BGT226 were prepared in N-
methyl-2-pyrrolidone (NMP) (Fluka Analytical, Sigma Aldrich, Castle Hill, Australia). All 
drugs were diluted in growth media to the indicated doses, and cells were subjected to 
drug/inhibitors for the duration of two days before determining the cell viability. In co-
treatment assay, ZVAD-fmk was added 30 minutes before other treatment.  
 
2.4.3 Colony forming efficiency assay 
For colony forming efficiency (CFE) assay cells were dissociated by trypsinisation and 
counted using a haemocytometer (Bright-line). Known number of cells, typically, ranging 
from 100 to 30 000 per well were seeded into a 6-well tissue culture plates and allowed to 
grow for 10 to 15 days or until colonies formed. Then, media was removed and cells were 
fixed and stained with 0.1% w/v Coomassie Blue (MP Biomedicals, Seven Hills, Australia), 
40% methanol, 10% acetic acid solution. Plates were incubated at room temperature for 30 to 
60 minutes. Cells were then destained with a 40% methanol and 10% acetic acid solution and 
rinsed with water and air-dried. Colonies were counted and CFE was expressed as the total 
number of colonies / total number of cells plated x 100.  
 
2.4.4 DNA synthesis 
A colorimetric enzyme linked immunosorbet assay (ELISA) (Roche Diagnostics) was used to 
determine the DNA synthesis by measuring incorporation of the thymidine analogue 5-
bromo-2-deoxyuridine (BrdU) in accordance with the manufacturers’ instructions. All 
reagents in this section are provided with the ELISA Kit unless otherwise indicated. The 
assay was performed with a density of 5000 cells per well in a 96-well plate in triplicate 
following cells to adhere overnight. The colorimetric reaction was stopped by adding 25 µL 
of a 1 M sulphuric acid solution to each well. The absorbance was read first at 490 nm as a 
reference reading and then at 405 nm on a Multiskan FC Microplate Photometer (Thermo 
Scientific) after 30 seconds of mixing. BrdU incorporation was calculated by subtracting the 
reference value from the absorbance value. The background absorbance (no BrdU) and a 
media only control absorbance were also determined, and the background absorbance was 
subtracted from each absorbance value.  
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2.4.5 Cell viability 
2.4.5.1 Proliferation assay 
The effect of infection with virus, UVB exposure and drugs or specific inhibitor treatments 
on cell viability was determined using the Cell Titer 96 Aquous One Solution Cell 
Proliferation assay (Promega, Alexandria, Australia) in accordance with the manufacturers’ 
instructions. The assay was performed with a density of 5000 cells per well in a 96-well plate 
in triplicate in a final volume of 100 µL. When cell viability was to be determined, cells were 
incubated with 20 µL of the reagent in the dark at 37°C/5% CO2 for 2 hours prior to 
absorbance reading at 490 nm using the MultiSkan FC Microplate Photometer (Thermo 
Scientific). The background absorbance was determined from a media only control and 
subtracted from each absorbance value.    
 
2.4.5.2 Trypan blue exclusion 
Cell viability was determined using Trypan Blue Solution, 0.4% (Gibco) and expressed as 
number of viable cell counts relative to initial plating counts or normalised to untreated cells. 
Cells were seeded and allowed to adhere overnight. The following day, cells were subjected 
to specific treatments. When cell viability was to be determined, 100 µL of 0.4% Trypan 
Blue solution was added to 1 mL of cell suspension. Cells were counted using a 
haemocytometer, and the number of blue stained and the number of total cells was 
determined. The number of viable cells per mL was expressed as the number of viable cells x 
10
4
 x 1.1. 
 
2.4.6 Sphingosine kinase activity assay 
Sphingosine kinase (Sphk1) activity was measured using an absorbance assay (Echelon 
Biosciences, Sapphire Bioscience, Waterloo, Australia) in accordance with the 
manufacturer’s instructions. All reagents in this section are provided with the Sphingosine 
Kinase Activity Assay Kit unless otherwise indicated. Total protein was extracted from 
cultured cells in which sphingosine activity was to be determined by lysis in radio 
immunoprecipitation assay buffer (RIPA buffer) (Appendix I). The sample reaction was 
consisted of 10 µL of sphingosine, 20 µL ATP and 10 µL of samples. ATP standards were 
consisted of 5 µL sample buffer, 5 µL complete reaction buffer, 10 µL sphingosine and 20 
µL ATP standard dilution. 2-fold series ATP standards ranging from 0-10 µM were prepared.  
The assay was performed in a 96-well plate supplied in duplicate, and the reaction was 
incubated at room temperature for two hours prior to luminescence reading using FLUOstar 
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OPTIMA microplate reader (BMG LABTECH, Mornington, Australia). Sample buffer was 
included as a buffer only background control and the background absorbance was subtracted 
from each absorbance value. Sphk1 concentration was estimated using Graph Pad Prism v6 
(Graph Pad Software, LA Jolla, USA). The linear regression function in Graph Pad Prism 
was used to generate a standard curve from the absorbance reading obtained from the 
standards. The standard curve was used to extrapolate relative sample values.    
 
2.4.7 Sphingosine-1-phosphate assay 
Quantification of sphingosine-1-phosphate was conducted using a Sphingosine-1-Phosphate 
(S1P) ELISA Kit (Echelon Biosciences, Sapphire Bioscience, Waterloo, Australia) in cell 
culture lysate in accordance with the manufacturer’s instructions. All reagents in this section 
are provided with the Sphingosine-1-Phosphate Assay Kit unless otherwise indicated. Cell 
culture lysate was prepared as per manufacturers’ instructions. Briefly, cells in which S1P 
levels to be determined were lysed in RIPA buffer. Protein concentration was measured using 
the Bradford protein assay as per Section 2.7.2 Protein Quantification. Cell lysate was diluted 
in 1:10 in delipidised human sera and analysed. The assay was performed in a 96-well 
microtiter plate supplied in duplicate and absorbance at 450 nm was then calculated using the 
MultiSkan FC Microplate Photometer (Thermo Scientific). Diluted streptavidin HRP solution 
only was included as the blank control and the absorbance was subtracted from each 
absorbance value. S1P concentration was estimated using Graph Pad Prism v6 (Graph Pad 
Software, LA Jolla, USA). A best fit curve for the standards was generated using non-linear 
regression analysis with Graph Pad Prism Software. The standard curve was used to 
extrapolate relative sample values, using the absorbance reading obtained. A dilution factor 
of 10 was included in the calculated protein concentration of S1P.  
 
2.4.8 RhoA/Rac1/Cdc42 Activation Assays 
Rho family activation was monitored using a RhoA/Rac1/Cdc42 Activation Assay Combo 
Biochem Kit (Cytoskeleton, Jomar Bioscience, Kensington, Australia) in whole cell lysate in 
accordance with the manufacturer’s instructions. All reagents in this section are provided 
with the RhoA/Rac1/Cdc42 Activation Assay Combo Biochem Kit unless otherwise 
indicated. Cells were not serum-starved or treated with Rho family activators prior to the 
assay. 300 µg total cell protein was added to a 50 µg of rhotekin-RBD (RhoA activation) or 
10 µg of PAK-PBD (Rac1 and Cdc42 activation) per assay and analysed by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) through a 12% SDS-PAGE gel. 
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Samples of 25 µg of total cell lysate per sample were also separated with SDS-PAGE through 
a 12% SDS-PAGE gel to detect total RhoA and Rac1. The amount of activated and total 
RhoA and Rac1 were determined by an immunoblot analysis as per Section 2.7.4 Immunoblot 
analysis using a RhoA and Rac1 specific antibodies. The RhoA and Rac1 antibodies were 
incubated with the PVDF membrane at 4°C overnight.  
 
2.5 Transfection 
2.5.1 Mouse primary keratinocytes 
Primary keratinocytes were transfected using Mirus Keratinocyte Transfection Reagent 
(Mirus, Geneworks, Adelaide, Australia) according to the manufacturers’ guidelines. Briefly, 
2.5 x 10
4
/cm
2 
cells were plated in a 6-well plate and grown overnight. The following day, 
cells were washed twice with PBS and the media was replaced with minimal KC-SFM 
medium (Invitrogen) containing no antibiotics, EGF or BPE. A 2.5 µg aliquot of plasmid 
DNA was diluted in 100 µL of Optimem Serum-Free Medium (Invitrogen). Then, 7.5 µL of 
Mirus Keratinocyte Transfection Reagent was added to the diluted plasmid DNA and the 
plasmid/tranfection reagent complex was incubated at room temperature for 15 minutes. Post 
incubation, the complex was added to the cells by dropwise fashion and gently rocking. The 
cells were washed twice with PBS following five to six hours transfection and the media was 
replaced with KC-SFM. Cells expressing the plasmid DNA were then analysed for 
expression 48 hours post transfection.    
 
2.5.2 SCC cell line 
SCC cell lines were transfected with expression plasmids and expression plasmids coding for 
four different shRNAs directed against Sphk1 and RacGAP1. Myc-DDK-tagged ORF clone 
of Sphk1 and Myc-DDK-tagged ORF clone of RacGAP1 plasmids were purchased from 
OriGene Technologies (Australian Biosearch, Karrinyup, Australia). The DDK epitope is 
also known as Flag tag epitope. Sphk1 and RacGAP1 shRNAs as well as control shRNA 
which does not contain any transgene were purchased from SuperArray Bioscience (SA 
Biosciences, Qiagen, Chadstone Centre, Australia). SCC cells were transfected using 
Lipofectamine 2000 Transfection Reagent (Invitrogen) according to the manufacturers’ 
guidelines. Briefly, 2 x 10
4
/cm
2 
cells were plated in a 6-well plate and grown overnight. The 
following day, cells were washed twice with PBS and the media was replaced with Optimem 
Serum-Free Medium (Invitrogen). An aliquot of 1.3 µg aliquot of plasmid DNA was diluted 
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in 250 µL of Optimem media (Invitrogen). 3.9 µL of Lipofectamine 2000 (Invitrogen) was 
diluted in 250 µL of Optimem media and incubated for five minutes. The diluted plasmid 
DNA and the diluted tranfection reagent complex were combined and incubated at room 
temperature for 20 minutes. Post incubation, the siRNA/Lipofectamine 2000 complex was 
added to the cells by dropwise fashion and gentle rocking. The cells were washed twice with 
PBS following five to six hours transfection and the media was replaced with SCC media. 
Cells expressing the plasmid DNA were then analysed for expression 48 hours post 
transfection.    
  
SCC cell lines were also transfected with siRNAs which the sequences are described in Table 
2.1. E2F7 siRNA and control siRNA directed against GFP and show no homology to other 
known genes were purchased from Sigma Aldrich. The E2F7 siRNA sequence was 
previously published (Panagiotis Zalmas, Zhao et al. 2008). Single stranded siRNAs were re-
constituted into solution using UltraPure DEPC-treated water (Ambion, Life Technologies) to 
a concentration of 100 µM upon receipt. An equal volume of sense and antisense strands 
were added to a 1.5 mL tube (Eppendorf) and heated at 99°C in a heating block (Eppendorf) 
for 10 minutes. Duplexed siRNAs were then left to cool down to room temperature for 30 
minutes. For siRNA transfection, SCC cells were transfected using Lipofectamine 2000 
Transfection Reagent (Invitrogen) according to the manufacturers’ guidelines. Briefly, 2 x 
10
4
/cm
2 
cells were plated in a 6-well plate and grown overnight. The following day, cells 
were washed twice with PBS and the media was replaced with Optimem Serum-Free 
Medium (Invitrogen). siRNAs (pmol) were diluted in 100 µL Optimem media (Invitrogen) to 
obtain a final concentration of 40 nM in the tissue culture vessel. 5 µL of Lipofectamine 2000 
(Invitrogen) was diluted in 250 µL of Optimem and incubated for five minutes. The diluted 
siRNA and the diluted tranfection reagent complex were combined and incubated at room 
temperature for 20 minutes. Post incubation, the siRNA/Lipofectamine 2000 complex was 
added to the cells by dropwise fashion and gentle rocking. The cells were washed twice with 
PBS following five to six hours transfection and the media was replaced with SCC media. 
Cells were then analysed for gene knockdown 48 hours post transfection.     
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Table 2.1 Sequences of siRNAs used in this study. siGFP was used as a non-specific 
siRNA control. Reference indicates the source of siRNa sequences were not designed by the 
author. 
Gene Sense 5'-3' Antisense 5'-3' Reference 
E2F7 siRNA_1 AAAGGUACGACGCCUCUAUGA UCAUAGAGGCGUCGUACCUUU (Panagiotis Zalmas, Zhao 
et al. 2008) 
E2F7 siRNA_2 AACAGAAGAGCGAGGUCGUAA UUACGACCUCGCUCUUCUGUU (Panagiotis Zalmas, Zhao 
et al. 2008) 
siGFP GCACGACUUCUUCAAGUCCUU AAGGACUUGAAGAAGUCGUGC  
 
2.6 Expression analysis 
2.6.1 RNA isolation 
Total RNA was isolated from cultured cells, using TRIzol Reagent (Invitrogen). Cells grown 
in tissue culture vessel were detached using 0.25% trypsin+EDTA as per Section 2.2.5 and 
Section 2.2.6 Serial cultivation of HEKs and SCC cell lines and pelleted by centrifugation. 
The cell pellet was then resuspended in 1 mL TRIzol reagent (Invitrogen) by pipetting up and 
down several times. Where cells were cultured in a 6-well plate for some experiments, 
TRIzol reagent was directly added to the cells after removing the media and washing the cells 
twice with PBS. Cells were then harvested by scraping and collected. Up to 3 x 10
6 
cells were 
lysed in 1 mL TRIzol. The TRIzol/cell mixture was lysed for 5 minutes at room temperature. 
200 µL chloroform was added and samples were mixed vigorously by hand followed by three 
minutes incubation at room temperature and centrifugation at 12 000 g at 4°C for 15 minutes. 
The aqueous layer containing the RNA was then removed and transferred to a fresh tube, and 
an equal volume of isopropanol (500 µL) was added to and mixed well, followed by a 10 
minutes incubation at room temperature. The samples were then centrifuged at 12 000 g for 
10 minutes. The RNA pellet was washed with 1 mL of 75% ethanol, followed by 
centrifugation at 7500 g for 5 minutes. The pellet was allowed to air dry completely at room 
temperature for approximately 10 minutes. The pellet was then resuspended in UltraPure 
DEPC-treated water (Ambion, Life Technologies) and the concentration was assessed using a 
NanoDrop 1000 spectrophotometer (Thermo Scientific). The RNA was stored at -80°C for 
future use. 
 
2.6.2 cDNA synthesis 
For complementary single stranded DNA (cDNA) synthesis, 2 µg total RNA was incubated 
with 0.5 µg oligo DT12-18 primer (Invitrogen) in a total volume of 12 µL at 70° for 5 minutes. 
The sample was then cooled down on ice. 4 µL of 10 mM dNTP mix (Finnzymes, 
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Genesearch, Arundel, Australia), 1X reaction buffer (Bioline), 0.25 µL (50units) of BioScript 
Reverse Transcriptase (BioLine) and 2.75 µL fo H2O were added to the sample and the 
reaction was incubated at 42°C for 1 hour. It was followed by an incubation step at 70°C for 
10 minutes to stop the reaction. The cDNA was stored at -20°C for future use.  
 
2.6.3 Quantitative real time (qRT) PCR analysis 
Quantification of PCR products was evaluated in duplicate using a Rotorgene 6000 Thermal 
Cycler (Corbett Life Sciences, Qiagen, Doncaster, Australia). The relative quantification of 
the gene of interest was determined using the standard curve method. Serial dilutions of a 
control cDNA to generate the standard curve were prepared in UltraPure DEPC-treated water 
(Ambion, Life Technologies). The dilutions were 1/10, 1/100, 1/1000, 1/10000, 1/100000 and 
undiluted control cDNA was included in the standard curve. A 20 µL reaction containing 10 
µL of Sensifast SYBR Mix (BioLine), 200 nM each of forward and reverse primers and 2 µL 
of a 1:10 dilution of cDNA or standard curve dilutions was subjected to PCR cycling for each 
gene to be analysed. Primers were designed to span exon-exon boundaries and to produce an 
amplicon with length between 75 and 150 nucleotides. Primers were ordered from 
Geneworks (Geneworks, Adelaide, Australia) or Integrated DNA Technologies (IDT, Skokie, 
USA). The SYBR Rotorgene profile was 95°C for 2 minutes, 40 cycles of 95°C for 5 
seconds, 60°C for 10 seconds and 72°C for 10 seconds, followed by a melt curve analysis 
where the total RNA product was subjected to temperature ranging from 62°C to 95°C. Data 
was analysed using Rotorgene Software Version 1.7 (Corbett Life Sciences). TATA box 
binding protein (TBP) for human and β-actin for murine samples were used as the 
housekeeping gene for the normalization of results to determine relative quantitation of the 
gene of interest. Table 2.2 details the sequence of primers used for qRT PCR.   
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Table 2.2 Sequence of primers used for genotyping, quantitative real time and 
chromatin immunoprecipitation PCR analysis. 
Gene Forward Primer Reverse Primer 
Genotyping   
E2f1 (Mix A) TCCAAGAATCATATCCAGTGGCT GCTGGAATGGTGTCAGCACAGCG 
E2f1 (Mix B) CTACCCGGTAGAATTGACCTGCA GCTGGAATGGTGTCAGCACAGCG 
E2f7 AGGCAGCACACTTGACACG ACTTTTGGGACAGAGGTAGGA 
  CCAAGATGAAGGCCGAGATGCTAC 
E2f8 TAAAAAGCTTTGCGGTCGTT AAGCCAACCTCGATGAATTG 
  CTCGCATCATCGTCTGCTAA 
Quantitative RT-PCR   
Actin GCTACAGCTTCACCACCACA TCTCCAGGGAGGAAGAGGAT 
CD44 AGCAACTGAGACAGCAACCA AGACGTACCAGCCATTTGTGT 
E2f1  GCCCTTGACTATCACTTTGGTCTC CCTTCCCATTTTGGTCTGCTC 
E2f7  GCCAAGCAGGAAACAGAAGA ACCGTGCCAACCATACTGAT 
E2f8  GAGAAATCCCAGCCGAGTC CATAAATCCGCCGACGTT 
E2F1 TGCAGAGCAGATGGTTATGG CTCAGGGCACAGGAAAACAT 
E2F7  GTCAGCCCTCACTAAACCTAAG TGCGTTGGATGCTCTTGG 
E2F8 GTGGATTACCTGAGGCCAAA CTTCGTCAAGGCAGATGTCA 
RACGAP1 GACGTTGAATAGGATGAGTCATGG GCTCAAACAGATTCCGCACA 
RRP8 TACTGAAGCCAGGGGGTCTC AATGGCTGTTGGTCAGGTCC 
SPHK1 AAGACCTCCTGACCAACTGC GGCTGAGCACAGAGAAGAGG 
TBP TCAAACCCAGAATTGTTCTCCTTAT CCTGAATCCCTTTAGAATAGGGTAGA 
Quantitative ChIP-PCR   
E2F1-promoter AGGAACCGCCGCCGTTGTTCCCGT GTTGACAGAAGAGAAAAGC 
RACGAP1-promoter GAAGTGAGTAGTGGGGGTGC TCCATCTTTCACACGAACACTCT 
SPHK1-promoter GGGACCCTTGGTTTCACCTC GAATTTCGGGTGGGCTAGGG 
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2.6.4 Immunohistochemistry 
Tissue samples were fixed in 4% formaldehyde (Histopot, Australian Biostain) for 24 hours 
and then transferred in 100% ethanol for storage. The fixed tissue was embedded in paraffin 
and sectioned to 5 µm thickness and mounted on Super Frost Plus slides (Menzel-Glaser, HD 
Scientific Supplies, Willawong, Australia) by Ms Crystal Chang (University of Queensland 
Diamantina Institute Histology Facility). Tissue sections were first incubated at 60ºC for one 
hour followed by dewaxing the sections with 100% xylene (Point of Care Diagnostics, 
Artarmon, Australia) 10 minutes. The sections were then rehydrated in 100% ethanol, 95% 
ethanol, 75% ethanol, distilled water for 10 minutes each wash. The antigen retrieval was 
carried out by heat activation method with 10 mM sodium citrate solution (pH 6.0) 
supplemented with 0.05% v/v Tween 20. For antigen retrieval, sections were microwaved in 
sodium citrate solution for 5 minutes and then left to cool down. This was repeated and then 
sections were cooled down under the running tap water for approximately 6 minutes. The 
sections were washed twice with PBS for 2 minutes, permeabilised of the sections with 
0.01% v/v Triton X-100 diluted in PBS for 10 minutes and washed twice with PBS for 5 
minutes.  
 
Around the tissue was drawn by a hydrophobic pen (DAKO, Botany, Australia). The tissue 
was then blocked with 10% BSA in PBS (blocking buffer) for one hour, followed by 
overnight incubation with the primary antibody diluted in blocking buffer in a humidified 
chamber at 4ºC. The list of primary antibodies used for immunohistochemistry is summarised 
in Table 2.3. The tissue was also incubated overnight at 4ºC with rabbit IgG serving as a 
negative control, after diluting rabbit IgG at the same concentration as the primary antibody. 
The following day, the primary antibody was removed and the sections were washed twice 
with PBS for 5 minutes. The sections were incubated with 0.3% v/v solution of hydrogen 
peroxide (Sigma Aldrich) in PBS for 10 minutes to block endogenous peroxidase, followed 
by washes twice with PBS for 5 minutes. A commercially available secondary antibody Kit, 
Starr Trek Universal Horseradish Peroxidase (HRP) Detection System (Biocare Medical, 
Applied medical, Stafford, Australia) secondary antibody Kit or directly conjugated 
secondary antibody was used on order to develop the immunohistochemistry staining. Where 
the Starr Trek system was used, the universal linker antibody was applied to the section for 
20 minutes at room temperature in a humidified chamber. The section was then washed twice 
with PBS and a streptavidin-HRP solution was applied to the section and incubated for 15 
minutes at room temperature in a humidified chamber. The section was then washed twice 
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with PBS. Where a directly conjugated secondary antibody was used, the section was 
incubated with the F(ab’)2 fragment of goat anti-rabbit IgG (H+L) HRP conjugate antibody 
(Invitrogen) for one hour at room temperature in a humidified chamber after diluting it at a 
half concentration of the primary antibody used. Cardassian DAB Chromogen (3,3’ 
diaminobenzidine) (Biocare Medical) was then diluted according to the manufacturer’s 
instructions and applied to the tissue section until a brown colour had developed. The slides 
were washed thoroughly in distilled water, followed by a 25 second incubation in filtered 
acid haematoxylin (Sigma Aldrich). The slides were washed thoroughly in tap water. The 
slide was then dehydrated through distilled water, 75%, 95%, 100% alcohol and 100% xylene 
for 2 minutes each. A 22 mm coverslip (ProSciTech) was mounted on the tissue section using 
DPX Neutral Mounting Medium (Ajax Fine Chemicals, Thermo Scientific, Scoresby, 
Australia). The section was left to dry at room temperature, visualized and imaged on a 
Nikon Eclipse 50i light microscope, using the NIS-Elements BR software  (version 3.2) 
(Nikon).  
 
2.6.5 Immunofluorescence: paraffin embedded sections 
Paraffin embedded tissue sections were de-waxed as per Section 2.6.4 Immunohistochemistry. 
The sections were de-waxed by two washes with 100% xylene 10 minutes each. The sections 
were then rehydrated in two washes of 100% ethanol for 5 minutes, 90% ethanol for 1 
minute, 80% ethanol for 1 minute, 70% ethanol for 1 minute, 50% ethanol for 1 minute, 30% 
ethanol for 1 minute and distilled water for 5 minutes. The antigen retrieval was carried out 
as per Section 2.6.4 Immunohistochemistry, with an exception of a cooling step in PBS for 20 
minutes. The sections were washed twice with PBS for 5 minutes and blocked in 1% BSA 
diluted in PBS and supplemented with 4% horse serum (Gibco) (blocking buffer) for 30 
minutes at room temperature in a humidified chamber. Excess solution was then removed and 
the sections were incubated with the primary antibody diluted in blocking buffer and 
supplemented with 0.1% Triton X-100 for one hour at room temperature in a humidified 
chamber. The list of primary antibodies used for immunofluorescence is summarised in Table 
2.3. The primary antibody was removed and the sections were washed with blocking buffer 
for 5 minutes, followed by a 5 minutes wash with 1% BSA diluted in PBS. The sections were 
then incubated with the secondary antibody for one hour at room temperature in a humidified 
chamber. The secondary antibody used was AlexaFluor conjugated antibody and used at a 
1:1000 concentration in blocking buffer. Table 2.3 details the secondary antibody used for 
immunofluorescence. The sections were washed four times with blocking buffer. The slides 
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were dipped briefly in distilled water and a 22 mm coverslip (ProSciTech) was mounted on 
the tissue section with VectaShield, a hard setting aqueous mounting medium containing the 
DNA stain 4',6-diamidino-2-phenylindole (DAPI) (Vector Labs, Abacus ALS, East Brisbane, 
Australia). The slides were left to dry for 30 minutes at 37⁰C. Immunofluorescent images 
were visualised and imaged on the Zeiss 510 Meta Confocal Microscope, using the 
AxioVision software (Carl Zeiss). 
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Table 2.3 Antibodies used for immunohistochemistry and immunofluorescence. IgG was 
used as a negative control at the same concentration as the corresponding primary antibody. α 
is ‘anti’.  
Antigen Species Antibody Dilution 
Immunohistochemistry    
Anti-Keratin 10 Rabbit Sigma Aldrich SAB4501656 1:200 
Anti-Proliferating Cell Nuclear 
Antigen  
Mouse Sigma Aldrich P8825 1:3000 
Anti-RACGAP1 [EPR9018] Rabbit Abcam ab134972 1:100 
Anti-RACGAP1 [EPR9018] 
(TMA) 
Rabbit Abcam ab134972 1:100 
Anti-Sphk1 (TMA) Rabbit Sigma Aldrich HPA022829 1:75 
Cleaved Caspase-3 (Asp175) Rabbit Cell Signaling #9661 1:50 
cytokeratin 1 Rabbit Abcam ab24643 1:500 
cytokeratin 5 Rabbit Abcam ab53121 1:2000 
cytokeratin 14 Rabbit Abcam ab53115 1:50 
E2F7 (TMA) Rabbit Abcam ab56022 1:250 
IgG Rabbit Cell Signaling #2729 Same as corresponding 
primary antibody 
Involucrin Rabbit Abcam ab28057 1:100 
Phospho-Akt (Ser473) (D9E) 
XP 
Rabbit Cell Signaling #4060 1:50 
    
Immunofluorescence    
Anti-Keratin 10 Rabbit Sigma Aldrich SAB4501656 1:200 
cytokeratin 5 Rabbit Abcam ab53121 1:200 
IgG Rabbit Cell Signaling #2729 Same as corresponding 
primary antibody 
Involucrin Rabbit Abcam ab28057 1:100 
α Rabbit AlexaFluor 488 Goat Molecular Probes #A11011 1:1000 
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2.7 Protein methods 
2.7.1 Protein extraction 
Total protein was extracted from cultured cells by lysis using RIPA buffer or 1x sample 
buffer supplemented with 1% v/v protease inhibitor cocktail (Sigma Aldrich). Cells grown to 
the desired confluency were washed twice with ice cold PBS and the PBS was aspirated 
completely. RIPA buffer or 1x sample buffer was then added to the culture vessel and 
cells/lysis buffer mix was collected by scraping all the cells from the surface of the culture 
vessel using a cell scraper (Grenier Bio One). Where protein extracted in RIPA buffer, the 
sample/lysis buffer mix was incubated on a rotating wheel at 4°C for 15 minutes, followed by 
a centrifugation at 15 000 g for 5 minutes. Post centrifugation, the supernatant representing 
total proteins was transferred into a new tube. Where protein extracted in 1x sample buffer, 
the sample/lysis buffer mix was sonicated for 4 seconds at amplitude of 50 with a 3 mm 
sonicator probe using a Sonic Materials Vibra Cell sonicator (Sonics and Materials). The total 
protein was stored at -80°C if not used immediately. 
 
2.7.2 Protein quantification 
Protein extracted using 1x sample buffer did not undergo protein estimation, rather protein 
extracted in RIPA buffer was subjected to protein estimation. The protein concentration 
estimation was carried out using the Bradford protein assay solution (BioRad, Gladesville, 
Australia). The standard curve was used to extrapolate relative sample values and was 
generated using serial dilutions of bovine serum albumin (BSA) (Sigma Aldrich). Briefly, to 
make the standard, BSA stock at a concentration of 10 µg/µL was diluted to 0.1 µg/µL in 
distilled water. A volume of diluted BSA and 5 µL of RIPA buffer were added to a final 
volume of 800 µL in distilled water. The concentrations of diluted BSA used for the standard 
curve were, 0 µg/mL (no protein control), 1 µg/mL, 2 µg/mL, 3 µg/mL, 5 µg/mL, 7 µg/mL, 
10 µg/mL, 15 µg/mL. 200 µL of Bradford protein assay solution was then added to each 
protein standard and mixed by inversion. For the samples for which protein concentration 
was to be estimated, 5 µL of each sample was diluted in 795 µL of distilled water. 200 µL of 
Bradford protein assay solution was then added to each protein standard and mixed by 
inversion. 200 µL of prepared protein standard or protein sample was transferred into a 96-
well plate (Corning) in triplicate. The protein reading was then taken at 595 nm using the 
MultiSkan FC Microplate Photometer (Thermo Scientific).  
 
52 
 
The protein concentration was estimated using Graph Pad Prism v6 (Graph Pad Software, LA 
Jolla, USA). The linear regression function in Graph Pad Prism was used to generate a 
standard curve from the absorbance reading obtained from the standards. The standard curve 
was used to extrapolate relative sample values. A dilution factor of 200 was applied to the 
calculated protein concentrations to obtain the concentration of the protein sample in µg/µL.  
 
2.7.3 Polyacrylamide gel electrophoresis 
Protein expression was examined by immunoblot of cell lysates. 20 μg of protein was mixed 
with 4x sample buffer (Appendix I), boiled at 99°C for 5 minutes and centrifuged briefly. 
Protein was separated with SDS-PAGE using the Protean 3 Mini Gel Apparatus (BioRad) 
through a 10-12% SDS-PAGE gel (Appendix I). Acrylamide SDS-PAGE gels were cast 
using 1.5 mm thickness mini gel plates (BioRad). The stacking gel was cast using a 15-well 
1.5 mm thick spacing comb (BioRad). Once the gels had polymerised, the gels were placed 
into the BioRad Protean III mini gel apparatus and submerged in electrophoresis running 
buffer (Appendix I). The protein samples and pre-stained protein marker (New England 
Biolabs, Genesearch, Arundel, Australia) were loaded into the wells of the gel and 
electrophoresed at 100 Volts for approximately 2 hours.  
 
2.7.4 Immunoblot analysis 
The polyvinylidene fluoride (PVDF) membrane (Immobilon FL, Millipore, Kilsyth, 
Australia) was equilibrated by washes in 100% methanol for 15 seconds followed by distilled 
water for 2 minutes and then transfer buffer for 5 minutes. The SDS-PAGE gel was removed 
and equilibrated in cold transfer buffer containing 20% v/v methanol (Appendix I) for 5 
minutes post electrophoresis. The ‘sandwich’ was then assembled into a transfer cassette with 
the gel and PVDF membrane. The protein was transferred from the gel to the PVDF 
membrane using a transfer cassette (BioRad) for 1 hour at 100 Volts in cold transfer buffer 
with an ice pack. The membrane was then removed and washed in TBS-T buffer (Appendix 
I) for 2 minutes post transfer. The membrane was blocked with 5% w/v skim milk powder 
(Diploma, Fonterra Food Services, Mount Waverly, Australia) in TBS-T for one hour at room 
temperature. The primary antibody was diluted at the appropriate concentration in 5% w/v 
skim milk powder in TBS-T and incubated with the PVDF membrane at 4°C overnight. The 
list of primary antibodies used for immunoblotting is summarised in Table 2.4. The following 
day, the PVDF membrane was washed three times with TBS-T for 5 minutes. Following 
rinsing in TBS-T, the membrane was incubated with a horseradish peroxidise (HRP) 
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secondary antibody diluted in 5% w/v skim milk powder in TBS-T at room temperature on a 
rotating platform for 1 hour. The list of secondary antibodies used for immunoblotting is 
summarised in Table 2.4. The PVDF membrane was washed three times with TBS-T for 5 
minutes. Following rinsing, the membrane was incubated for 5 minutes with Super Signal 
West Pico (Pierce, Thermo Scientific) or Super Signal West Femto Chemiluminescent 
Substrate (Pierce) in accordance with the manufacturer’s instructions. An X-Ray film (Kodak 
Australia) was then applied to the membrane and the film was kept until a detectable signal 
was observed. The film was visualised with standard X-Ray developing and fixing techniques 
using Kodak developer and Kodak fixer solutions. The film was then washed in tap water and 
allowed to dry. Where protein loading was visualised by staining with Coomassie Blue (R-
250) (MP Biomedicals), the PVDF membrane was stained in Coomassie Blue solution 
prepared as per Section 2.4.3 for 1 minute, followed by complete destain using a 25% acetic 
acid and 50% methanol solution and washes with TBS-T to rid background. Films or stained 
PVDF membranes were scanned with an Epson 7000 Photo Perfection scanner (Epson, North 
Ryde, Australia). Quantitative analysis of protein concentration was performed using Image J 
(Wayne Rasband, National Institutes of Health, USA) and results represent relative protein 
levels normalised to β-actin.  
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Table 2.4 Antibodies used for immunoblotting. 
Antigen Species Antibody Dilution 
Immunoblotting    
AE1/AE3 Mouse ICN Biomedical #69145 1:1000 
Anti-Cre Rabbit Novagen 69050-3 1:10000 
Anti-Mouse HRP Donkey Molecular Probes #G21040  
Anti-RACGAP1 
[EPR9018] 
Rabbit Abcam ab134972 1:2000 
Anti-Rabbit HRP Donkey GE Healthcare #NA934V 1:500-1:5000 
Anti-Sphk1 Rabbit Sigma Aldrich HPA022829 1:1000 
Akt Rabbit Cell Signaling #9272 1:2000 
cdc2 Rabbit Upstate 06-141 1:1000 
Cleaved Caspase-3  
(Asp 175) 
Rabbit Cell Signaling #9661 1:1000 
E2F1 (C-20) Rabbit Santa Cruz sc-193 1:1000 
E2F7 Rabbit Abcam ab56022 1:1000 
ERK 1 (C-16)  Rabbit Santa Cruz sc-93 1:2000 
Involucrin Rabbit Abcam ab28057 1:1000 
PARP Rabbit Cell Signaling #9542 1:1000 
Phospho-Akt (Ser473) 
(D9E) XP 
Rabbit Cell Signaling #4060 1:2000 
Phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) 
(E10)  
Mouse Cell Signaling #9106 1:2000 
β-actin Rabbit Sigma Aldrich A2228 1:10000 
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2.8 Microarray analysis 
2.8.1 RNA preparation 
RNA which had been isolated using TRIzol reagent (Invitrogen) was further purified using 
the RNAeasy Kit (Qiagen) in accordance with the manufacturer’s instructions. All reagents in 
this section are provided with the RNAeasy Kit (Qiagen) unless otherwise indicated. 10 µg of 
total RNA was purified and eluted in 50 µL sterile nuclease free water. RNA concentration 
was determined using a NanoDrop 1000 spectrophotometer (Thermo Scientific). The RNA 
was stored at -80°C for future use. 
 
2.8.2 RNA quality control 
RNA was analysed for integrity using a 2100 BioAnalyzer (Agilent, Forest Hill, Australia). 
Briefly, to prepare a BioAnalyzer chip, 1 µL of Agilent RNA 6000 Nano dye was added to a 
65 µL aliquot of filtered gel matrix, mixed by vortexing, and the dye/gel matrix mix was 
loaded to the Agilent RNA 6000 Nano chip. 1.2 µL aliquots of RNA were then denatured at 
70°C for 2 minutes in a thermal cycler, along with a 1.5 µL aliquot of RNA ladder (Agilent). 
Samples were then cooled on ice. RNA Nano chip was then prepared according to 
manufacturers’ instructions. 1 µL of each denatured RNA sample and ladder were then 
loaded into wells and the chip was read using the Agilent BioAnalyzer, using the 2100 Expert 
Software Package (Agilent). A RNA Integrity Number (RIN) score which gives information 
about the quality of the RNA was assigned to each sample by this software. Samples with a 
RIN score of greater than 8 were considered suitable for microarray analysis. The integrity of 
cRNA samples (Section 2.8.3 generation of biotinylated amplified cRNA for microarray 
hybridisation) were also assessed via BioAnalyzer prior to microarray hybridisation. Visual 
inspection of BioAnalyzer traces, A260/280 ratios and cRNA concentrations obtained using a 
NanoDrop spectrophotometer (Thermo Scientific) were used to determine whether the RNA 
had amplified appropriately rather than a RIN score for cRNA. High quality cRNA samples 
had A260/280 ratios of 1.9 – 2, and had s size distribution of 250 to 5000 nucleotides with an 
average size of 1200 nucleotides. 
 
2.8.3 Generation of biotinylated amplified cRNA for microarray hybridisation 
RNA samples which had passed quality control by the Agilent BioAnalyzer (RIN score of 8 
or greater) were amplified and biotinylated using the Illumina TotalPrep RNA amplification 
Kit (Illumina, Scoresby, Australia), in accordance with the manufacturer’s instructions. All 
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reagents in this section are provided with the Illumina TotalPrep RNA amplification Kit 
(Illumina) unless otherwise indicated. The RNA analysed was i) untreated, KJDSV40 cells, 
ii) doxorubicin-treated KJDSV40 cells, iii) empty vector transfected, untreated KJDSV40 
cells, iv) empty vector transfected, doxorubicin-treated KJDSV40 cells, v) E2F7 expression 
plasmid transfected, untreated KJDSV40 cells, vi) E2F7 expression plasmid transfected, 
doxorubicin-treated  KJDSV40 cells, vii) untreated, SCC25 cells, viii) doxorubicin-treated 
SCC25 cells, ix) control siRNA transfected, untreated SCC25 cells, x) control siRNA 
transfected, doxorubicin-treated SCC25 cells, xi) E2F7siRNA transfected, untreated SCC25 
cells, xii) E2F7siRNA transfected, doxorubicin-treated SCC25 cells. Three independent 
biological replicates were used for each condition. RNA of biological replicates was pooled 
to account for the minor biological variations expected under standard cell culture conditions. 
A total of 12 samples were run in duplicate. 11 µL of total RNA at 45 ng/µL (a total of 500 
ng) was used for each sample. The biotinylated, amplified and purified cRNA was assessed 
for the integrity using the Agilent 2000 BioAnalyzer and for quantitation using the NanoDrop 
spectrophotometer (Thermo Scientific).  
 
2.8.4 Microarray hybridisation 
The hybridization of biotinylated cRNA to the microarray chip was carried out by Ms Karena 
Pryce (University of Queensland Diamantina Institute Genomics Facility). Microarrays were 
performed using Illumina Human HT-12 Expression BeadChip (Illumina). The BeadChip had 
a capacity for 12 samples; two chips were acquired in this study. Chips were hybridised with 
cRNA using the Human HT-12 v4 Expression BeadChips Kit (Illumina) in accordance with 
the manufacturer’s instructions. All reagents in this section are provided with the RNAeasy 
Kit (Qiagen) unless otherwise indicated. The chips were scanned using an Illumina 
BeadArray Reader (Illumina). BeadStudio 3.2 Software (Illumina) was used for initial data 
visualization and export.   
 
2.8.5 Microarray analysis 
Microarray analysis was performed by Dr Pamela Mukhopadhyay, University of Queensland 
Diamantina Institute Bioinformatics Department. Raw signal intensity was calculated using 
Illumina BeadStudio 3.2 Software. Subsequently data was processed with the R programming 
language with Bioconductor v2.3 (Fred Hutchinson Cancer Centre, Seattle, USA). The 
analysis required two freely available, open source packages ‘lumi’ (Du, Kibbe et al. 2008) 
and ‘limma’ (Smyth 2005). Probe intensities were variance stabilized and normalized using 
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robust spline normalization method with the lumi Bioconductor package. Differential 
expression analysis between each comparison was performed by fitting linear model to 
normalized intensities and statistical significance was assigned by a Bayesian approach based 
on the t test using the limma package. Genes were selected using a B statistic cut off (B>0). P 
values were adjusted for multiple testing using Benjamini and Hochberg's method. Only 
genes with a fold change of 1 (in either direction) or greater and a B-value of greater than 3 
(exceeding the 95% probability of differential expression) were considered to be 
differentially expressed and further analysed. The B-value is a parameter that describes the 
natural log of the odds that a gene was truly differentially expressed. Differentially expressed 
probe sets were analysed as pair-wise contrasts. Microarray data has been uploaded to Gene 
Expression Omnibus under the reference: GSE58074.  
 
2.9 Chromatin immunoprecipitation experiments 
Chromatin Immunoprecipitation (ChIP) was performed using the SimpleChIP Enzymatic 
Chromatin IP Kit (Magnetic Beads) (Cell Signaling, Genesearch, Arundel, Australia), in 
accordance with the manufacturer’s instructions with some modifications, summarized 
below. All reagents in this section are provided with the SimpleChIP Enzymatic Chromatin 
IP Kit (Magnetic Beads) (Cell Signaling) unless otherwise indicated.  
 
Cell harvesting and crosslinking were carried out according to the Farhman Lab protocol, 
available online at 
http://farnham.genomecenter.ucdavis.edu/pdf/FarnhamLabChIP%20Protocol.pdf. SCC cell 
lines were cultured as per Section 2.2.6 Serial cultivation of squamous cell carcinoma. The 
cells were trypsinised, counted using the Countess Automated Cell Counter (Invitrogen, Life 
Technlogies), and resuspended in a 50 mL Falcon tube at a final concentration of 4 x 10
6
 cells 
in 50 mL of SCC media. Formaldehyde (Asia Pacific Specialty Chemicals, Seven Hills, 
Australia) was added to a final concentration of 1% and the cells were incubated on a rocking 
platform at room temperature for 8 minutes prior to addition of Glycine (Amresco, Astral 
Scientific, Sydney, Australia) to a final concentration of 0.125M. The cells were incubated 
with Glycine at room temperature for 5 minutes, centrifuged at 2000 g at 4°C for 10 minutes 
and washed twice with ice cold PBS. The supernatant was removed and the cell pellet was 
snap frozen in a dry ice and 100% ethanol bath and stored at -80°C until use. 4 x 10
6
 cells per 
ChIP were used. To break nuclear membrane and lyse nuclei completely, the samples were 
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subjected to sonication using a Sonic Materials Vibra Cell sonicator (Sonics and Materials, 
Newton, CT, USA). The cells nuclei were completely lysed after 4 sets of 20 seconds pulses 
with 30 seconds incubation on wet ice between pulses at amplitude of 50 with a 3 mm 
sonicator probe. Prior to immunoprecipitation step, the chromatin was subjected to pre-
clearing using Protein G magnetic beads (Cell Signaling). A 10 µL aliquot of Protein G 
magnetic beads was incubated with the cross-linked and lysed chromatin on a rotating wheel 
at 4°C for 20 minutes. The Protein G magnetic beads were pelleted by placing the tubes in a 
magnetic separation rack. The supernatant was then carefully removed after waiting for one 
to two minutes for solution to clear. A sample corresponding to 2% total chromatin sample 
was served as ‘input’. Two micrograms of E2F7 antibody (Table 2.3), 5 µL of Histone H3 
(D2B12) XP Rabbit antibody (SimpleChIP Enzymatic Chromatin IP Kit) and 2 µL of normal 
Rabbit IgG (SimpleChIP Enzymatic Chromatin IP Kit) were added to the corresponding 
diluted chromatin and the samples were incubated on a rotating wheel at 4°C overnight. 
Immunoprecipitated chromatin was washed, eluted from antibody/Protein G beads and 
subjected to reversal of cross-links, following the manufacturer’s protocol. The ChIP samples 
were then subjected to DNA purification using spin columns as per the manufacturer’s 
protocol, and the immunoprecipitated DNA was quantitated by real time PCR.  
 
ChIP analysis was performed using real time quantitative PCR. Cycling conditions and 
preparation of reaction mix including 1X SYBR and 200 nM forward and reverse primers 
were as per Section 2.6.3 Quantitative real time PCR analysis. Quantitative real time PCR 
primers were designed for two genes which are downstream effectors of E2F7. To determine 
ChIP enrichment, the comparative threshold cycle (Ct) method was used rather than the 
standard curve method, as the quantitation was not relative to a housekeeping gene. The Ct 
value was calculated for each ChIP and input sample using the following formula: 
 
2% x 2 
(2% Input Ct-ChIP Ct) 
 
2.10 Tissue Microarray Analysis 
Tissue microarrays (TMAs) were constructed by Dr Marcin Dzienis (Princess Alexandra 
Hospital Medical Oncology Department) and Dr Ana Cristina Vargas (Princess Alexandra 
Hospital Pathology Department) following pre-designed maps and according to published 
guidelines (Avninder, Ylaya et al. 2008; Eckel-Passow, Lohse et al. 2010). A Hematoxylin 
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and Eosin (H&E) slide with representative primary tumour, its matched normal squamous 
epithelium (when available) and lymph node metastasis were selected for each patient. 
Depending on the availability of the tissue, 2 to 4 replicates cores were selected to be arrayed. 
A Manual Tissue Arrayer (MTA-1) (Beecher Instruments, Estigen Tissue Science) and 0.6 
mm punches (Beecher Instruments) was used for TMA construction by the Department of 
Pathology at the Princess Alexandra Hospital. TMA blocks were placed in a 37°C oven for 2 
hours followed by 4°C incubation overnight, and 4 µm tissue sections were then cut for 
immunohistochemistry by the Department of Pathology at the Princess Alexandra Hospital. 
Immunohistochemistry was conducted using Dako EnVision+System-HRP (DAB) Kit in 
accordance with the manufacturer’s instructions, with an addition of antigen retrieval step as 
per Section 2.6.4 Immunohistochemistry. TMAs were incubated with the primary antibody 
overnight at 4ºC in a humidified chamber. The list of primary antibodies used for TMA 
analysis is summarised in Table 2.3. 
 
The staining pattern was determined using a modified quickscore method as previously 
described (Detre, Saclani Jotti et al. 1995) where the tumour and metastatic epithelial cells 
were evaluated by two blinded pathologists, Dr Samuel Boros and Dr Ana Cristina Vargas, to 
determine the percentage of cells stained (0-100%) and the intensity of staining (1+ to 3+). 
The scoring was performed with no knowledge of the position of the replicates within the 
TMA block. The value of individual cores was obtained by multiplying percentage by 
intensity and the final sample score was the result of the average of replicate cores. Missing 
replicates or those showing artefactual staining (i.e. “edge artefact”) were excluded and the 
final score was obtained from the remaining core/s. To determine the intensity of the stain, 
tumour or metastatic cells were compared with normal non-neoplastic foreskin and squamous 
epithelium, which showed lack of staining (0+) or only weak staining (1+). Intervening 
lymphocytes were identified to express the protein and were used as internal positive control.   
 
2.11 Animal studies 
2.11.1 Establishment of tumour xenografts 
Animal work was performed in accordance with University of Queensland Ethics Guidelines. 
Six to ten weeks old female non-obese diabetic/severe combined immunodeficient 
(NOD/SCID) mice (Animal Resources Centre, Perth, Australia) were used in this study. 
Establishment of tumour xenografts were uniform, regardless of any cell lines used. 2 x 10
6
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cells were resuspended in 50 µL of PBS per injection with a 100 µL dead volume where 
solution is entrapped in the syringe and injected with a 23 gauge needle subcutaneously into 
the flanks of anaesthetised mice.    
 
2.11.2 Treatment with Doxorubicin, Sphingosine kinase Inhibitor (SK1-I) and BGT226  
Mice were randomly divided into 2 groups (n = 6/group). One group of mice were inoculated 
with SCC25 cells transfected with control vector as control group. The other group was 
inoculated with SCC25 cells transfected with Sphk1shRNA construct. When tumours were 
around 3 mm in diameter (about 3 weeks after injection), each group of mice were further 
randomised into two groups and received either vehicle only (DMSO) or doxorubicin 0.5 
mg/kg, respectively, twice per week with intraperitoneal (i.p.) injections. Injection of an 
equivalent volume of DMSO in PBS served as a vehicle control. 
 
For studies where the effect of SK1-I was tested, mice were implanted with SCC25 cells. 
When tumours were around 4 to 5 mm in diameter, animals were randomly assigned to 6 
groups (n = 5/group) and received the following treatments: (i) vehicle only, (ii) doxorubicin 
0.5 mg/kg, (iii) SK1-I 5 mg/kg, (iv) SK1-I 10 mg/kg, (v) SK1-I 5 mg/kg + doxorubicin 0.5 
mg/kg or (vi) SK1-I 10 mg/kg + doxorubicin 0.5 mg/kg, respectively, twice per week by i.p. 
injections. Injection of an equivalent volume of DMSO in PBS served as a vehicle control.  
 
The above experiment where the effectiveness of SK1-I in combination with doxorubicin was 
assessed was repeated using FaDu cells. When tumours were around 2 mm in diameter, 
animals were randomised and received treatments (n = 2/group). Injection of an equivalent 
volume of DMSO in PBS served as a vehicle control.   
 
In the experiment testing the effect of BGT226 combined with SK1-I, mice were implanted 
with SCC25 cells. When tumours were around 4 to 5 mm diameter, animals were randomly 
assigned to 4 groups (n = 4/group) and received the following treatments: (i) vehicle only, (ii) 
doxorubicin 0.5 mg/kg, (iii) BGT226 10 mg/kg or (iv) BGT226 10 mg/kg + doxorubicin 0.5 
mg/kg, respectively, twice per week by i.p. injections. Injection of an equivalent volume of 
DMSO in PBS served as a vehicle control.   
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2.11.3 Mouse monitoring 
Tumour growth and animal weights were monitored regularly for a period of up to 3 weeks. 
Tumour diameter was measured using callipers. Experiments terminated when the tumours 
reached a diameter of 10 mm. Animals were euthanized and tumours were excised, imaged, 
and subjected to pathologic examination after being fixed in a 4% formaldehyde (Histopot) 
for 24 hours. Tumour volumes were determined with the following formula: π/6 x (length in 
millimeters) x (width in millimeters)
2
.  
 
2.11.4 Statistical analysis 
Graphs were generated using GraphPad Prism (GraphPad software) version 6.0. Graphs 
depict mean values ± SEM of triplicate determinations from at least three independent 
experiments. Statistical differences were determined by Student’s t test with a 95% 
confidence level. A P value greater than 0.05 was deemed not significant. For in vivo 
experiments, animals were randomly assigned into treatment or control groups. The sample 
size for animal studies was based on previous studies reported in the literature. Control and 
treatment cohorts had tight tumor growth curves and were adequately powered with 
experimental recipient cohorts of average size n = 4 to 6. In vivo experimental data points 
represent means ± SEM of the measurements of each mouse tumour.  
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3 Identification of Isoform-Specific Functions for E2F7 and 
E2F8 
3.1 Introduction 
E2Fs are a family of multifunctional context-specific transcription factors (Field, Tsai et al. 
1996; Pierce, Schneider-Broussard et al. 1999; Hazar-Rethinam, Endo-Munoz et al. 2011). 
Work from my laboratory has previously shown that E2F1 and E2F7 may play important 
roles in KC proliferation, differentiation and apoptotic responses in human keratinocytes 
(Dicker, Popa et al. 2000; Endo-Munoz, Dahler et al. 2009; Hazar-Rethinam, Cameron et al. 
2011; Hazar-Rethinam, Endo-Munoz et al. 2011). However, these studies relied heavily on 
overexpression analysis and therefore may be subject to errors associated with high levels of 
overexpression of specific isoforms. Moreover, the potential role of E2F8 in squamous 
differentiation or squamous neoplasia has not been addressed at this time. In order to 
interrogate the roles of E2F1, E2F7 and E2F8 in KC proliferation, differentiation, apoptosis 
and neoplasia, we needed to establish strategies to knockdown E2F1, 7 and 8 expressions in 
the context of KCs in vitro. Moreover, we needed to establish in vitro and in vivo assays to 
measure proliferation, differentiation and apoptosis in murine epidermal keratinocytes 
(MEK). Previous studies from my laboratory have focused on human KCs and epidermis, so 
we needed to adapt some of these techniques to the murine system. Thus, in this chapter we 
have validated in vitro assays and in vivo markers of MEKs and epidermis. In addition, we 
have generated E2F7, E2F8 and E2F7/8 deficient KCs in vitro using a Cre/lox system with 
which to characterise the roles of E2F1, 7 and 8 on KC proliferation, differentiation and 
apoptosis. Specifically, we obtained E2F1 conventional KO mice and E2F7 or E2F8 floxed 
mice, and then generated KCs deficient in E2F7, E2F8 or both E2F7 and 8 following 
infection with Cre expressing adenovirus viral construct. These KCs were then assayed for 
their ability to differentiate in response to calcium or to die in response to UVB radiation, 
doxorubicin, etoposide or cisplatin. We now have strong evidence, from these in vitro 
experiments, that E2F7 plays a unique and non-redundant role in modulating apoptosis 
whereas E2F8 has a unique and non-redundant capacity to regulate squamous differentiation. 
In addition, we report on a unique feedback loop between E2F1, E2F7 and E2F8 that 
highlights a previously unreported interdependent axis. These findings provide evidence 
implicating the atypical E2F proteins as potent and biologically relevant modulators of 
squamous differentiation and cytotoxic responses. 
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3.1.1 Mouse model 
In this study we aim to generate a series of models in which E2F family members are 
deliberately dysregulated in order to examine their role in normal epithelial maturation as 
well as sensitivity to cytotoxic stimuli. These studies will identify potential targets for 
preventing or treating SCC. The Cre/loxP system thus provides a powerful means by which 
we can study the roles of atypical E2Fs, in vitro.  
 
Targeting of E2F7 and E2F8 was achieved by flanking exon 4 in E2F7 and exon 3 and 4 in 
E2F8 with loxP sites using homologous recombination techniques (Figure 3.1). These mice 
were a kind gift from Gustavo Leone (Li, Ran et al. 2008). These mice will be used as a 
source of KCs for in vitro studies. These mice are a unique and powerful resource that will 
help us to elucidate the role of atypical E2Fs in KC biology. 
 
 
Figure 3.1 Schematic representation of generation of E2F7 and E2F8 conditional 
knockout alleles. (Li, Ran et al. 2008). 
 
3.1.2 Adenovirus mediated gene delivery 
We wanted to employ a method for studying the roles of atypical E2Fs in vitro. A strategy 
was to utilise adenovirus-mediated Cre deletion of floxed sequences in primary cells isolated 
from floxed mice. In this approach, the isolated primary KCs carrying flanked sequences are 
infected with Cre expressing adenovirus particles at a low multiplicity of infection for a short 
period of time in tissue culture flasks in order to achieve successful recombination. 
 
Cre expressing adenoviruses have been successfully used as an alternative to Cre transgenic 
mice (Anton and Graham 1995; Wang, Krushel et al. 1996). Studies have shown that 
infection of primary cells is rapid, efficient and less labour intensive (Hunt, Deng et al. 1997; 
65 
 
Rijnkels and Rosen 2001; Deyrieux, Rosas-Acosta et al. 2007). Successful gene delivery can 
easily be achieved at a low multiplicity of infection avoiding potential toxicity (Prost, 
Sheahan et al. 2001). There are many advantages of this method including the tissue 
specificity achieved by the isolation method, the time of recombination and toxicity 
controlled by the intervals of infection, the reduction to a minimum number of animals used 
in subsequent in vivo work (Prost, Sheahan et al. 2001). Besides, it offers a convenient and 
flexible study system (Prost, Sheahan et al. 2001). Several papers have demonstrated that 
many epithelial cell types can easily be infected at a high level by this technology (Ohba, 
Ishino et al. 1998; Bielefeld, Amini-Nik et al. 2011; Hwang, Kita et al. 2011). The caveat to 
this approach is the Cre-dependent toxicicty where prolonged exposure to a Cre protein can 
lead to genetic instability.   
 
3.2 Results 
3.2.1 Characterisation of differentiation in MEKs 
The morphology of human skin is routinely examined by analysing the expression of 
proliferation and differentiation markers. Since there are inherent structural differences in 
skin between humans and mice (Ratushny, Gober et al. 2012), we wanted to characterise the 
expression of established differentiation markers of differentiation in MEKs. For this study, 
we used skin derived from C57/BL6 pups. To evaluate the state of differentiation and 
proliferation, deparaffinised paraffin sections were stained immunohistochemically or by 
immunofluorescence using various primary antibodies. Consistent with human epidermis, in 
all basal layer cells, keratins 5 and 14, which are markers of undifferentiated and 
proliferation-competent KCs, respectively, were found to be expressed (Figure 3.2). Once 
again, consistent with human epidermis, early differentiation markers keratin 1 and 10 were 
detected in all suprabasal layers of mouse epidermis (Figure 3.2). Moreover, among the 
terminal differentiation marker, involucrin was expressed in the upper spinous and granular 
layers of mouse epidermis in agreement with the expression profile seen in human skin 
(Figure 3.2) 
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Figure 3.2 Immunostaining of proliferation and differentiation markers in the control 
mouse epidermis. Postnatal day 3 control mice skin samples were fixed, paraffin embedded, 
sectioned and mounted on slides. Tissue was stained with an antibody against keratin5, 
keratin14, keratin 1, keratin 10, Involucrin and IgG. Epidermis proliferation markers, keratin 
5 and keratin 14 are localized to the basal layers of the epidermis. Early differentiation 
markers, keratin 1 and keratin 10 are expressed evenly throughout the suprabasal layers of 
mouse epidermis. In mouse skin, involucrin is localized only to the suprabasal layer of the 
epidermis. Antibody staining is specific as an IgG negative control shows no staining. 
Positive staining is shown by brown staining. IgG control was used as a control. Bar = 100 
µm.   
 
We repeated these investigations using immunofluorescent detection rather than 
immunohistochemistry and found similar results (Figure 3.3). Immunofluorescence images 
demonstrated that, mouse epidermis has the same degree of maturation compared to human 
skin as reflected by the expression of early differentiation marker, keratin 10 (Figure 3.3), in 
the suprabasal layer and by the expression of terminal differentiation marker, involucrin, in 
the upper spinous and granular layers of mouse epidermis (Figure 3.3). Additionally, the 
proliferation marker, keratin 5 (Figure 3.3) was also expressed in all the basal cells in the 
mouse epidermis. These immunohistochemistry and immunofluorescence analyses highlight 
the fact that there are marked similarities between human and mouse epidermis. More 
importantly, these data indicate that we have excellent markers to interrogate squamous 
differentiation in both human and murine KCs in vitro and in vivo. 
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Figure 3.3 Proliferation marker and cytokeratin expression status in the control mice 
epidermis. Postnatal day 3 control mice skin was subjected to dual colour immunostaining 
with antibodies to keratin 5, keratin 1 and involucrin and visualised using confocal 
microscope. Immunostaining with normal rabbit IgG reveals the lack of non-specific staining. 
Blue represent nuclei stained with DAPI, green represents Alexa Fluor 488 stained keratin 1, 
5 and involucrin positive cells. Original magnification, x25.  
 
3.2.2 Adenoviral infection of primary KCs is highly efficient and has no effect on cell 
viability, mRNA synthesis, protein expression, differentiation and response to stress 
To test the hypothesis that E2F7 and E2F8 are important regulators of KC biology, we have 
initiated a series of in vitro experiments in which we engineer E2F7, E2F8 or E2F7 and E2F8 
knockdown in MEKs by utilizing adenovirus-mediated Cre deletion of floxed sequences. 
Cre-expressing adenoviruses have been used successfully in primary cells as an efficient tool 
for gene deletion in vitro (Ohba, Ishino et al. 1998; Prost, Sheahan et al. 2001; Rijnkels and 
Rosen 2001).  
 
We started with titration experiments using a control adenovirus, Ad-GFP, in order to 
optimize the conditions of viral infection including the amount of virus particles to be used 
and the duration of infection. Multiplicity of infection (MOI) of 50 48 hours post-infection 
with virus showed low toxicity and the highest infection efficiency among all (Figure 3.4A). 
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There was no effect of control Ad-CMV-Null virus, an empty CMV viral construct, on 
proliferation measured by cell proliferation assay (Figure 3.4B). Further, it did not have any 
effect on E2F7 mRNA expression evidence by qRT-PCR analysis (Figure 3.4C). We also 
looked at the possible effect of viral infection on differentiation. Ad-CMV-Null infected and 
CaCl2 treated MEKs, isolated from control mice, showed an increase in involucrin protein 
levels (Figure 3.4D) as expected. Moreover, control adenovirus infected cells were able to 
respond normally to stress such as UVB irradiation (Figure 3.4E), doxorubicin (Figure 3.4F) 
and cisplatin (Figure 3.4G) treatments compared to uninfected control MEKs. These data 
demonstrate that differentiation and cytotoxicity responses of KCs are unaltered by infection 
with an adenovirus.  
 
High gene delivery efficiency (>90%) was achieved with Ad-Cre-GFP, at a MOI of 50 
(Figure 3.5A), and expression of Cre recombinase was detected by immunoblotting 48 hours 
post-infection (Figure 3.5B). Importantly, we further validated target cell specificity by 
examining the expression levels of epithelial cell specific marker, AE1/AE3. Immunoblotting 
results confirmed that we were able to deliver and consequently cause recombination only in 
the epithelial cells and not other cell populations including fibroblast (Figure 3.5C). In 
agreement with gene delivery efficiency, analysis of recombination and subsequent gene 
deletion of Ad-Cre-GFP infected KCs isolated from E2F7, 8 and 7/8 floxed mice 
demonstrated that we were able to efficiently knockdown the cognate transcript with high 
efficiency (Figure 3.5D, E and F). It is noteworthy that the knockdown (KD) efficiency of 
the E2F7/8 double floxed KCs was less than that for the individually floxed KCs. The 
recombination rate was around 60% for E2F7 and 70% for E2F8 (Figure 3.5F). E2F1 gene 
expression levels were also examined in KCs isolated from conventional E2F1KO mice. 
E2F1 levels were only reduced by 70% (Figure 3.5G). We confirmed by sequencing that the 
PCR product in the E2F1 KO experiment was E2F1. In addition to gene recombination 
analysis, we also evaluated the levels of E2F7 proteins in E2F7 deficient KCs. The results 
demonstrated that we were able to totally delete E2F7 protein in those cells (Figure 3.5D). 
This analysis could not be possible in E2F8 deficient KCs due to lack of reliable antibody 
against E2F8. Moreover, E2F1 protein levels were also evaluated and results were in 
agreement with the qRT-PCR results. Surprisingly, once again, only modest level of 
reduction in E2F1 protein levels was observed (Figure 3.5G). 
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Figure 3.4 Adenovirus infection of MEKs is highly efficient and has no adverse effect on 
cellular functions. Fluorescence microscopy images of control MEKs infected with differing 
MOI of control virus, Ad-GFP (A). Images were taken 48 hours post-infection. Cell viability 
following 48 hours post-infection with Ad-CMV-Null, at a MOI of 50, was measured by cell 
proliferation assay (B). Quantitative RT-PCR was performed on control (uninfected) MEKs 
and MEKs which were infected with Ad-CMV-Null virus (C). Ad-CMV-Null control virus 
infected MEKs were cultured with 1.2 mM CaCl2 for 48 hours to induce differentiation and 
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differentiation marker, involucrin, levels were detected by immunoblotting (D). β-actin was 
used as a loading control. Control (uninfected) and Ad-CMV-Null infected MEKs were 
subjected to variable doses of UVB (E), doxorubicin (F) or cisplatin (G). Cell viability was 
assessed following 48 hours post-treatment and plotted as percentage of untreated cells. 
Quantitative data represent the mean ± SEM obtained from triplicate determinations of three 
independent experiments. Real time PCR data are the mean ± SEM of duplicate determinants 
normalized for expression of the housekeeping gene β-actin; n = 3. Western blot figures are 
representative of three independent experiments.  
 
Overall, we were able generate KCs that are deficient in E2F7, E2F8, and E2F7/8 following 
infection with Ad-Cre-GFP viral constructs without any significant effect on the cellular 
functions that have been studied.  
 
3.2.3 E2F8-deficient MEKs display an abnormal phenotype in response to elevated 
CaCl2 
Although our previously published work clearly showed that E2F7 plays a critical role in 
differentiation initiation by repressing key regulators of differentiation in proliferating cells, 
this effect was restricted to a subset of genes and cannot be considered a global regulator of 
differentiation (Hazar-Rethinam, Cameron et al. 2011). Moreover, given the lack on data on 
E2F8’s contribution to differentiation, we examined the role that E2F8 plays with regards to 
differentiation. To date, there is no data about E2F8 on squamous differentiation and 
neoplasia.  
 
There are several physiologically relevant agents that are able to alter growth and 
differentiation in KCs in vitro. These agents are capable of mimicking in vivo processes of 
squamous differentiation when included in KC tissue culture. In this study, we utilised 
elevated calcium levels to induce differentiation. It was previously shown that 
supplementation of KC medium with calcium induces the expression of differentiation 
specific genes (Poumay and Pittelkow 1995). Initial experiments demonstrated that by 
increasing the calcium concentration from 0.05 mM to 1.2 mM CaCl2 after a 48 hour 
treatment was sufficient to induce the protein levels of differentiation specific genes such as 
involucrin (Figure 3.6A) and repress the protein levels of proliferation specific genes such as 
cdc2 (Figure 3.6B). This treatment scheme was followed for the differentiation study. 
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Figure 3.5 Generation of E2F7 and E2F8 deficient MEKs and the validation of E2F1 
levels in E2F1KO mice. High level of Cre gene delivery was evident from microscopic 
analysis of Ad-Cre-GFP infected KCs isolated from E2F8 floxed mice (A). Immunoblotting 
for Cre recombinase expression post-infection was carried out in uninfected E2F8 floxed 
MEKs, control Ad infected E2F8 floxed MEKs and Ad-Cre-GFP infected E2F8 floxed 
MEKs (B). Immunoblotting for AE1/AE3 expression post-infection was carried out in Ad-
Cre-GFP infected E2F8 fl/fl MEKs (C). The membrane was stained with Coomassie blue for 
loading control. Levels of E2F7 mRNA expression and protein levels were measured in E2F7 
fl/fl MEKs following infections with Ad-Cre-GFP by qRT-PCR and immunoblotting, 
respectively (D). E2F8 (E) or E2F7/8 (F) mRNA expression was measured in the relevant 
fl/fl MEKs following infections with Ad-Cre-GFP and compared to uninfected MEKs. Levels 
of E2F1 mRNA expression and protein levels were measured in MEKs isolated from 
E2F1KO mice and compared with uninfected MEKs isolated from control mice by qRT-PCR 
and immunoblotting, respectively (G). Real time PCR data are the mean ± SEM of duplicate 
determinants normalized for expression of the housekeeping gene β-actin; n = 3. Western blot 
figures are representative of three independent experiments. β-actin was used as a loading 
control for (D) and (G). **, P < 0.01, ***, P < 0.001.  
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Figure 3.6 Calcium time-course: the elevated levels of calcium in culture medium was 
sufficient to induce differentiation. Time course analysis of involucrin protein expression in 
MEKs isolated from control mice which are cultured in KC-SFM supplemented with 1.2 mM 
CaCl2. The membrane was stained with Coomassie blue for loading control. Immunoblotting 
for proliferation marker cdc2 expression in differentiated MEKs following 48 hours CaCl2 
(1.2 mM) treatment (B). β-actin was used as a loading control. Western blot figures are 
representative of three independent experiments. Prol is proliferative; Conf is confluent 
keratinocytes.  
 
Microscopy of Ad-Cre-GFP infected KCs isolated from E2F8 fl/fl mice revealed differences 
in their phenotype compared to E2F1, E2F7 an E2F7/8 deficient keratinocytes in the presence 
of calcium (Figure 3.7A). Moreover, when these cells were exposed to elevated levels of 
calcium, they did not induce differentiation markers as measured by immunoblotting, 
indicating that E2F8 may be required for cells to undergo squamous differentiation (Figure 
3.7B and C). In contrast, E2F1 and E2F7 deficient MEKs retained their ability to respond to 
increased levels of calcium (Figure 3.7B and C). These results identified a novel non-
redundant activity for E2F8 in modulating involucrin expression and suggested that E2F8 
may be a key regulator of differentiation.  
 
Given the unexpected and unique role of E2F8 in differentiation, we also looked at the 
mRNA expression levels of E2F1, E2F7 and E2F8 in differentiated MEKs following calcium 
treatment. In agreement with our protein results, E2F1 and E2F7 levels were significantly 
reduced in differentiated MEKs (Figure 3.7E). Whereas the mRNA level of E2F8 was 
downregulated only by 20% (Figure 3.7E). This result further confirmed that E2F8 plays a 
non-redundant and significant role in squamous differentiation and perhaps in squamous cell 
carcinoma development.  
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Figure 3.7 Loss of E2F8 in MEKs inhibits the induction of differentiation. Phase-contrast 
microscopy images of E2F7, E2F8, E2F7/8 or E2F1 deficient MEKs in the presence and 
absence of calcium chloride (A). E2F1 deficient MEKs (B) or uninfected, Ad-CMV-Null or 
Ad-Cre-GFP infected E2F7 (C), E2F8 (D), E2F7/8 (E) or were either left untreated or treated 
with 1.2 mM CaCl2 for 48 hours following viral infection at which time expression of 
involucrin protein was visualized by immunoblotting. β-Actin is provided as a loading 
control. Densitometric analysis of involucrin was quantified using ImageJ. Expression level 
was normalized against β-Actin and plotted as relative involucrin level (F). Western blot 
figures are representative of three independent experiments. mRNA expression levels of 
E2F1, E2F7 and E2F8 in undifferentiated or 1.2 mM CaCl2 treated MEKs were examined by 
qRT-PCR (G). Real time PCR data are the mean ± SEM of duplicate determinants 
normalized for expression of the housekeeping gene β-actin; n = 3. ns is not significant, **, P 
< 0.01, ***, P < 0.001.  
 
3.2.4 Cytotoxic responses to UV are selectively enhanced in E2F7-deficient MEKs 
We previously reported that E2F7 overexpression could reduce the E2F1-dependent response 
of KCs to respond to the major cutaneous carcinogen, UV radiation (Endo-Munoz, Dahler et 
al. 2009). To confirm our previous findings and extend these findings to include E2F8, we 
performed UV-induced cytotoxicity experiments on uninfected control and Ad-Cre-GFP 
infected KCs isolated from cognate floxed mice. When infected MEKs were subjected to 
varying doses of UVB ranging from 0-0.06 J/cm
2
, E2F1-deficient cells had an attenuated 
response to UV (Figure 3.8). This suggests that E2F1 is involved in UV-mediated apoptosis. 
In contrast, E2F7-deficient (E2F7KD) MEKs became more sensitive to UV (Figure 3.8). 
Finally, E2F8 deficient (E2F8KD) and E2F7/8 deficient (E2F7/8KD) MEKs displayed 
unaltered responses to UV (Figure 3.8). These data indicate that UV-induced cytotoxic 
responses may involve E2F1 and E2F7-dependent processes. This is more obvious if one 
compares the E2F1KO dose response curve to that of the E2F7KD data.  
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Figure 3.8 Cytotoxic responses to UVB selectively enhanced in E2F7-deficient MEKs. 
Uninfected and Cre treated proliferative E2F1, E2F7, E2F8 and E2F7/8 MEKs were exposed 
to varying doses of UVB irradiation and left for 24 hours. Cell viability was then measured. 
Results are expressed as a percentage of uninfected MEKs, and quantitative data represent the 
mean ± SEM obtained from triplicate determinations of three independent experiments. 
Significant differences between Uninfected and E2F1KO or Uninfected and E2F7KD are 
indicated (ns is not significant, **, P < 0.01).    
 
3.2.5 Cytotoxic responses to doxorubicin are selectively enhanced in E2F7-deficient 
MEKs 
In order to find out whether the ability of E2F7 to regulate stress responses is selective for 
UVB radiation, we also looked at the chemotherapy-induced cytotoxicity. For this, we 
examined the effects of E2F1, 7, 8 and 7/8 on cytotoxic responses to doxorubicin, cisplatin 
and etoposide. These experiments indicated that E2F7, but not E2F8, may play a role as a 
modulator of doxorubicin-induced cytotoxic responses (Figure 3.9A). Significantly, E2F7 
deficiency only had minimal effect on cisplatin sensitivity (Figure 3.9B) and no impact on 
etoposide sensitivity (Figure 3.9C). E2F8 and E2F7/8 had no effect on cytotoxic responses to 
any of the drugs (Figure 3.9A, B and C). E2F1 deficiency had a modest protective role 
against doxorubicin or cisplatin-induced cytotoxicity (Figure 3.9A, B and C). Combined, 
these data indicate that E2F1 and E2F7 may play opposing roles in the modulation of 
doxorubicin sensitivity. These results highlight a potentially unique and isoform-specific 
function of E2F7 in modulating sensitivity to doxorubicin. 
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Figure 3.9 Cytotoxic responses to doxorubicin selectively enhanced in E2F7-deficient 
MEKs. Dose response curve of uninfected, E2F1, E2F7, E2F8 and E2F7/8 deficient 
proliferative KCs to doxorubicin (A), cisplatin (B) and etoposide (C). Cells were exposed to 
chemotherapeutic drugs for 2 days. Viability was then assessed and plotted as percentage 
uninfected KCs. Quantitative data represent the mean ± SEM obtained from triplicate 
determinations of three independent experiments. Significant differences between Uninfected 
and E2F1KO or Uninfected and E2F7KD are indicated (ns is not significant, *, P < 0.05, **, 
P < 0.01).    
   
3.2.6 E2F1/E2F7/8 exist as an interdependent axis in KCs 
We examined the expression levels of E2F1, 7 and 8 in E2F deficient MEKs. Quantitative 
RT-PCR results confirmed previously published data showing the existence of a negative 
feedback loop between E2F1 and E2F7 (Figure 3.10A and B). Loss of E2F8 resulted in 
elevation in E2F1 and E2F7 expressions (Figure 3.10C), whereas loss of E2F1 caused 
reductions in E2F7 and E2F8 expressions (Figure 3.10A). Unexpectedly, qRT-PCR results 
demonstrated a unique and unknown transcriptional relationship between E2F7 and E2F8. 
E2F8 appeared to suppress E2F7 transcription in agreement with it being a transcription 
inhibitor, whereas E2F7 functioned as an activator and E2F7 deficiency caused an increase in 
E2F8 expression (Figure 3.10B and C). These results clearly demonstrate the existence of a 
complex and interdependent network between E2F1, E2F7 and E2F8 in KCs. 
77 
 
 
Figure 3.10 E2F1/E2F7/E2F8 exist in an interdependent network. E2F1, E2F7 and E2F8 
expression levels were measured by qRT-PCR in E2F1 deficient (A), E2F7 deficient (B) and 
E2F8 (C) deficient MEKs. Schematic model summarising the interdependent network 
between E2F1, E2F7 and E2F8 at the transcriptional level (D). Results expressed as 
percentage of relevant uninfected floxed MEKs. The expression levels are the mean ± SEM 
of duplicate determinants normalized for expression of the housekeeping gene β-actin by the 
standard curve method; n = 3. *, P < 0.05, **, P < 0.01, ***, P < 0.001, ****, P < 0.0001. P  
value was calculated using Student’s t test.  
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3.3 Discussion 
To characterise the actions of E2F7 and E2F8 in KCs of stratified epithelia in vitro, we 
conducted a series of in vitro studies on the contribution of E2F1, E2F7 and E2F8 to 
squamous differentiation using cultured MEKs derived from wildtype, E2F1 KO or E2F7, 
E2F8, E2F7/8 floxed mice. E2F deficient KCs were generated in vitro by utilizing 
adenovirus-delivered Cre-mediated gene deletion. Our early experiments showed that 
infection occurred in almost all cells and had little effect on biological processes such as 
proliferation, differentiation and apoptosis. It should be noted that the recombination rate of 
the double knockdown KCs was lower than that of the individual ones. Surprisingly, 
conventional E2F1KO KCs still expressed measurable levels of E2F1 transcript. This residual 
E2F1 expression was confirmed by sequencing and thus significant reduction of E2F1 
occurred but was not absolute. Predictably, significant knockdown of E2F7 mRNA and 
protein was achieved whilst the lack of commercially useful E2F8 antibodies meant we could 
only confirm E2F8 knockdown at the mRNA level. These preliminary studies have provided 
us with the unique resources to assess differentiation and apoptosis in vitro in MEKs that are 
selectively deficient for specific E2F isoforms. 
 
Dysregulation of apoptosis is common amongst SCC (Pierce, Gimenez-Conti et al. 1998; 
Hanahan and Weinberg 2000; Wang, Russell et al. 2000; DeGregori and Johnson 2006). 
Similarly, dysregulation of E2F1 and E2F7 expression is common in SCC (Endo-Munoz, 
Dahler et al. 2009). It has been shown that some apoptotic responses are regulated by E2F in 
an E2F isoform-specific manner (Li, Ran et al. 2008; Panagiotis Zalmas, Zhao et al. 2008; 
Endo-Munoz, Dahler et al. 2009). E2F1 is one of those E2F isoforms. The role of E2F1 in the 
regulation of apoptosis is well-documented (Bell and Ryan 2003; Jamshidi-Parsian, Dong et 
al. 2005; Lazzerini Denchi and Helin 2005; Stanelle and Pützer 2006; Hallstrom, Mori et al. 
2008; Wu, Zheng et al. 2009). In this chapter, we showed that E2F7 deficiency selectively 
enhanced the cytotoxic responses of KCs to UVB and doxorubicin. In contrast, E2F1 
deficiency protected the KCs from UVB and doxorubicin-induced cytotoxicity. These data 
indicate that E2F1 and E2F7 appear to antagonise one another with respect to cytotoxic 
responses. Significantly, E2F8 and E2F7/8 had no effect on cytotoxic responses indicating 
that the role of E2F7 and E2F1 are, to an extent, isoform specific. Clearly, the overexpression 
of E2F7 seen in SCC patients (100 fold overexpression) (Endo-Munoz, Dahler et al. 2009) 
would be predicted to render them resistant to the apoptotic effects of UVB radiation, and 
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supports the idea that E2F7 overexpression could contribute to UV-induced malignant 
transformation. Moreover, these data would suggest that E2F7 overexpression may also 
modulate chemotherapeutic sensitivity in SCC. 
 
Although doxorubicin and etoposide are established type II Toposiomerase blocking agents, 
E2F7 deficient cells only responded to the cytotoxic effects of doxorubicin. Type II 
Topoisomerases are ATP-dependent enzymes, and play an important role in DNA 
metabolism by catalysing topological changes in DNA (Dong, Yang et al. 2002). Whilst the 
doxorubicin-selectivity was unexpected, it is not unprecedented. For example, Bug and 
Dobbelstein (2011) reported that chemotherapeutic agents which are closely related, like 
anthracyclines, can have differing biochemical functions (Bug and Dobbelstein 2011). They 
ascribed these compound-specific biochemical functions to the efficiency and sequence 
specificity of drug intercalation with DNA. Similarly, the extent of DNA cleavage and drug-
induced DNA lesions produced by these two drugs showed marked differences in non small 
cell lung cancer cells (Binaschi, Capranico et al. 1990).   
 
Doxorubicin is one of the commonly employed drugs in chemotherapy for a number of 
cancer types (Zhang, Liu et al. 2012; Tacar, Sriamornsak et al. 2013). It is not however in use 
clinically for SCC treatment. To date there has been no data on the possible reasons behind 
this insensitivity. In this regard, our data may provide a possible explanation. The 
overexpression of E2F7 seen in SCC patients would have a protective effect against the 
cytotoxic actions of doxorubicin. Collectively, these data highlight a unique, significant and 
isoform-specific function for E2F7 regulating sensitivity to cytotoxic (doxorubicin) or 
carcinogenic (UVB) stimuli. Linked with the overexpression of E2F7 in SCCs, our data 
would suggest i) that E2F7 may suppress UV-induced apoptosis and hence contribute to SCC 
development and ii) that targeting E2F7 may sensitise SCCs to an expanded suite of 
chemotherapeutics. This will be examined in future chapters.  
 
A number of transcription factors have been shown to regulate squamous differentiation 
(Chapter 1 in this study). In particular, the E2F family appears to be prominent amongst them 
(Wang, Helin et al. 1995; Dicker, Popa et al. 2000; Wong, Barnes et al. 2003; Hazar-
Rethinam, Cameron et al. 2011). E2F inhibition is required for squamous differentiation, and 
induces growth arrest and sensitises KCs to subsequent differentiation stimuli (Jones, Dicker 
et al. 1997; Dicker, Popa et al. 2000; Wong, Barnes et al. 2003; Hazar-Rethinam, Cameron et 
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al. 2011). Consistent with its E2F inhibitory role, we recently showed that E2F7 is able to 
repress the expression of the Sp1 transcription factor, a key factor involved in the induction 
of differentiation genes (Hazar-Rethinam, Cameron et al. 2011). These data suggest that loss 
of E2F7 would lead to the derepression of differentiation genes (Hazar-Rethinam, Cameron 
et al. 2011). Similarly, overexpression of E2F7 (as seen in SCC) would be predicted to 
suppress differentiation (Hazar-Rethinam, Cameron et al. 2011). However, these studies 
utilised an in vitro system of KCs in which E2F7 was manipulated using various transfection 
strategies. Significantly, the potential role of E2F8 has not been examined to date. 
Preliminary data from this chapter highlights a previously unknown and unique function for 
E2F8 in modulation squamous differentiation. E2F8 deficient MEKs did not show the typical 
differentiated KC morphology compared to E2F1, E2F7 and E2F7/8 deficient KCs in the 
presence of elevated levels of calcium. Moreover, loss of E2F8 inhibited the ability of these 
cells to undergo calcium-induced squamous differentiation in vitro. On the other hand, E2F1 
and E2F7 deficient MEKs retained a capacity to differentiate. This data is in agreement with 
the qRT-PCR analysis confirming that E2F1 and E2F7 were downregulated during calcium-
induced differentiation. It is important to note that earlier studies with E2F8 KO mice did not 
report a “skin phenotype” which may suggest that differentiation is not absolutely dependent 
upon E2F8 and that E2F8 may operate in concert with other differentiation factors or may 
only act on a subset of differentiation genes. 
 
The present study indicates that E2F1, E2F7 and E2F8 may contribute to SCC via various 
independent mechanisms such as apoptosis or differentiation dysregulation. It is noteworthy 
that earlier studies have reported that E2F1 can induce E2F7 and E2F8 transcription which in 
turn suppresses E2F1 transcription (Di Stefano, Jensen et al. 2003; Christensen, Cloos et al. 
2005; Li, Ran et al. 2008; Panagiotis Zalmas, Zhao et al. 2008; Endo-Munoz, Dahler et al. 
2009). This provides for a regulatory feedback loop for E2F activity. These findings 
prompted us to look for a similar feedback loop in KCs. Quantitative RT-PCR results from 
MEKs which are deficient for E2F1, E2F7 or E2F8 confirmed the existence of a negative 
feed-back loop between E2F1 and atypical E2Fs. However, we also found evidence that 
E2F7 is able to induce E2F8 expression. To our knowledge this has not been shown before. 
These findings suggest that E2F7 may act as an activator contrary to its well-documented 
function as a transcriptional repressor whereas E2F8 retains its function as transcription 
inhibitor. This is not entirely unprecedented since a recent report from Weijts et al (2012), 
demonstrates that E2F7 can act as an activator through binding and activating the 
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transcription of HIF1α (Weijts, Bakker et al. 2012). Surprisingly, there are two other recent 
studies suggesting a similar role for E2F7 in the activation of TERT promoter and for E2F8 
in the stimulation of cyclin D1 promoters in liver (Deng, Wang et al. 2010; Sirma, Kumar et 
al.). Curiously, this study highlights the existence of a complex and interdependent network 
between E2F1, E2F7 and E2F8 which is thought to be contributing to normal squamous 
differentiation and cytotoxic responses, consequently dysregulation within this network 
contributes to SCC formation.  
 
In conclusion, these preliminary screens highlight isoform-specific activities of E2F7 and 
E2F8 in responses to UV- or chemotherapy-induced cytotoxicity and squamous 
differentiation, respectively. These observations provide new avenues towards improving our 
understanding of KC differentiation, KC neoplasia and chemotherapeutic sensitivity in 
squamous cell carcinoma. Therefore, understanding the molecular basis for E2F7 and E2F8 
action and novel factors that regulate E2F7 and E2F8 activity may lead to a better 
understanding of SCCgenesis and new therapeutic strategies to treat SCC patients. In the 
following chapters we will explore the E2F7 dependent pathways that regulate cytotoxic 
responses in KCs. 
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CHAPTER FOUR 
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4 Identification of Downstream Effectors of E2F7 in the 
Regulation of Doxorubicin Sensitivity 
4.1 Introduction 
In the previous chapter, detailed analysis of E2F7 and E2F8KDs in KCs implicated the 
atypical E2Fs as potent biologically relevant modulators of squamous differentiation and 
cytotoxic responses, respectively. In particular, E2F7 could contribute to the modulation of 
chemoresistance in SCC. Linked with the overexpression of E2F7 in SCC, the results from 
the previous chapter would predict that targeting E2F7 may sensitise SCCs to the cytotoxic 
action of chemotherapeutics. Targeting transcription factors is a promising anticancer 
strategy because of the direct involvement of transcription factors in many cancer-associated 
events or these event indirectly modulating transcription factors. However, targeting ligand-
independent transcription factors remains a considerable challenge. Therefore, an unbiased 
transcriptome-wide approach was taken to identify downstream effectors of E2F7-mediated 
suppression of doxorubicin cytotoxicity in doxorubicin sensitive and doxorubicin insensitive 
cell lines. Importantly, identifying genes whose expression is regulated by E2F7 may aid in 
understanding the mechanism by which E2F7 modulates doxorubicin sensitivity. Moreover, it 
would provide an opportunity to introduce doxorubicin in SCC patient treatment schedules 
and expand the suite of chemotherapeutics that can be offered to SCC patients. In order to 
identify downstream effectors of E2F7 in the regulation of doxorubicin sensitivity, a number 
of experimental design strategies were incorporated. Firstly, a number of SCC cell lines were 
screened for doxorubicin sensitivity in order to distinguish the ones which are doxorubicin 
sensitive and insensitive. Secondly, a correlation between expression levels of E2F7 and 
sensitivity to doxorubicin was made to enrich for the cell lines which can be a good candidate 
for transcriptomics analysis. Thirdly, E2F7 levels were manipulated with overexpression or 
silencing approaches in those selected cell lines in the presence or absence of doxorubicin to 
identify the list of differentially expressed genes. These approaches will be explained in detail 
in the following results section. Genes that were responsible for E2F7-mediated sensitivity to 
doxorubicin warrant further analysis. 
 
4.2 Results 
4.2.1 E2F7 selectively regulates cytotoxic responses to doxorubicin in KCs 
In the previous chapter, we examined the dose-dependent cytotoxic profiles of uninfected 
control, E2F7KD, E2F8KD and E2F1KO MEKs to increasing concentrations of doxorubicin 
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and made the observation that E2F7 plays an important role in the regulation of sensitivity to 
doxorubicin and the action of E2F7 in suppressing doxorubicin sensitivity is isoform 
selective since E2F8 failed to modulate doxorubicin sensitivity. To confirm that the effect of 
E2F7 deficiency was attributable to E2F7, we reintroduced E2F7 back into E2F7 deficient 
MEKs, and demonstrated that reintroduction of E2F7 into E2F7 deficient MEKs was 
sufficient to reverse E2F7-mediated sensitivity to doxorubicin (Figure 4.1A). We then 
determined whether E2F7-mediated reduction in cell survival is due to activation of apoptotic 
pathways. Uninfected control MEKs isolated from E2F7 floxed mice showed a modest 
increase in cleaved caspase-3 levels after 48 hours treatment with 0.3 µM doxorubicin 
(Figure 4.1B). In contrast, there was a profound activation of caspase-3 when E2F7 deficient 
MEKs were treated with 0.3 μM doxorubicin (Figure 4.1B). This is consistent with previous 
reports that DNA damage caused by doxorubicin results in double-strand breaks that leads to 
apoptosis (Tacar, Sriamornsak et al. 2013). Combined, these data confirms the findings that a 
unique and isoform-specific function of E2F7 does exist in modulating sensitivity to 
doxorubicin in KCs.  
 
 
Figure 4.1 E2F7 modulates sensitivity to doxorubicin in MEKs, and it is due to 
activation of apoptotic pathways. Dose response curve of doxorubicin-induced cytotoxicity 
at 48 hour in E2F7KD MEKs which were transfected with either an E2F7b, or pcDNA3.1(+) 
control plasmid (A). Viability is plotted as percentage control (untreated). Quantitative data 
represent the mean ± SEM obtained from triplicate determinations of three independent 
experiments. Activation of caspase-3 was determined by immunoblotting extracts of vehicle 
treated and 0.3 µM doxorubicin treated E2F7 floxed and E2F7 deficient KCs (B). β-Actin is a 
loading control. Western blot figures are representative of three independent experiments. *, 
P < 0.05, ****, P < 0.0001. P  value was calculated using Student’s t test.   
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4.2.2 Dysregulation of E2F7 expression in human SCC cell lines contributes to 
insensitivity to the cytotoxic action of doxorubicin 
It was previously shown that human SCCs overexpress E2F7 transcripts (Endo-Munoz, 
Dahler et al. 2009). Since we have shown that E2F7 overexpression can suppress sensitivity 
to doxorubicin in normal KCs, it is reasonable to speculate that the overexpression of E2F7, 
observed in human SCCs, may invoke insensitivity to doxorubicin. We screened a suite of 7 
SCC cell lines: Cal27, Colo16, Detroit562, FaDu, KJDSV40, SCC15 and SCC25, as well as 
normal HEKs for their sensitivity to doxorubicin-induced cytotoxicity (Figure 4.2A). These 
studies identified variable responses of SCC cell lines to doxorubicin. In particular, 
KJDSV40 cell line exhibited the highest sensitivity to doxorubicin treatment with only 30% 
of cells remaining viable at 1 µM (Figure 4.2A). On the other hand, SCC25 cells displayed 
poor sensitivity where 80% of the cells were still viable at 1 µM (Figure 4.2A). Examination 
of E2F1 and E2F7 protein expression levels demonstrated that insensitive SCC25 cells had 
high levels of E2F7 to E2F1 whilst sensitive KJDSV40 cells had low levels of E2F7 relative 
to E2F1 (Figure 4.2B). Overall the insensitive SCC25 cells had 10-fold greater E2F7 
expression relative to E2F1 than did sensitive KJDSV40 cells (Figure 4.2B). These data are 
consistent with our previous report on the relative mRNA expression levels in human SCC 
samples compared with normal human epithelium (Endo-Munoz, Dahler et al. 2009).  
 
 
Figure 4.2 E2F7/E2F1 ratio is disrupted in SCC and contributes to doxorubicin 
sensitivity. HEK, Cal27, Colo16, Detroit562, FaDu, KJDSV40, SCC15 and SCC25 cells 
were treated with doxorubicin for 48 hours and viability plotted as percentage of untreated 
cells (A) Quantitative data represent the mean ± SEM obtained from triplicate determinations 
of three independent experiments. E2F1 and E2F7 protein expression was determined by 
immunoblotting extracts of HEK, KJDSV40 and SCC25 cell lines (B). β-Actin is provided as 
a loading control. Densitometric analysis of E2F1 and E2F7 in KJDSV40 and SCC25 cell 
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lines was quantified using ImageJ. Expression level was normalized against β-Actin and 
plotted as E2F7/E2F1 (B). Western blot figures are representative of three independent 
experiments.  
 
Given that there is a close correlation between the level of E2F7 protein and sensitivity to 
doxorubicin in SCC cells, we sought to determine whether selective upregulation or reduction 
of E2F7 expression by expression plasmid or siRNA, respectively, would change the dose 
response profile of KJDSV40 and SCC25 cells to doxorubicin. Selective upregulation of 
E2F7 was achieved by transfecting KJDSV40 cells with E2F7 expression plasmid as evident 
by qRT-PCR and immunoblot results (Figure 4.3A). As a results, previously sensitive 
KJDSV40 cells became resistant to doxorubicin compared to vector only control cells when 
transfected with E2F7 expression plasmid (Figure 4.3B). To obtain efficient gene 
knockdown, we tested two different siRNAs. SCC25 cells were transfected with 
E2F7.siRNA1 and E2F7.siRNA2 constructs as well as control siRNA, and E2F7 transcript 
and protein levels were examined 48 hours post transfection. Results demonstrated that we 
were able to efficiently knockdown E2F7 transcript and E2F7 protein when transfected with 
E2F7.siRNA2 construct (Figure 4.3C). Results showed that silencing of E2F7 in insensitive 
SCC25 cells could enhance doxorubicin-induced cytotoxicity compared to control siRNA 
transfected SCC25 cells (Figure 4.3D). These data unequivocally demonstrate that resistance 
to doxorubicin is E2F7-dependent in SCC cells. 
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Figure 4.3 The sensitivity to doxorubicin is E2F7-dependent in SCC cells. KJDSV40 
cells were transfected with E2F7b overexpression plasmid or pcDNA3.1(+) control plasmid, 
and E2F7 protein and transcript levels were determined by immunoblotting and qRT-PCR, 
respectively (A). SCC25 cells were transfected with siRNA-targeting E2F7 or a control 
siRNA, and E2F7 protein and transcript levels were determined by immunoblotting and qRT-
PCR, respectively (C). In both instances (B and D), cells were left for 48 hours after 
transfection and then treated with 0, 0.2, 0.5 and 1 µM doxorubicin after which viability was 
estimated by trypan blue exclusion. Viability was expressed as percent viable cells and 
plotted as a percent untreated control. Quantitative data represent the mean ± SEM obtained 
from triplicate determinations of three independent experiments. Western blot figures are 
representative of three independent experiments for (A) and (C). β-Actin is provided as a 
loading control. Real time PCR data are the mean ± SEM of duplicate determinants 
normalized for expression of the housekeeping gene TBP; n = 3 for (A) and (C). *, P ≤ 0.05, 
**, P < 0.01, ***, P < 0.001, ****, P < 0.0001. P  value was calculated using Student’s t test.  
 
4.2.3 Microarray experimental design 
We performed transcriptomic analyses and generated transcriptomic profiles for differentially 
expressed transcripts between two different SCC cell lines. This allowed us to identify genes 
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regulated by E2F7 that contribute to chemoresistance seen in SCC. Table 4.1 summarises the 
cell lines used and their E2F7 and sensitivity status.  
 
Table 4.1 Table of cell lines used in transcriptomics analysis. 
 KJDSV40 SCC25 
E2F7/E2F1 ratio Low High 
Doxorubicin sensitivity sensitive insensitive 
 
Before proceeding with the microarray experiments, we conducted time-course experiments 
where KJDSV40 and SCC25 cells were treated with 1 µM of doxorubicin and RNA was 
harvested at 4, 8, 16, 24 and 48 hours post-treatment for qRT-PCR analysis in order to 
optimise the time points when the transcriptional effects are fully evident. Moreover, 
selecting the right time point will further ensure transcriptional changes to be measured 
before the onset of indirect transcriptional effects through an E2F1 feedback loop. Therefore, 
we identified a time point at which E2F7 transcript reaches its maximum levels without yet 
reducing transcript levels of E2F1. As demonstrated in Figure 4.2B, KJDSV40 cells express 
high levels of E2F1 and almost no E2F7 protein. Moreover they respond to the effects of 
doxorubicin with a significant reduction in cell survival. Upon treatment with 1 µM 
doxorubicin, E2F1 transcript levels remained the same during the course of treatment (Figure 
4.4A) in KJDSV40 cells. On the other hand, there was a time-dependent decrease in E2F7 
transcript levels, where the most significant reduction observed was following 24 hours 
treatment with 1 µM doxorubicin. Time-course analysis of the response of SCC25 cells to 
doxorubicin treatment demonstrated that E2F7 reaches its maximum levels after 24 hours of 
treatment with 1 µM doxorubicin, whilst there is no significant change in E2F1 transcripts 
levels at any of the time points examined (Figure 4.4B). On the basis of these findings, 24 
hour time point was chosen for the treatment of cells with 1 µM doxorubicin prior to RNA 
extraction and subsequent microarray experiments.  
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Figure 4.4 Time-course of E2F1 and E2F7 expressions. 0, 4, 8, 16, 24 and 48 hours after 
treatment with 1 µM doxorubicin, RNA was extracted, and E2F1 and E2F7 expressions were 
analysed by qRT-PCR. Shown are graphs for qRT-PCR results for E2F1 (left) and E2F7 
(right) expressions in KJDSV40 cells (A), and E2F1 (left) and E2F7 (right) expression in 
SCC25 cells (B). mRNA expression is in arbitrary units normalised for expression of the 
housekeeping gene TBP; n = 3. ns is not significant. **** is P < 0.0001. P  value was 
calculated using Student’s t test.  
  
Duplicate SCC cultures were established and RNA was harvested. RNA of biological 
replicates was pooled to account for the biological variations expected under standard tissue 
culture conditions. The RNA analysed were described in Figure 4.5. Briefly, where 
KJDSV40 cells were transfected, two different strategies were taken. KJDSV40 cells were 
either transfected with 3 µg of E2F7 expression plasmid for selective upregulation since these 
cells do not express high levels of E2F7 or with equal concentration of control plasmid 
(pcDNA3.1(+)). RNA was collected 48 hours post-transfection. Where KJDSV40 cells 
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treated with doxorubicin following transfection or not, cells were treated with doxorubicin for 
24 hours and then subjected to RNA isolation.  
 
Where SCC25 cells were transfected two different strategies were taken. SCC25 cells were 
either transfected with 40 nM of siRNA targeting E2F7 for selective downregulation since 
these cells express high levels of E2F7 or with equal concentration of control siRNA. RNA 
was collected 48 hours post-transfection. Where SCC25 cells treated with doxorubicin 
following transfection or not, cells were treated with doxorubicin for 24 hours and then 
subjected to RNA isolation.   
 
 
Figure 4.5 Sample preparation workflow for microarray analysis. Independent duplicate 
samples of RNA were isolated from cells. Subconfluent KJDSV40 cells were treated with 1 
μM dxr for 48 hours. KJDSV40 cells were transfected with either 3 μg E2F7 expression 
plasmid or equivalent concentration of control (empty) vector. KJDSV40 cells were first 
transfected as described and then treated with dxr as described. Subconfluent SCC25 cells 
were treated with 1 μM dxr for 48 hours. SCC25 cells were transfected with either 40 nM 
KJDSV40 
Two biological replicates 
Untreated 
dxr treated 
empty vector 
transfected, 
untreated 
empty vector 
transfected, dxr 
treated 
E2F7 expression 
plasmid 
transfected, 
untreated 
E2F7 expression 
plasmid 
transfected, dxr 
treated 
SCC25 
Two biological replicates 
Untreated 
dxr treated  
control siRNA 
transfected, 
untreated 
control siRNA 
transfected, dxr 
treated 
E2F7 siRNA 
transfected, 
untreated 
E2F7 siRNA 
transfected, dxr 
treated 
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E2F7 siRNA or equivalent concentration of control siRNA. SCC25 cells were first 
transfected as described and then treated with dxr as described. dxr is doxorubicin.  
 
Detailed methodological information including RNA preparation, RNA quality control, 
generation of biotinylated amplified cRNA for microarray hybridisation, microarray 
hybridisation and microarray analysis is available in Section 2.8 Microarray Analysis. Raw 
microarray data was normalised and analysed as pairwise comparisons to identify 
differentially expressed genes. Specifically, we generated transcriptomic profiles for 
differentially expressed transcripts between KJDSV40 and SCC25, and any genes co-
regulated in these groups represented as List X (Figure 4.6). This strategy was taken based on 
previously demonstrated data in this chapter that KJDSV40 cells expressed very low levels of 
E2F7 and were sensitive to the effects of doxorubicin whereas SCC25 cells express greater 
than 10 fold more E2F7 and are insensitive to doxorubicin. Genes which were up-regulated in 
KJDSV40 cells and genes which were down-regulated in SCC25 cells formed this list. The 
second list of differentially expressed genes, representing List Y, were generated following 
comparisons between SCC25 cells and SCC25 cells in which E2F7 had been silenced with 
siRNA (Figure 4.6) (genes were regulated in the same direction). Any genes that were 
regulated in the same direction (up-regulated or down-regulated) by control siRNA and by 
E2F7.siRNA were excluded from List Y for further analysis. List Y genes were cross-
referenced against List X to identify E2F7-modulated transcripts. This list of genes will be 
referred to as List A (Figure 4.6). E2F7 is known to regulate many genes involved in cell 
cycle traverse that are unlikely to be involved in chemosensitivity. Thus, it was important to 
design the microarray experiments in such a way that genes unlikely to be associated with 
doxorubicin-mediated chemoresistance could be excluded from the analysis. Therefore, in 
order to identify E2F7-regulated transcripts that may modulate sensitivity to doxorubicin, we 
generated a new list of genes (List Z) from a comparison between SCC25 cells and SCC25 
cells in which E2F7 had first been silenced and then treated with 1 µM of doxorubicin 
(Figure 4.6). List Z was cross-referenced with genes generated in List Y, co-regulated genes 
representing List B (Figure 4.6). List B identified E2F7-modulated transcripts in modulating 
sensitivity to doxorubicin. Noticeably, all candidate genes identified in List A as 
differentially regulated by E2F7 were represented in List B (Figure 4.6), confirming the 
practical validity of the microarray design. Finally, combining genes generated in List A and 
List B allowed for the identification of genes which are downstream effectors of E2F7-
dependent cytotoxic sensitivity.  
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It should be noted that the pairwise comparisons between KJDSV40 cells and KJDSV40 cells 
in which E2F7 had been overexpressed failed to detect E2F7 as one of the significantly 
overexpressed genes. As a consequence, data from KJDSV40 cells, except the data from 
untreated KJDSV40, was excluded from the resultant list for further analysis. Therefore, only 
the comparisons represented in Figure 4.6 were considered in microarray analysis.  
 
 
Figure 4.6 Summary of microarray analysis strategy used to enrich for differentially 
expressed genes. Transcriptomic profiles were generated from each comparisons presented 
above. Any genes that were regulated in the same direction by control siRNA in SCC25 cell 
line in which E2F7 was silenced by siRNA were excluded from further analysis. The lists of 
differentially expressed genes, List A (A) and List B (B), were combined, representing 
downstream effectors of E2F7-dependent cytotoxic sensitivity genes.  
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Table 4.2 Differentially expressed genes identified as E2F7-dependent cytotoxic 
sensitivity genes. Statistical cutoffs of greater than ±1-fold change and B-value greater than 3 
have been applied as criteria for inclusion in this list. Negative fold change indicates a 
decrease in expression. B-value is a measure of statistical significance, with a B-value greater 
than 3 indicating 95% chance of the gene being differentially expressed. Sphk1 and 
RacGAP1 were selected for further analysis.  
Gene 
name 
Entrez 
ID 
Fold 
change 
 
KJDSV40 
vs SCC25 
 
B-value 
 
 
KJDSV40 
vs SCC25 
 
Fold 
change 
 
SCC25 
vs 
SCC25.
E2F7si
RNA 
 
B-
value 
 
SCC25 
vs 
SCC25.
E2F7si
RNA 
 
Fold change 
 
SCC25 vs 
SCC25.E2F7siRNA+
doxorubicin 
 
B-value 
 
 
SCC25 vs 
SCC25.E2F7siRNA+
doxorubicin 
 
CD44 960 -1.7 15.6 1.34 12.3 1.0 8.1 
RRP8 23378 -1.16 13 1.17 13.9 1.0 11.5 
Sphk1 8877 -1.22 3.2 1.16 3 1.2 3.6 
RacGAP1 29127   1.3 11 1.9 17 
 
We were able to identify 4 genes, CD44, RRP8, SPHK1, RACGAP1, following stringent 
analysis (Table 4.2). Genes had to be up- or down-regulated by at least 1-fold in both the 
groups compared to be reported for differential expression, with a B-value of at least 3 in 
both groups compared (Table 4.2). The B-value was calculated as a measure of the likelihood 
a gene is truly expressed, where a value greater than 3 corresponding to 95% likelihood of 
differential expression. Microarray data has been deposited to gene expression omnibus 
(GEO) under the reference GSE58074.  
 
Real time PCR analysis of these four genes was undertaken to validate the results of the 
microarray analysis. Indeed, all of the genes found by microarray analysis to be differentially 
expressed could be confirmed by PCR. Moreover, induction of all four genes was confirmed 
in SCC25 cells compared with KJDSV40 cells (Figure 4.7). In addition, induction of all four 
genes modulated by E2F7 observed by microarray was also confirmed using real time PCR in 
SCC25 in which E2F7 had been depleted compared to SCC25 cells (Figure 4.7).  
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Figure 4.7 Microarray results were validated by qRT-PCR analysis. Quantitative RT-
PCR was used to determine the expression of CD44 (A), RRP8 (B), Sphk1 (C) and RacGAP1 
(D) transcripts using cDNA from KJDSV40 cells, SCC25 cells and SCC25 cells in which 
E2F7 had been depleted by siRNA. Data are the mean ± SEM of duplicate determinants 
normalized for expression of the housekeeping gene TBP; n = 3. ***, P < 0.001 versus 
SCC25, ****, P < 0.0001 versus SCC25. P  value was calculated using Student’s t test.  
 
Some of the differentially expressed genes, CD44 and Sphk1, were known to be involved in 
chemotherapeutic sensitivity, whilst the association of others, RRP8 and RacGAP1, appear 
novel. CD44 is one of the well established cancer stem cell markers and already examined in 
detail in several other studies. Although RRP8 is of one of the novel transcripts identified in 
our microarray experiments, it was not examined further due to lack of commercially 
available reagents and antibodies. On the other hand, Sphk1 was selected to be investigated 
further for E2F7-mediated chemosensitivity, on the basis of an existing literature reporting 
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Sphk1 upregulation in SCC and the availability of pharmacological inhibitors. RacGAP1 
identified from microarray was also selected for further analysis as a potential mediator of 
E2F7-dependent cytotoxic responses in SCC due to its novelty.  
 
4.3 Discussion 
In this chapter we used transcriptomic profiling to identify 4 potential downstream effectors 
of E2F7-dependent doxorubicin resistance. It has been shown that some apoptotic responses 
are regulated by E2F in an E2F isoform-specific manner (Kwong, Nguyen et al. 2003; Li, 
Ran et al. 2008; Endo-Munoz, Dahler et al. 2009). In this regards, the overexpression of E2F7 
seen in SCC patients (100 fold overexpression) supports the idea that E2F7 overexpression 
could confer resistance to the apoptotic effects of chemotherapy in SCC. Significantly, the 
E2F7-selective action appears to be restricted to the anthracyclines which suggests that if we 
identify ways to manipulate the E2F7 effectors they may allow us to use anthracyclines to 
treat SCC. The antiapoptotic function of E2F7 is well-documented and is reported to be due 
to the inhibition of E2F1-induced apoptosis. To this end, our data indicates that the ratio of 
E2F7 relative to E2F1 protein closely correlates with sensitivity to doxorubicin in SCC cells 
and KCs. Recent global profiling of gene expression changes in E2F7 KO embryos identified 
stress responses as being regulated by E2F7. Although, dysregulation of apoptosis is common 
in SCC, it is incomplete and hence SCC cells retain a capacity for apoptosis under certain 
circumstances (Dahler, Rickwood et al. 2007; Endo-Munoz, Dahler et al. 2009). Thus, it is 
tempting to speculate that it is possible to target E2F7 and sensitise SCC to the cytotoxic 
actions of doxorubicin by targeting downstream effectors of E2F7.  
 
In this chapter I identified CD44, RRP8, SPHK1 and RACGAP1 as potential downstream 
effectors of E2F7-dependent doxorubicin sensitivity. Significantly, all 4 genes showed 
excellent concordance with the microarray data, evaluated by qRT-PCR. Sphk1 and 
RacGAP1 were deemed suitable for further study to evaluate whether they play a role in 
E2F7-mediated resistance to doxorubicin. I will explore the potential role of Sphk1 and 
RacGAP1 in Chapters 5 and Chapter 6.    
 
4.3.1 Sphingosine kinase 1 and Rac GTPase activating protein 1 in SCC 
Sphingosine kinase 1 (Sphk1) is a kinase responsible for the conversion of sphingosine to 
sphingosine-1-phosphate (S1P) (Shida, Takabe et al. 2008; Fyrst and Saba 2010; Pyne and 
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Pyne 2010). Interrogation of publicly available microarray data (www.oncomine.org) shows 
statistically significant increases in Sphk1 expression in a number of solid tumours, including 
breast, colon, lung, ovary, prostate, melanoma, stomach, uterus as well as squamous cell 
carcinoma and it’s precursor actinic keratosis. Importantly, Sphk1 has been shown to 
modulate proliferation, differentiation and apoptosis in KCs (Facchinetti, Gandini et al. 
2010). Facchinetti and colleagues recently reported that Sphk1 is overexpressed in malignant 
oral epithelia compared with nonmalignant tissue, and the expression of Sphk1 was 
correlated with poor prognosis, shorter patient survival and loss of p21 expression in HNSCC 
(Facchinetti, Gandini et al. 2010). Of relevance to the present study, Bonhoure and colleagues 
reported that forced expression of Sphk1 led to resistance to doxorubicin- and etoposide-
induced cell death in HL-60 leukemia cells (Bonhoure, Pchejetski et al. 2005), and 
degradation of Sphk1 resulted in induction of apoptosis in MCF7 breast cancer cells treated 
with doxorubicin (Sarkar, Maceyka et al. 2005). Therefore, this could, in part, explain why 
Sphk1 was detected in our microarray analysis as one of the differentially expressed genes is 
doxorubicin sensitive KJDSV40 cells. Sphk1 activity in vitro, in HNSCC patient samples and 
in vivo will be examined in the next chapter.  
 
Rac GTPase activating protein (RacGAP1) is an evolutionarily conserved GAP protein 
towards Rho family GTPases. It plays a crucial role in cytokinesis and is essential for the 
induction and completion of cytokinesis, thus RacGAP1 depletion results in impairment of 
cell division in vitro and in vivo (Nishimura, Oki et al. 2013). RacGAP1 is also involved in 
IL6-induced macrophage differentiation, nuclear transport of STAT3/5 transcription factors 
and STAT3 activation by forming a complex with Rac1 and STAT3 (Kawashima, Hirose et 
al. 2000; Tonozuka, Minoshima et al. 2004). A positive correlation between RacGAP1 and a 
known proliferation marker Ki67 has been reported (Saigusa, Tanaka et al. 2014). Moreover, 
RacGAP1 has been shown to contribute to cancer progression through PRC1 by enhancing 
cell motility, proliferation and survival (Wang, Ooi et al. 2011). PI3K/AKT signalling 
pathway was among the most significantly altered canonical pathways following the 
silencing of RacGAP1 expression in hepatocellular carcinoma cells (Wang, Ooi et al. 2011). 
To the best of our knowledge, RacGAP1 has not been implicated in squamous cell carcinoma 
before. However, the clinical significance of RacGAP1 has been reported in several 
malignancies including meningioma, breast cancer, nonsmall-cell lung cancer and 
hepatocellular carcinoma (Fritz, Brachetti et al. 2002; Wang, Ooi et al. 2011; Ke, Ke et al. 
2013; Kotoula, Kalogeras et al. 2013; Pliarchopoulou, Kalogeras et al. 2013). Moreover, high 
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RacGAP1 mRNA levels were significantly associated with tumour recurrence and poor 
prognosis in meningiomas (Ke, Ke et al. 2013). Therefore, upregulation of RacGAP1 in 
SCC25 cells could be clinically relevant and involved in doxorubicin resistance. These 
possibilities will be investigated using in vitro and in vivo approaches in the final results 
chapter of this thesis. 
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CHAPTER FIVE 
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5 Sphingosine kinase 1 is a novel downstream effector of E2F7 
and regulates doxorubicin sensitivity in squamous cell 
carcinoma 
 
5.1 Foreword 
All of the experimental data of this chapter were presented in a manuscript which has been 
published in Clinical Cancer Research (Hazar-Rethinam, Merida de Long et al. 2014) and a 
PDF version of the paper is inserted in the next section of this chapter. It is then followed by 
supplementary figures that accompany the published version of the manuscript. Detailed 
materials and methods for these experiments have been included in Chapter 2. 
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5.2 A novel E2F/Sphingosine kinase 1 axis regulates anthracycline 
response in squamous cell carcinoma 
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Abstract 
Purpose: Head and neck squamous cell carcinomas (HNSCC) are frequently drug resistant 
and have a mortality rate of 45%. We have previously shown that E2F7 may contribute to 
drug resistance in SCC cells. However, the mechanism and pathways involved remain 
unknown.  
Experimental Design: We used transcriptomic profiling to identify candidate pathways that 
may contribute to E2F7-dependent resistance to anthracyclines. We then manipulated the 
activity/expression of the candidate pathway using overexpression, knockdown and 
pharmacological inhibitors in in vitro and in vivo models of SCC to demonstrate causality. In 
addition, we examined the expression of E2F7 and a downstream effector in a tissue 
microarray (TMA) generated from HNSCC patient samples.  
Results: E2F7-deficient keratinocytes were selectively sensitive to doxorubicin and this was 
reversed by overexpressing E2F7. Transcriptomic profiling identified Sphingosine kinase 1 
(Sphk1) as a potential mediator of E2F7-dependent drug resistance. Knockdown and 
overexpression studies revealed that Sphk1 was a downstream target of E2F7. TMA studies 
showed that E2F7 overexpression correlated with Sphk1 overexpression in human HNSCC. 
Moreover, inhibition of Sphk1 by shRNA or the Sphk1 specific inhibitor, SK1-I (BML-
EI411), enhanced the sensitivity of SCC cells to doxorubicin in vitro and in vivo. 
Furthermore, E2F7 induced doxorubicin resistance was mediated via Sphk1-dependent 
activation of AKT in vitro and in vivo. 
Conclusion: We identify a novel drugable pathway in which E2F7 directly increases the 
transcription and activity of the Sphk1/S1P axis resulting in activation of AKT and 
subsequent drug resistance. Collectively, this novel combinatorial therapy can potentially be 
trialed in humans using existing agents. 
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Translational Relevance 
Head and neck squamous cell carcinoma (HNSCC) is one of the most prevalent cancers 
diagnosed worldwide. Current chemotherapies are not considered a curative option for 
HNSCC.  Thus, there is a need for new and selective therapies. In this regard, the E2F family 
of transcription factors has been shown to contribute to the development and maintenance of 
HNSCC. However, E2F-based therapies are currently not available. To circumvent this 
problem we embarked on a transcriptomics screen to identify factors that were responsible 
for E2F7-dependent resistance to anthracyclines in HNSCC. The present study demonstrates 
that E2F7 directly controls the expression of Sphk1 resulting in increases in AKT 
phosphorylation which drives drug resistance. Thus, we have identified a previously 
undescribed E2F7/Sphingosine kinase 1/Sphingosine-1-phosphate/AKT axis that contributes 
to anthracycline resistance in HNSCC. A significant implication of this finding is that 
combining an anthracycline with a Sphk1 inhibitor may provide a curative option for treating 
HNSCC. 
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Introduction 
Head and neck squamous cell carcinomas (HNSCC) arise from stratified squamous epithelia 
of the mucosae of the upper aerodigestive tract. At present the mainstay of treatment for 
advanced HNSCC is surgery and/or radiation plus adjuvant chemotherapy (1). The use of 
adjuvant chemotherapy provides modest improvements to overall survival but are not 
considered curative in their own right (1). Thus, if we are to improve outcomes in patients 
with advanced HNSCC we need to develop systemic therapies that target novel pathways 
activated in HNSCC cells.  
 
HNSCC is a complex cancer associated with a large mutational burden (2, 3) and 
accompanied by dysregulation of proliferation, differentiation and apoptosis. HNSCC is also 
accompanied by dysregulation of the main functions of the E2F transcription factor family (4, 
5). E2F refers to a family of 10 gene products from 8 genes (E2Fs 1, 2, 3a, 3b, 4, 5, 6, 7a, 7b, 
8) that have been broadly divided into activators (E2F1-E2F3a) and inhibitors (E2F3b and 
E2F4-E2F8) (6).  The E2F family regulates a diverse array of functions such as proliferation, 
differentiation, apoptosis and stress responses (7, 8). The way in which the E2F family co-
ordinate such diversity of action is through isoform specific functions of the individual E2Fs 
(e.g. activators vs inhibitors) coupled with context-specific interacting partner proteins such 
as pocket proteins and HDACs (7, 8). In the context of keratinocytes (KCs), it has been 
shown that normal human and murine KCs express all members of the E2F family with the 
exception of E2F6 (9, 10). It has been shown that proliferation and differentiation of KCs is 
regulated by the opposing actions of E2F1 and E2F7 (4, 9, 11, 12).  Significantly, E2F1 and 
E2F7 are overexpressed in patient SCCs (10) and contribute to the development of cutaneous 
SCC (13, 14).  
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In addition, to the role of E2Fs in proliferation and differentiation, E2Fs are also key 
regulators of apoptosis and stress responses (7, 8). For example, E2F1 has been shown to 
have potent pro-apoptotic actions that regulate the numbers of thymic lymphocytes (15). 
Intriguingly, E2F1 mediated-apoptosis has been reported to be via p53-dependent and p53-
independent pathways (16) suggesting that cellular context may determine the mechanism by 
which E2F1 induces apoptosis. More recently, E2F7 was reported to antagonise the pro-
apoptotic actions of E2F1 in the context of etoposide or doxorubicin induced DNA damage 
(10, 17). Thus, the ratio of E2F1 to E2F7 determines apoptotic responses.  However, the 
mechanism by which E2Fs control apoptotic responses remains unknown. In the present 
study, we examined downstream effectors of E2F7 that modulate resistance to chemotherapy. 
We now identify a previously undescribed E2F7/Sphk1/S1P/AKT axis that contributes to 
anthracycline resistance in SCC. In addition, we identify a novel drug combination that could 
represent a potentially curative option for advanced SCC. 
Cancer Research. 
on December 10, 2014. © 2014 American Association forclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 19, 2014; DOI: 10.1158/1078-0432.CCR-14-1962 
7 
 
Materials and Methods 
Animal studies 
All animal experiments were approved by the Institutional Animal Ethics Committee. 
E2F7
Flox/Flox
, E2F8
Flox/Flox
 and E2f1 KO mice have been described (15, 18). FVB X C57BL/6 
crosses were generated in house. In vivo tumour studies used female nonobese diabetic/severe 
combined immunodeficient (NOD/SCID). 
 
Reagents and viability assays 
The following drugs were purchased; doxorubicin (Sigma Aldrich), SK1-I (BML-EI411) 
(Enzo Life Sciences), S1P (Cayman Chemicals). Stocks of BGT226 were prepared as 
described (19). Viability was determined using trypan blue, Cell Titer 96 Aqueous One 
Solution Cell Proliferation Assay (Promega), or western blot for cleaved caspase 3 or PARP 
cleavage as described (20, 21).  Sphk1 activity and S1P levels were estimated using 
commercially available kits (Echelon Biosciences).  
 
Tissue culture and adenovirus infection 
Murine epidermal keratinocytes (MEKs) and human epidermal keratinocytes (HEKs) were 
isolated and cultured as described (22, 23). SCC25 cells were obtained from the American 
Type Culture Collection. FaDu was a kind gift from Dr. Elizabeth Musgrove (Garvan 
Institute, New South Wales, Australia) and were verified by short tandem repeat genotyping 
(11). KJDSV40 cells were maintained as described previously (11). To generate E2F7 and 
E2F8 KO keratinocytes, we incubated MEKs with ready-to-use Ad-CMV-Cre as per 
manufacturer’s recommendations (MOI of 50) (Vector Biolabs).    
 
Gene expression studies 
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Total RNA was isolated, cDNA prepared and quantitative reverse transcriptase PCR (qRT-
PCR) performed as described (10, 24). For microarray analysis, complementary RNA was 
generated with the Illumina TotalPrep RNA Amplification Kit and hybridised with Illumina 
HumanHT-12 v4 Expression BeadChips (Illumina) as per manufacturer’s protocol. 
Expression data from the microarrays was analysed as previously described (25).  The 
microarray data reported in this article have been deposited in NCBI’s Gene Expression 
Omnibus (GEO) database under the accession number GSE58074. Chromatin 
immunoprecipitation (ChIP) was conducted using the SimpleChIP Enzymatic Chromatin IP 
Kit (Magnetic Beads) (Cell Signaling) in accordance with the manufacturer’s instructions.  
 
shRNA studies, siRNA delivery and transfections 
Control and overexpression plasmids and siRNAs used for manipulating E2F7 have been 
described previously (10, 17). SureSilencing shRNA plasmids directed against Sphk1 were 
purchased from SuperArray Bioscience Corp. A Sphk1 expression (TrueORF Gold Clones) 
and control plasmids were purchased from OriGene Technologies.  
 
Immunoblot 
The following primary antibodies were used: E2F-1 (C-20) 1:1,000 (Santa Cruz), Anti-E2F7 
1:2,000 (Abcam), cleaved caspase-3 (Asp 175) 1:1,000 (Cell Signaling), Anti-SPHK1 
1:1,000 (Sigma), PARP 1:1,000 (Cell Signaling), phospho-Akt (Ser473) (D9E) XP 1:2,000 
(Cell Signaling), Akt 1:2,000 (Cell Signaling), and β-actin 1:10,000 (Sigma Aldrich). Where 
a western blot has been quantitated, results represent relative protein levels normalised to β-
actin as quantified by Image J (Wayne Rasband, National Institutes of Health, USA).   
 
Immunohistochemistry and tissue microarrays 
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Immunohistochemistry was conducted as described (20, 21). The following primary 
antibodies were used: PCNA 1:3,000 (Sigma Aldrich), cleaved caspase-3 (Asp 175) 1:50 
(Cell Signaling), phospho-Akt (Ser473) (D9E) XP 1:50 (Cell Signaling). Secondary antibody 
was Starr Trek Universal HRP Detection System followed by colorimetric 
immunohistochemical staining with Cardassian DAB Chromogen as per manufacturer’s 
instructions (Biocare Medical). TMAs were generated using duplicate 1 mm cores of 
matched a) adjacent normal tissue, b) primary HNSCC lesion and c) matched metastatic 
lymph node from patients treated for HNSCC at the PAH. Immunohistochemistry was 
conducted using Dako EnVision + System-HRP (DAB) kit in accordance with the 
manufacturer’s instructions. Sections were incubated with Anti-E2F7 1:250 (Abcam) and 
Anti-SPHK1 1:75 (Sigma Aldrich) antibodies. Staining intensity was evaluated by two 
Pathologists in a blinded fashion using a modified quickscore method as described (26).  
 
Statistical analysis 
Statistical significance was calculated by a Student’s t test with a 95% confidence level using 
GraphPad Prism v5 (GraphPad software).  
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Results 
E2F7 selectively regulates cytotoxic responses to doxorubicin in KCs 
To examine the downstream pathways involved we generated primary cultures of MEKs 
from E2f1 KO mice (15), or from E2f7
Flox/Flox 
or E2f8
Flox/Flox  
mice (18). We generated E2f7, 
and E2f8 knock down (KD) MEKs via adenovirus (Ad) mediated Cre deletion of floxed 
sequences in primary KCs isolated from E2f7 and E2f8 floxed mice. E2f1 gene expression 
levels in KCs isolated from conventional E2f1KO mice were reduced by 70% whilst E2f7 and 
E2f8 mRNA expression was reduced more than 90% following 48 hour infection of the 
cognate floxed KCs with Ad-CMV-Cre (Figure S1). The reduction in E2f1 expression was 
less than expected but sequencing confirmed the PCR product was E2f1. Significantly, 
infection with an empty Ad viral vector did not alter cell viability, mRNA expression, 
differentiation-competence or cytotoxic responses to UVB, doxorubicin or cisplatin (Figure 
S2).  
 
We examined the dose-dependent cytotoxic profiles of uninfected control, E2f7 KD, E2f8 KD 
and E2f1KO cells to increasing concentrations of doxorubicin (0-1 µM) for 48 hours. E2f7 
deficient MEKs were hypersensitive to the cytotoxic actions of doxorubicin (Figure 1A) or 
another anthracycline, epirubicin (Figure S3A). Significantly, E2f7 deficiency only had 
minimal effect on cisplatin sensitivity (Figure S3B) and no impact on etoposide sensitivity 
(Figure S3C). E2f8 had no effect on cytotoxic responses to any of the drugs (Figures 1A and 
S3) whilst E2f1 deficiency resulted in modest protection against doxorubicin-induced 
cytotoxicity (Figure 1A). To confirm that the effect of E2f7 deficiency was attributable to 
E2f7 we reintroduced E2f7 into E2f7-deficient KCs to confirm that it suppressed doxorubicin 
sensitivity.  Reintroduction of E2f7 into E2f7 deficient MEKs resulted in a 2.5 fold increase 
in E2F7 mRNA expression determined by qRT-PCR and was sufficient to re-instate 
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doxorubicin resistance  (Figure 1B). We then determined whether E2f7-mediated reduction in 
cell survival is due to activation of apoptotic pathways. Uninfected control MEKs isolated 
from floxed E2f7 mice showed a modest increase in cleaved caspase-3 levels after 48 hours 
treatment with 0.3 µM doxorubicin (Figure 1C). In contrast, there was a profound activation 
of caspase-3 when E2f7 deficient MEKs were treated with 0.3 μM doxorubicin (Figure 1C). 
Combined, these data identify a unique and isoform-specific function of E2f7 in modulating 
sensitivity to anthracyclines in KCs.  
 
Dysregulation of E2F7 expression in human SCC cell lines contributes to insensitivity to 
the cytotoxic action of doxorubicin 
It is reasonable to speculate that the overexpression of E2F7, observed in human SCCs (10), 
may invoke insensitivity to doxorubicin. We screened a suite of SCC cell lines (FaDu, 
KJDSV40 and SCC25) as well as normal human epidermal keratinocytes (HEKs) for their 
sensitivity to doxorubicin-induced cytotoxicity (Figure 1D).  These studies showed that 
KJDSV40 cell lines were the most sensitive to doxorubicin treatment with 70% reduction in 
cell viability at 1 µM (Figure 1D). On the other hand, SCC25 cells displayed the least 
sensitivity where 80% of the cells were still viable at 1 µM (Figure 1D). Examination of 
E2F1 and E2F7 protein expression levels demonstrated that insensitive SCC25 cells had high 
levels of E2F7 to E2F1 whilst sensitive KJDSV40 cells had low levels of E2F7 relative to 
E2F1 (Figure 1E).  Overall the insensitive SCC25 cells had 10 fold greater E2F7 expression 
relative to E2F1 than did sensitive KJDSV40 cells.  It was not possible to generate values for 
the HEKs due to their low levels of expression of E2F1 and E2F7.  
 
We next sought to determine whether selective upregulation or reduction of E2F7 expression 
by expression plasmid or siRNA (validation of siRNA is shown in Figure S4A), respectively, 
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would change the dose response profile of KJDSV40 and SCC25 cells to doxorubicin. 
Results showed that previously sensitive KJDSV40 cells became resistant to doxorubicin 
compared to vector only control cells when transfected with E2F7 expression plasmid (Figure 
1F). In contrast, silencing of E2F7 in insensitive SCC25 cells resulted in a 2.2 fold reduction 
in E2F7 mRNA expression determined by qRT-PCR and could enhance doxorubicin-induced 
cytotoxicity compared to control siRNA transfected SCC25 cells (Figure 1G). These data 
unequivocally demonstrate that resistance to doxorubicin is E2F7-dependent in SCC cells. 
 
Sphingosine kinase 1 (Sphk1) is a downstream effector of E2F7-mediated suppression of 
doxorubicin-induced cytotoxicity 
To identify the downstream effectors of E2F7 in SCC cells, we generated transcriptomic 
profiles for differentially expressed transcripts between the KJDSV40 cells (sensitive and low 
E2F7/E2F1 ratio) and SCC25 cells (insensitive and high E2F7/E2F1 ratio). We also 
generated a list of upregulated genes between SCC25 cells and SCC25 cells in which E2F7 
had been silenced with siRNA. This latter list identified E2F7-modulated transcripts which 
were then cross-referenced against the list of genes identified as downregulated in KJDSV40 
cells compared with SCC25 cells. A detailed explanation of this analysis is being prepared 
for publication elsewhere (Hazar-Rethinam et al, in preparation). By selecting for genes with 
a B-value greater than 3 (exceeding the 95% confidence interval) and a fold change greater 
than 1, we were able to identify 4 genes (Sphk1, RACGAP1, CD44, RRP8) that were 
differentially upregulated.  
 
Of the transcripts identified in our screen, sphingosine kinase 1 (Sphk1) was the most 
significantly overexpressed. Sphk1 is a kinase responsible for the conversion of sphingosine 
to sphingosine-1-phosphate (S1P) (27-29). Interrogation of publicly available microarray data 
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indicates statistically significant increases in Sphk1 expression in breast, colon, lung, ovary, 
prostate, melanoma, stomach, uterus as well as squamous cell carcinoma and it’s precursor 
actinic keratosis (28). Importantly, Sphk1 has been shown to modulate proliferation, 
differentiation and apoptosis in KCs (30). Facchinetti and colleagues recently reported that 
Sphk1 is overexpressed in malignant oral epithelia compared with nonmalignant tissue, and 
the expression of Sphk1 was correlated with poor prognosis, shorter patient survival and loss 
of p21 expression in HNSCC (30). Of relevance to the present study,  Bonhoure and 
colleagues reported that forced expression of Sphk1 led to resistance to doxorubicin- and 
etoposide-induced cell death in HL-60 leukemia cells (31), and degradation of Sphk1 resulted 
in induction of apoptosis in MCF7 breast cancer cells treated with doxorubicin (32). Thus, 
there is sufficient evidence to speculate that a novel E2F7/Sphk1/S1P axis may exist in SCC 
cells that regulates doxorubicin sensitivity.   
 
Quantitative RT-PCR was used to confirm that Sphk1 was more highly expressed in SCC25 
cells than in KJDSV40 cells (Figure 2A). Consistent with this, we show that transfection of 
SCC25 cells with siRNA directed against E2F7 resulted in profound inhibition of Sphk1 
expression (Figure 2A) whilst E2F1 mRNA expression was derepressed (Figure S4B). 
Similarly, Sphk1 activity was significantly elevated in SCC25 cells compared with KJDSV40 
(Figure 2B). Moreover, we showed that knockdown of E2F7, by siRNA, in SCC25 cells 
reduced Sphk1 protein expression (Figure 2C) whilst transient overexpression of E2F7 in 
KJDSV40 cells resulted in an increase in Sphk1 protein levels (Figure 2C). These data 
suggested  that Sphk1 may be a downstream effector of E2F7-induced resistance to 
doxorubicin. As shown in Figure 2D (Left and center panels), E2F7 overexpression did not 
protect from Sphk1 knockdown or SK1-I-enhanced cytotoxicity in KJDSV40 cells. Similarly, 
Sphk1 overexpression in SCC25 cells overrides doxorubicin sensitivity induced by E2F7 
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siRNA (Figure 2D, Right panel). These data unequivocally demonstrate that Sphk1 is the 
downstream effector of E2F7-dependent sensitivity of SCC cells to doxorubicin. It remains 
unclear whether Sphk1 is a direct or indirect target of E2F7. In this regard, ChIP assays 
showed that E2F7 could bind the Sphk1 and E2F1 promotersin SCC25 cells compared with 
low levels of binding in KJDSV40 cells indicating that the Sphk1 and E2F1 promoters are 
direct binding targets of E2F7 (Figure 2E).  
Next, we sought to determine whether there was evidence that Sphk1 was overexpressed in 
primary human SCC tumours.  We have generated tissue microarrays (TMAs) comprising 
duplicates of normal, primary tumour and matched metastasis from HNSCC patients treated 
at the Princess Alexandra Hospital (PAH), Queensland, Australia. The TMAs were stained 
for E2F7 and Sphk1 protein expression by immunohistochemistry and scored by two 
Pathologists. Figure 2F shows that Sphk1 and E2F7 are overexpressed in HNSCC compared 
to matched adjacent normal tissue.  Figure 2F also shows that primary tumour and metastatic 
tumour do not differ significantly in the levels of E2F7 or Sphk1.  
 
Sphk1 inhibition sensitizes SCC cells to doxorubicin-induced cytotoxicity 
In order to determine whether Sphk1 contributes to doxorubicin sensitivity, we studied the 
effects of silencing Sphk1 in insensitive SCC25 cells. Sphk1 gene silencing was achieved via 
shRNA and caused a marked decrease in Sphk1 protein level (Figure 3A), Sphk1 enzyme 
activity (Figure 3B) and S1P (a product of Sphk1) measured in cell lysates (Figure 3C) and 
significantly enhanced sensitivity of SCC25 cells to doxorubicin (Figure 3D). Conversely, 
overexpression of Sphk1 in insensitive KJDSV40 cells resulted in increases in Sphk1 protein 
level (Figure 3E), enzyme activity (Figure 3F), S1P production (Figure 3G) and reduced 
sensitivity to doxorubicin compared to vector control (Figure 3H). S1P is the product of 
Sphk1-catalysed phosphorylation of sphingosine, and has been shown to mediate the anti-
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apoptotic effects of Sphk1 (27, 29).  Consistent with this, we found that treatment of 
KJDSV40 cells with 1 M S1P reduced cytotoxicity by 2.6 fold (Figure 3I). Combined, these 
data indicate that sensitivity to doxorubicin is mediated via a novel E2F7/Sphk1/S1P axis in 
SCCs.   
 
Knockdown of Sphk1 sensitizes resistant SCC cells to doxorubicin-induced cytotoxicity 
in vivo 
Our data suggest that inhibition of Sphk1 activity, in combination with doxorubicin, may be a 
viable therapeutic strategy for treating SCC. To answer this question, SCC25 cells were 
constructed to stably express either vector control or Sphk1 shRNA and inoculated in 
NOD/SCID mice. When tumours were approximately 3 mm in diameter, mice were 
randomized into four groups and treated with vehicle dimethyl sulfoxide (DMSO) or 0.5 
mg/kg doxorubicin by intraperitoneal (i.p.) injections twice per week (Figure 4A). Treatment 
of mice bearing vector control SCC25 tumours with/without 0.5 mg/kg doxorubicin had 
minimal effect on body weight (Figure 4B) or tumour growth rates (Figure 4C). Knockdown 
of Sphk1 in SCC25 cells did not affect tumour growth in vivo. In contrast, Sphk1 deficient 
SCC25 tumours treated with doxorubicin started to regress by day 7 post-treatment (Figure 
4C) with no effect on body weight (Figure 4B). Strikingly, on day 13 post-treatment there 
was a complete loss of tumours in doxorubicin treated mice inoculated with 
SCC25/Sphk1shRNA cells (Figure 4C).  
 
We next examined whether we could achieve similar tumour regression when tumours are 
larger at the commencement of therapy. Since the tumours derived from Sphk1 deficient 
SCC25 cells treated with vehicle (Figures 4C and 4D; blue triangle) were similar in growth 
rate and size to tumours in mice bearing vector control transfected SCC25 tumours that had 
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been treated with 0.5 mg/kg doxorubicin (Figures 4C and 4D; red square), we started to treat 
these mice when their tumours reached around 0.5 cm
3
 with 0.5mg/kg doxorubicin (Figure 
4D). As shown in Figure 4D, doxorubicin treatment dramatically reduced the tumour volume 
showing profound regression one week after doxorubicin was started in Sphk1 deficient 
group of animals as compared with those inoculated with control vector (Figure 4D). All 
mice were sacrificed at day 28 post-treatment when the tumour burden in the control mice 
reached the ethically approved maximum size. Upon autopsy, the mice inoculated with the 
Sphk1-deficient SCC cells (Figures 4C and 4D; green triangle) only contained a fragile 
cluster of cellular material that could not be harvested for histopathology.  
 
The Sphk1 specific inhibitor, SK1-I (BML-EI411), sensitises SCC cells to doxorubicin in 
vitro and in vivo 
SK1-I is a water-soluble sphingosine analog with a Ki value of approximately 10 µM which 
potently inhibits Sphk1 activity (33). Importantly, SK1-I does not significantly inhibit 
SPHK2, PKA, AKT1, ERK1, EGFR or CDK2 (33). We treated SCC25 cells with increasing 
doses of SK1-I for 48 hours and then measured Sphk1 enzyme activity. As anticipated, SK1-I 
significantly reduced Sphk1 activity in a dose-dependent manner, indicating inhibition of 
Sphk1 activity (Figure 5A). Moreover, we confirmed that the inhibition was not due to the 
loss of Sphk1 protein expression (Figure 5B).  
 
Next, we investigated whether Sphk1 specific inhibition can enhance the cytotoxic effects of 
doxorubicin in insensitive SCC25. After 48 hours incubation with SK1-I alone, the viability 
of control HEK (Figure S5A) and resistant SCC25 cells did not change (Figure 5C). 
However, treatment of doxorubicin-resistant SCC25 cells with 1 µM doxorubicin with 
increasing doses of SK1-I resulted in profound and dose dependent loss of cell viability 
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(Figure 5C). Predictably, SK1-I did not enhance doxorubicin sensitivity in KJDSV40 cells 
(Figure S5B). In contrast to SCC25 cells, the addition of increasing doses of SK1-I to 
doxorubicin, in HEKs, did not enhance the cytotoxicity obtained with doxorubicin alone 
(Figure S5A). Next, we examined whether the cell death effects of SK1-I and doxorubicin 
were mediated via apoptosis. Consistent with an apoptotic reaction, we observed increases in 
cleaved caspase-3 and cleaved PARP1 in response to doxorubicin + SK1-I (Figure 5D).  
 
We inoculated NOD/SCID mice with SCC25 cells and allowed tumours to establish 
subcutaneously. When tumours were around 4 to 5 mm in diameter, mice were randomized 
into six groups and treated with DMSO, 0.5 mg/kg doxorubicin, 5 mg/kg SK1-I, 10 mg/kg 
SK1-I, 5 mg/kg SK1-I + 0.5 mg/kg doxorubicin or 10 mg/kg SK1-I + 0.5 mg/kg doxorubicin 
by i.p. injection twice per week. Treatment with 5 and 10 mg/kg SK1-I was well tolerated by 
the NOD/SCID mice, and the body weights remained stable (Figure 5E). Tumours in animals 
treated with 5 and 10 mg/kg doses of SK1-I alone showed modest, yet significant, decreases 
in tumour growth rate (Figure 5G). Doxorubicin treatment alone did not affect the tumour 
size (Figures 5F and 5G). However, in sharp contrast to doxorubicin treatment alone, 
treatment with 10 mg/kg SK1-I + 0.5 mg/kg doxorubicin as well as 5 mg/kg SK1-I + 0.5 
mg/kg doxorubicin resulted in profound regression of explanted tumours (Figures 5F and 
5G). After 13 days post-treatment, animals had to be sacrificed due to the tumour burden in 
control mice. Tumours were excised, photographed and histologically examined (Figure 5H). 
The benefit of combining SK1-I with doxorubicin was not restricted to the SCC25 cell line.  
Specifically, we show that the FaDu cell line displays intermediate sensitivity to doxorubicin 
in vitro and in vivo and are completely insensitive to SK1-I in vitro and modestly so in vivo 
(Figure S6).  However, combining doxorubicin + SK1-I in vitro or in vivo induces profound 
cytotoxicity (Figures S6A and S6B).  
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Sphk1/S1P has been shown to exert its antiapoptotic activity via signaling through a family of 
S1P receptors linked to the PI3K/AKT pathway (34, 35). Consistent with this, we found that 
SK1-I could reduce phospho-AKT (p-AKT) (Ser473) in a dose dependent manner (Figure 
6A). Previous reports have shown that p-AKT is a downstream effector of the pro-survival 
effects of increased Sphk1 activity and S1P production (36).  Moreover, it is established that 
the PI3K/AKT pathway is frequently dysregulated via mutations in PI3K family members, 
gene amplifications or pathway activation in HNSCC (37). Thus, we examined whether E2F7 
induced prosurvival responses were mediated via increased Sphk1/S1P and subsequent AKT 
phosphorylation. Transient overexpression of E2F7 in KJDSV40 cells results in an increase 
in Sphk1 protein levels (Figure 2C, Bottom) and an increase in the p-AKT relative to total 
levels (Figure 6B). Conversely, siRNA-induced knockdown of E2F7 in SCC25 cells resulted 
in a reduction in Sphk1 expression (Figure 2C, Top) and a reduced p-AKT/total AKT ratio 
(Figure 6C).  Furthermore, transient overexpression of Sphk1 in KJDSV40 cells or 
knockdown of Sphk1 with shRNA in SCC25 cells resulted in increased and decreased p-AKT 
respectively (Figures 6D and 6E).  These data indicate that the changes in AKT activity lie 
downstream of Sphk1, which in turn is downstream of E2F7. These data would predict that 
the profound tumour regression observed as a result of a doxorubicin/SK1-I combination 
could be recapitulated using doxorubicin + AKT inhibitor. 
 
We have previously shown that the mTOR/PI3K inhibitor, BGT226, is able to reduce tumour 
growth rates in mice transplanted with SCC cells (19).  In the present study, mice were 
injected with SCC25 cells and when the tumours were between 4 to 5 mm
 
in diameter we 
treated them with i) vehicle, ii) 0.5 mg/kg doxorubicin i.p. twice weekly, iii) 10 mg/kg 
BGT226 i.p. twice weekly or iv) 10 mg/kg BGT226 + 0.5 mg/kg doxorubicin i.p. twice 
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weekly.  Tumour growth in the vehicle control (DMSO) and doxorubicin treated mice was 
unchanged whilst those mice treated with BGT226 alone displayed a modest reduction in 
tumour growth rate (Figure 6F). Mice treated with the doxorubicin/BGT226 combination 
displayed significant regression of the tumour mass (Figure 6F).   
 
We next examined levels of PCNA, cleaved caspase-3 and p-AKT levels within the tumours 
resected from mice treated with 10 mg/kg SK1-I or 10 mg/kg BGT226, alone or in 
combination with 0.5 mg/kg doxorubicin. Immunohistochemical examinations showed that 
combination treatment inhibited intratumoral proliferation (at either dose) as measured by the 
levels of PCNA staining (Figure 6G). SK1-I or BGT226 treatment markedly elevated the 
number of apoptotic cells induced by doxorubicin treatment as shown by examination of 
apoptotic indices of tumours by immunohistochemical staining with antibody against cleaved 
caspase-3 compared with drug alone treated tumours (Figure 6G). Consistent with p-AKT 
lying downstream of Sphk1 we found significant inhibition of p-AKT (Ser473) in tumours 
treated with SK1-I or BGT226 (Figure 6G). 
 
DISCUSSION 
In the present study we provide, in vitro, in vivo and patient data that identifies a novel 
E2F7/Sphk1/S1P/AKT axis that regulates sensitivity to anthracyclines in SCC. Specifically, 
we show that (i) E2F7 selectively modulates sensitivity to doxorubicin in KCs and SCC, (ii) 
that E2F7-dependent doxorubicin resistance is mediated via induction of Sphk1 which in turn 
activates AKT and (iii) that pharmacological inhibition of Sphk1 or AKT sensitizes SCC 
cells to the cytotoxic actions of doxorubicin in vitro and in vivo. Combined, these findings 
highlight a novel mechanism through which SCC cells acquire resistance to anthracyclines. 
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Overall, current data relating to the mechanisms regulating E2F control of apoptosis are 
complex.  For example, E2F1 is known to be induced by cytotoxic stimuli and DNA damage 
(7, 8). This induction can occur at the level of post-translational modification and protein 
stabilization and/or can occur through increased E2F1 transcription (16, 38). The main 
outcome of the increased E2F activity is mediated via ARF stimulated inhibition of MDM2 
resulting in increased p53-dependent apoptosis. However, complicating this is the 
observation that E2F1 can recognize double strand breaks induced by UV and recruit NER 
machinery to the DNA break (16).  In this way E2F1 has been proposed to display anti-
apoptotic actions (16). This latter pathway has been demonstrated to exist in normal MEKs 
(39). Further complicating this is the observation that E2F7 can antagonize the pro-apoptotic 
activity of E2F1 in embryonic tissues as well as in normal or cancer cells (10, 17, 18, 40). 
Thus, in order to determine the role of E2F7 in regulating cytotoxic responses in HNSCC it is 
important to consider the tissue context and the nature of the cytotoxic stimulus or DNA 
damage.    
 
In the present study we show that E2F7 and E2F1 suppress and induce doxorubicin 
sensitivity in SCC cells respectively.  . We also show that cytotoxic responses to etoposide or 
cisplatin were not altered by E2F7.  Since doxorubicin and etoposide are established type II 
topoisomerase blocking agents, and E2F7 did not alter etoposide sensitivity it is reasonable to 
suggest that the effects of E2F7 were independent of the topoisomerase inhibitory actions of 
doxorubicin.  We also show that regulation of doxorubicin sensitivity in SCC cells is E2F 
isoform-specific since the other inhibitory E2F, E2F8, did not modify the sensitivity of KCs 
to doxorubicin or any other drug studied. In addition, we show that E2F7 suppresses 
doxorubicin sensitivity via increases in the expression of Sphk1 resulting in increased levels 
of S1P which in turn enhance the Ser473 p-AKT-dependent pro-survival response.  The E2F-
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dependence of S1P/AKT-mediated drug resistance has not been described before and has 
significant pathological and clinical implications in SCC.   
 
The relevance of an E2F/Sphk1/S1P/AKT axis in SCC is highlighted by a number of 
independent observations. In particular E2F1 (5, 11), E2F7 (10), Sphk1 (30, 42), S1P (41), 
PI3K and AKT (37) are all increased in SCC. Part of these increases may be explained by 
activation of signaling pathways that regulate their activity/expression such as MAPK-
mediated activation of AKT and/or Sphk1 (35, 37) or disrupted Rb activity mediated via p16 
deletion or cyclin D amplification for E2F1/E2F7 (7, 8). However, PI3K/AKT is commonly 
mutated or amplified in SCC (2, 3, 37). Regardless of the underlying mechanism it is clear 
that the individual members of the E2F/Sphk1/S1P/AKT axis are all overexpressed and active 
in SCC.  Whilst the events that initiate disruption of this axis remain unknown it is likely that 
dysregulation of the E2F/Rb or PI3K/AKT pathway result from mutational events early in 
tumour formation which could lead to overexpression of E2F7 (a direct E2F1 target) and 
Sphk1 (a direct E2F7 target). The mechanism by which E2F7 induces Sphk1 transcription 
was not established in this study.  Although E2F7 is an established transcriptional repressor, 
it has recently been reported that an E2F7-HIF1 transcriptional complex activates the 
transcription of VEGFA (42). Thus, it is a formal possibility that E2F7 may be a direct 
activator of Sphk1 transcription. Alternatively, E2F7 could act in a dominant-negative 
manner by blocking the binding of other E2F repressor complexes.  Regardless of the 
mechanism, our functional data shows that E2F7 regulates S1P levels via induction of Sphk1 
expression. 
 
Sphingolipid metabolites have emerged as bioactive signaling molecules that regulate cell 
movement, differentiation, survival, inflammation, angiogenesis, tumorigenesis and 
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immunity (29). In particular, ceramide and sphingosine have been shown to be profoundly 
pro-apoptotic whilst phosphorylated sphingosine (S1P) is profoundly anti-apoptotic (27-29). 
Thus, the kinase, Sphk1, responsible for catalyzing the conversion of sphingosine to S1P, is 
also responsible for changing the physiology of the cell from pro-apoptotic to anti-apoptotic.  
Many of the anti-apoptotic effects of S1P are mediated via a family of G protein coupled S1P 
receptors which in turn activate PI3K/AKT (27-29, 43).  Interestingly, the use of an AKT 
inhibitor was able to induce modest levels of cell death and reduced tumour growth in vivo.  
Given that Sphk1 inhibitors profoundly inhibited p-AKT (Ser473), these data would suggest 
that some of the cytotoxic effects observed for BGT226 alone may be mediated via non-AKT 
targets. Finally, doxorubicin alone displayed no measurable anticancer activity in our 
xenotransplant model.  These data suggest that the cytotoxicity observed with the SK1-I or 
BGT226 plus doxorubicin combination reflects an unidentified synthetic lethal reaction. The 
clinical potential for this novel combination (e.g. Sphk1 or AKT inhibitor combined with an 
anthracycline) is highlighted by the profound tumour regression observed in this study.   
 
A previous report had shown that the activation of AKT in ovarian and breast cancer 
suppressed E2F1-induced apoptosis and was associated with a poor prognosis and chemo-
resistance (44). Similarly, Reimer and colleagues reported that poor prognosis and 
chemoresistance of ovarian tumours was associated with a high E2F7/E2F1 ratio (45).  We 
now provide an integrated model in which E2F7 is causally linked to the overexpression of 
Sphk1, the activation of the AKT pathway and doxorubicin resistance.  This is definitively 
shown by our observation that Sphk1, S1P and p-AKT (Ser473) are all directly modulated by 
E2F7. Secondly, Sphk1 inhibition or overexpression directly effects the Ser473 
phosphorylation of AKT.  Finally, inhibition of Sphk1 or AKT sensitises SCC cells in vivo to 
the cytotoxic effects of doxorubicin.  The observation that anti-apoptotic effects of S1P are 
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mediated via the PI3K/AKT pathway has been previously reported (35, 36).  What is new in 
our study is that the dysregulation of the E2F pathway, in SCC, directly activates the 
Sphk1/S1P/PI3K/AKT pathway resulting in selective resistance to doxorubicin.  This is an 
advance that can be immediately translated to a clinical trial with existing pharmacological 
agents. 
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FIGURE LEGENDS 
 
Figure 1. E2F7 selectively regulates sensitivity to doxorubicin in MEKs. A, dose response 
curve of doxorubicin-induced cytotoxicity at 48 hour in uninfected, E2F1KO, E2F7KD, 
E2F8KDs MEKs. B, dose response curve of doxorubicin-induced cytotoxicity at 48 hour in 
E2F7KD MEKs which were transfected with either an E2F7b overexpression plasmid, or 
pcDNA3.1(+) control plasmid. Viability is plotted as percentage control (untreated). C, 
activation of caspase-3 was determined by immunoblotting extracts of untreated and 0.3 µM 
doxorubicin treated E2F7 floxed and E2F7 deficient MEKs. β-Actin is a loading control. D, 
HEK, FaDu, KJDSV40 and SCC25 cells were treated with doxorubicin for 48 hours and 
viability plotted as percentage of untreated cells. E, E2F1 and E2F7 protein expression was 
determined by immunoblotting extracts of HEK, KJDSV40 and SCC25 cell lines. β-Actin is 
provided as a loading control. Densitometric analysis of E2F1 and E2F7 in KJDSV40 and 
SCC25 cell lines was quantified using ImageJ.  Expression level was normalized against β-
Actin and plotted as E2F7/E2F1. F, SCC25 cells were transfected with E2F7b overexpression 
plasmid or pcDNA3.1(+) control plasmid. G, SCC25 cells were treated with siRNA-targeting 
E2F7 or a control siRNA. In both instances (F and G), cells were left for 48 hours after 
transfection after which viability was estimated by trypan blue exclusion. Viability was 
expressed as percent viable cells and plotted as a percent untreated control. Western blot 
figures are representative of three independent experiments. Quantitative data represent the 
mean ± SEM obtained from triplicate determinations of three independent experiments for A, 
B, D, F and G. *, P ≤ 0.05, **, P < 0.01, ***, P < 0.001. 
 
Figure 2. Sphk1 is a downstream effector of E2F7 and is elevated in expression in SCCs. A, 
RNA was extracted from KJDSV40, SCC25 and SCC25 cells in which E2F7 was silenced 
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with siRNA. Quantitative RT-PCR was used to determine the expression of Sphk1 
transcripts. Data are the mean ± SEM of duplicate determinants normalized for expression of 
the housekeeping gene TBP; n = 3. B, Sphk1 activity is shown for the KJDSV40 and SCC25 
cell lines. Data represent the mean ± SEM obtained from triplicate determinations of three 
independent experiments. C, (Top) SCC25 cells were transfected with siRNA-targeting E2F7 
or a control siRNA. (Bottom) Sphk1 protein levels are shown for KJDSV40 cells in which 
E2F7 was overexpressed. Immunoblot was used to determine Sphk1 levels 48 hours post-
transfection. β-Actin is provided as a loading control. Western blot figure is representative of 
three independent experiments. D, (Left) empty vector, E2F7 expression plasmid, E2F7 
expression plasmid and Sphk1 shRNA plasmids transfected KJDSV40 cells were exposed to 
1 µM doxorubicin. (Center) empty vector transfected, E2F7 expression plasmid transfected, 
E2F7 expression plasmid transfected and 10 µM SK1-I treated KJDSV40 cells were exposed 
to 1 µM doxorubicin. (Right) control siRNA, E2F7 siRNA, E2F7 siRNA and Sphk1 
expression plasmid transfected SCC25 cells were exposed to 1 µM doxorubicin. Viability 
was assessed 48 hours post-treatment and is expressed in arbitrary units. E, quantitative 
determinations of E2F7 binding to the E2F1 and Sphk1 promoters. ChIPs were performed 
using an E2F7 antibody or non-immune IgG as control in KJDSV40 and SCC25 cell lines. 
Each ChIP and quantitative RT-PCR were repeated, respectively, 3 and 2 times. SDs refer to 
the 3 independent experiments. F, quantitation of E2F7 and Sphk1 staining intensity in 
matched samples of primary tumour, its matched normal squamous epithelium and lymph 
node metastasis (n = 37). Tissue sections were scored using a modified quickscore method to 
determine the percentage of cells stained (0-100%) and the intensity of staining (1+ to 3+). 
Data is shown as the mean ± SEM. **, P < 0.01, ****, P < 0.0001.  
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Figure 3. Sphk1 contributes at a functional level to doxorubicin sensitivity. A, SCC25 cells 
were transfected with 4 different constructs coding for shRNAs directed against Sphk1. After 
48 hours, Sphk1 protein expression was determined by immunoblotting. β-Actin is provided 
as a loading control. SCC25 cells were transfected with the Sphk1shRNA.2 and a scrambled 
shRNA constructs. After 48 hours, B, Sphk1 activity or C, S1P levels were measured. Data 
presented as percentage of control shRNA. D, Sphk1shRNA and control shRNA transfected 
SCC25 cells were treated with doxorubicin (1µM) for 48 hours and viability estimated by 
trypan blue exclusion. Viability was expressed as number of viable cell counts and plotted as 
percentage control (untreated). E, KJDSV40 cells were transfected with Sphk1 
overexpression plasmid or a noncoding empty vector. After 48 hours, Sphk1 protein 
expression was determined by immunoblotting. β-Actin is a loading control. KJDSV40 cells 
were transfected with Sphk1 overexpression plasmid or a noncoding empty vector. After 48 
hours, F, Sphk1 activity or G, S1P levels were estimated. Data presented as percentage of 
control vector. H, Sphk1 overexpression plasmid or empty vector transfected KJDSV40 cells 
were treated with doxorubicin (1µM) for 48 hours before viability was conducted by trypan 
blue exclusion. Viability was expressed as number of viable cell counts and plotted as 
percentage control (untreated). I, KJDSV40 cells were treated with varying doses of 
doxorubicin in the presence or absence of 1 µM S1P. Viability was then assessed and plotted 
as percentage control (untreated). Western blot figures are representative of three independent 
experiments. Quantification of S1P in cell lysate from same number of cells was achieved by 
the S1P ELISA kit. Quantification of S1P was done following the manufacturer’s guidelines. 
All quantitative data presented as mean ± SEM obtained from triplicate determinations of 
three independent experiments. *, P ≤ 0.05 versus empty vector, **, P <  0.01 versus control 
shRNA and versus empty vector. ***, P <  0.001 versus empty vector.  
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Figure 4. Sphk1 suppression enhanced sensitivity of SCC25 to the cytotoxic actions of 
doxorubicin in vivo. A, schematic representing xenograft treatment cohorts. All animals were 
inoculated subcutaneously with SCC25 cells expressing vector alone (scrambled shRNA) or 
Sphk1 shRNA and tumours allowed establishing till they reached the indicated sizes. 
Established tumours were then treated with vehicle or 0.5 mg /kg doxorubicin twice per week 
at day 1 (B, C) or day 13 (D) post-inoculation. B, animal weight was determined twice per 
week. C, tumour volumes were monitored twice weekly. D, dotted line indicates beginning of 
treatment for distinct groups. Data presented as mean ± SEM of individual measurements 
from six mice per group.    
 
Figure 5. Pharmacological inhibition of Sphk1 sensitizes SCC cells to the cytotoxic actions 
of doxorubicin in vitro and in vivo. A, SK1-I induces a dose-dependent inhibition of Sphk1 
activity in SCC25 cells that is B, independent of alterations in Sphk1 protein expression. β-
Actin is provided as a loading control. C, dose response curve of SK1-I alone or in 
combination with doxorubicin in SCC25 cells was determined following 48 hours of 
treatment. Viability is plotted as percentage control (untreated). D, cleavage of PARP and 
activation of caspase-3 was determined by immunoblotting extracts of SK1-I and doxorubicin 
treated SCC25 cells. β-Actin is provided as a loading control. E, animal weight was 
determined twice per week. F, tumour growth curves of SCC25 xenografts treated with 
doxorubicin, SK1-I (5 or 10 mg/kg) or the described combinations. G, after 13 days of 
treatment, animals were sacrificed and tumours excised. Representative results from distinct 
groups are shown. H, paraffin-embedded tumour sections were stained with hematoxylin and 
eosin. Representative images from each group are shown (Bar = 100µm). Western blot 
figures are representative of three independent experiments.  Data represent the mean ± SEM 
obtained from triplicate determinations of three independent experiments for A and C. Data 
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represented as mean ± SEM of individual measurements from five mice per group for E and 
F. P  value was calculated using Student’s t test.  
 
Figure 6. Sphk1 Exerts Its Anti-Apoptotic Activity via the PI3K/AKT Pathway. A, p-AKT 
and total AKT protein levels were determined by immunblotting following treatment of 
SCC25 cells with varying doses of SK1-I. B, Densitometric analysis of p-AKT and total AKT 
was determined from immunoblots of KJDSV40 cells in which E2F7 was overexpressed. The 
protein levels were quantified using ImageJ, normalized for expression of total AKT and 
plotted as p-AKT/total AKT. C, densitometric analysis of p-AKT and total AKT was 
determined from immunoblots of SCC25 cells in which E2F7 was silenced. The protein 
levels were quantified using ImageJ, normalized for expression of total AKT and plotted as 
p-AKT/total AKT. D, p-AKT and total AKT levels are shown for SCC25 cells in which 
Sphk1 was overexpressed or E, silenced. F, tumour growth curves of SCC25 xenografts 
treated with doxorubicin, BGT226 or the described combinations. G, immunostaining for 
PCNA, cleaved caspase-3 and p-AKT. Representative images of at least three independent 
tumours are shown for each group (Bar = 100µm). Western blot figures are representative of 
three independent experiments. Data represented as mean ± SEM of individual measurements 
from four mice per group for F.  
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SUPPLEMENTARY  INFORMATION  
SUPPLEMENTARY FIGURE LEGENDS 
 
Figure S1. Generation of E2F7 and E2F8 deficient murine keratinocytes and the 
validation of E2F1 levels in E2F1KO mice. A, level of E2F7 and B, E2F8 mRNA 
expression was measured by qRT-PCR in the relevant floxed keratinocytes following 
infection with Ad-CMV-Cre. C, quantitative RT-PCR analysis of E2F1 expression in KCs 
isolated from conventional E2F1KO mice. Expression is plotted as percentage uninfected 
control for A and B, and as percentage control murine keratinocytes for C. Data are the mean 
± SEM of duplicate determinants from 3 biological replicates normalized for expression of 
the housekeeping gene β-actin.  
 
Figure S2. Adenovirus infection of murine keratinocytes does not alter normal cell 
responses. A, cell viability 48 hours after infection of control murine keratinocytes (MEKs) 
with Ad-GFP was measured. B, quantitative RT-PCR was performed on MEKs isolated from 
control mice and MEKs which had been infected with Ad-Null. Data are the mean ± SEM of 
duplicate determinants or 3 biological replicates normalized for expression of the 
housekeeping gene β-actin. C, Uninfected and Ad-Null infected control MEKs were cultured 
with 1.5 mM Ca
2+
 for 48 hours to induce differentiation. Differentiation marker, involucrin, 
level was then detected by Western Blotting. β-actin was used as a loading control. 
Uninfected and Ad-Null infected control MEKs were subjected to varying doses of D, UVB, 
E, doxorubicin or F, cisplatin. Cell viability was assessed following 48 hours of treatment. 
Data represent the mean ± SEM obtained from triplicate determinations of three independent 
experiments for A, B, D, E and F. Western blot figures are representative of three 
independent experiments.  
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Figure S3. Cytotoxic responses to doxorubicin selectively enhanced in E2F7-deficient 
murine keratinocytes. Dose response curve of control, E2F1, E2F7 and E2F8 deficient 
murine keratinocyes to A, epirubicin, B, cisplatin and C, etoposide. Cells were exposed to 
drugs for 48 hours. Viability was then assessed and plotted as percentage control (untreated). 
Data represent the mean ± SEM obtained from triplicate determinations of three independent 
experiments.  
 
Figure S4. Validation of siRNA directed against E2F7 and E2F1 mRNA expression level 
in SCC25 cells in which E2F7 had been silenced by siRNA. A, SCC25 cells were 
transfected with control siRNA or a siRNA for E2F7. Two different siRNAs were tested. 
Cells were harvested 48 hours after transfection. Knockdown was confirmed with qRT-PCR 
(Right) and immunoblotting (Left). B, SCC25 cells were transfected with E2F7.siRNA 
construct 2. Cells were harvested 48 hours after transfection. E2F1 mRNA expression was 
determined by qRT-PCR. Data are the mean ± SEM of duplicate determinants normalized for 
expression of the housekeeping gene TBP; n = 3. Western blot figures are representative of 
three independent experiments. β-actin was used as a loading control.  
 
Figure S5. SK1-I did not enhance doxorubicin sensitivity in KJDSV40 cells in vitro. A, 
dose response curve of SK1-I alone or in combination with doxorubicin in HEK and B, 
KJDSV40 cells was determined following 48 hours of treatment. Viability is plotted as 
percentage control. Data represent the mean ± SEM obtained from triplicate determinations 
of three independent experiments. 
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Figure S6. Inhibition of Sphk1 sensitizes FaDu cells to the cytotoxic actions of 
doxorubicin in vitro and in vivo. A, FaDu cells were treated with vehicle, 1 µM 
doxorubicin, 30 µM SK1-I or 30 µM SK1-I + 1 µM doxorubicin for 48 hours after which 
viability was estimated and referenced against vehicle treated controls. Data represent the 
mean ± SEM obtained from triplicate determinations of three independent experiments. B, 
tumour growth curves of FaDu-derived xenografts treated with doxorubicin, SK1-I or the 
described combinations. Data represented as mean ± SEM of individual measurements from 
two mice per group.  
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5.3 Supplementary data 
 
 
 
Figure 5.1 Figure S1. Generation of E2F7 and E2F8 deficient murine keratinocytes and 
the validation of E2F1 levels in E2F1KO mice. A, level of E2F7 and B, E2F8 mRNA 
expression was measured by qRT-PCR in the relevant floxed keratinocytes following 
infection with Ad-CMV-Cre. C, quantitative RT-PCR analysis of E2F1 expression in KCs 
isolated from conventional E2F1KO mice. Expression is plotted as percentage uninfected 
control for A and B, and as percentage control murine keratinocytes for C. Data are the mean 
± SEM of duplicate determinants from 3 biological replicates normalized for expression of 
the housekeeping gene β-actin.  
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Figure 5.2 Figure S2. Adenovirus infection of murine keratinocytes does not alter 
normal cell responses. A, cell viability 48 hours after infection of control murine 
keratinocytes (MEKs) with Ad-GFP was measured. B, quantitative RT-PCR was performed 
on MEKs isolated from control mice and MEKs which had been infected with Ad-Null. Data 
are the mean ± SEM of duplicate determinants or 3 biological replicates normalized for 
expression of the housekeeping gene β-actin. C, Uninfected and Ad-Null infected control 
MEKs were cultured with 1.5 mM Ca
2+
 for 48 hours to induce differentiation. Differentiation 
marker, involucrin, level was then detected by Western Blotting. β-actin was used as a 
loading control. Uninfected and Ad-Null infected control MEKs were subjected to varying 
doses of D, UVB, E, doxorubicin or F, cisplatin. Cell viability was assessed following 48 
hours of treatment. Data represent the mean ± SEM obtained from triplicate determinations of 
three independent experiments for A, B, D, E and F. Western blot figures are representative 
of three independent experiments.  
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Figure 5.3 Figure S3. Cytotoxic responses to doxorubicin selectively enhanced in E2F7-
deficient murine keratinocytes. Dose response curve of control, E2F1, E2F7 and E2F8 
deficient murine keratinocyes to A, epirubicin, B, cisplatin and C, etoposide. Cells were 
exposed to drugs for 48 hours. Viability was then assessed and plotted as percentage control 
(untreated). Data represent the mean ± SEM obtained from triplicate determinations of three 
independent experiments.  
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Figure 5.4 Figure S4. Validation of siRNA directed against E2F7 and E2F1 mRNA 
expression level in SCC25 cells in which E2F7 had been silenced by siRNA. A, SCC25 
cells were transfected with control siRNA or a siRNA for E2F7. Two different siRNAs were 
tested. Cells were harvested 48 hours after transfection. Knockdown was confirmed with 
qRT-PCR (Right) and immunoblotting (Left). B, SCC25 cells were transfected with 
E2F7.siRNA construct 2. Cells were harvested 48 hours after transfection. E2F1 mRNA 
expression was determined by qRT-PCR. Data are the mean ± SEM of duplicate determinants 
normalized for expression of the housekeeping gene TBP; n = 3. Western blot figures are 
representative of three independent experiments. β-actin was used as a loading control.  
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Figure 5.5 Figure S5. SK1-I did not enhance doxorubicin sensitivity in KJDSV40 cells in 
vitro. A, dose response curve of SK1-I alone or in combination with doxorubicin in HEK and 
B, KJDSV40 cells was determined following 48 hours of treatment. Viability is plotted as 
percentage control. Data represent the mean ± SEM obtained from triplicate determinations 
of three independent experiments. 
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Figure 5.6 Figure S6. Inhibition of Sphk1 sensitises FaDu cells to the cytotoxic actions of 
doxorubicin in vitro and in vivo. A, FaDu cells were treated with vehicle, 1 µM 
doxorubicin, 30 µM SK1-I or 30 µM SK1-I + 1 µM doxorubicin for 48 hours after which 
viability was estimated and referenced against vehicle treated controls. Data represent the 
mean ± SEM obtained from triplicate determinations of three independent experiments. B, 
tumour growth curves of FaDu-derived xenografts treated with doxorubicin, SK1-I or the 
described combinations. Data represented as mean ± SEM of individual measurements from 
two mice per group. 
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6 A Novel E2F/RacGAP1 Axis Regulates Doxorubicin Response 
in Squamous Cell Carcinoma 
6.1 Foreword 
As detailed in Chapter 3 and Chapter 4, E2F7 contributes to drug resistance in SCC. 
However, the mechanism and pathways involved remain unknown. We therefore embarked 
on a microarray study as described in Chapter 4 in order to identify the downstream effectors 
which are responsible for E2F7-mediated resistance to doxorubicin. These studies resulted in 
generating a gene signature of SCC which characterized E2F7-mediated chemosensitivity. 
Gene signature of HNSCC via microarray analysis has been described in many reports which 
characterise HNSCC compared to normal tissue (Alevizos, Mahadevappa et al. 2001; Ginos, 
Page et al. 2004; Jeon, Lee et al. 2004; Jarvinen, Autio et al. 2006) and which accounts for 
chemoresistance (Akervall, Guo et al. 2004; van den Broek, Wildeman et al. 2009). Notably, 
RacGAP1 could not be found in any of these papers. Given the unique design of the 
experiments presented here, it is not unexpected. Moreover, it indicates the novelty of our 
microarray screen. Importantly, the role of RacGAP1 in SCC has not been reported before 
whilst accumulating evidence has demonstrated that RacGAP1 is upregulated in various 
tumour types (Fritz, Brachetti et al. 2002; Wang, Ooi et al. 2011; Ke, Ke et al. 2013; Kotoula, 
Kalogeras et al. 2013; Liang, Liu et al. 2013; Pliarchopoulou, Kalogeras et al. 2013; Saigusa, 
Tanaka et al. 2014). Hence, by distilling RacGAP1 expression as a prognostic marker, we can 
progress more rapidly towards personalized treatments for SCC. The aim of this chapter 
therefore is to examine the biological activities of RacGAP1 and its contribution to genetic 
changes which ultimately lead to the formation of SCC (SCCgenesis) and to determine 
whether inhibition of RacGAP1, in combination with doxorubicin, could be a viable 
therapeutic strategy for treating SCC in vitro and in vivo models of SCC.  
 
We validated E2F7-dependent upregulation of RacGAP1 in doxorubicin insensitive SCC25 
cells whilst demonstrating that doxorubicin sensitive KJDSV40 cells express low levels of 
RacGAP1. Extending this, we found that selective up-regulation of RacGAP1 made 
previously sensitive KJDSV40 cells resistance to doxorubicin. Similarly, stable knockdown 
of RacGAP1 in insensitive SCC25 cells sensitised cells to doxorubicin in vitro. Consistent 
with this, ChIP analysis of RacGAP1 promoter showed that E2F7 could bind the RacGAP1 
promoter. RacGAP1 expression was validated in HNSCC patient samples utilising a custom 
TMA that was constructed in-house, providing first line of evidence of RacGAP1 expression 
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in HNSCC patient tumours. Significantly, we showed that HNSCCs that overexpress 
RacGAP1 are associated with a poorer overall survival following Kaplan Meier analysis. 
Furthermore, it was established that E2F7-induced doxorubicin resistance was mediated via 
RacGAP1-dependent activation of AKT. In addition, our results revealed the existence of an 
unidentified positive feedback loop between RacGAP1 and Sphk1 (Chapter 5) in the Ser473 
p-AKT-dependent pro-survival response. We also show that SCC cells deficient in RacGAP1 
grow slower in vivo and are sensitized to the cytotoxic actions of doxorubicin in vivo.    
 
These experimental results were presented in a manuscript which has been submitted to 
Oncogene. It has been included here in a slightly amended format to fit with the style of this 
thesis. Detailed materials and methods for these experiments have been included in Chapter 
2. 
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6.2 Abstract 
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Advanced head and neck squamous cell carcinomas (HNSCC) are frequently drug resistant 
and have a mortality rate of 40%. We have previously shown that overexpression of E2F7 
may contribute to drug sensitivity in HNSCC cells. In the present study, we conducted a 
transcriptomic screen to identify downstream factors that contribute to E2F7-dependent 
resistance to anthracyclines in HNSCC. We provide, in vitro, in vivo and patient data that 
identifies a novel E2F7/RacGAP1 pathway that regulates sensitivity to anthracyclines in 
HNSCC. Specifically, we show that E2F7-dependent resistance to doxorubicin occurs via 
induction of RacGAP1 and is associated with reduced GTP-loading of RhoA and increased 
GTP-loading of Rac1. Moreover, we show that an interdependent pathway exists between 
E2F7, Sphk1, RacGAP1 and AKT that regulates doxorubicin sensitivity. We also show that 
SCC cells deficient in RacGAP1 grow slower in vivo and are sensitised to the cytotoxic 
actions of doxorubicin in vivo. Finally, we show that RacGAP1 is significantly overexpressed 
in 73 % of primary and metastatic human SCCs compared with adjacent “normal” tissue and 
that HNSCCs that overexpress RacGAP1 are associated with a significantly poorer overall 
survival. Combined, these findings identify RacGAP1 overexpression as a novel prognostic 
marker of survival and a potential target to sensitise SCC to anthracyclines. 
 
Keywords: squamous cell carcinoma, E2F7, RacGAP1, chemosensitivity  
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6.3 Introduction 
Cutaneous squamous cell carcinomas (CSCC) and head and neck SCC (HNSCC) are amongst 
the most common malignancies afflicting man (Li, Zang et al. 2009; Shen, Dong et al. 2011). 
Current treatment options for advanced SCC include adjuvant chemotherapy with platinum-
based drugs such as taxanes, 5-Fluorouracil or therapeutic antibodies against EGFR (Haddad, 
Colevas et al. 2003; Posner and Lefebvre 2003; Sharafinski, Ferris et al. 2010; Dai, Xie et al. 
2011; Hansen and Siu 2013). However, the response is generally transient and characterised 
by the development of drug resistance. Thus, there is a need to identify new therapeutic 
strategies that can bypass the emergence of a drug resistant phenotype.  
 
The E2F transcription factor complex comprises a family of activating (E2F1, 2, 3a) or 
repressive/inhibitory (E2F3b, 4, 5, 6, 7 or 8) E2Fs that regulate key cellular functions such as 
transcription, differentiation and apoptosis. In the context of keratinocytes (KCs), the E2F 
transcription factor family has been shown to control i) proliferation, ii) differentiation, iii) 
stress responses and iv) apoptosis (Wikonkal, Remenyik et al. 2003; Berton, Mitchell et al. 
2005; Johnson and Degregori 2006; Li, Ran et al. 2008; Panagiotis Zalmas, Zhao et al. 2008; 
Hazar-Rethinam, Endo-Munoz et al. 2011). Consistent with their roles in KCs, dysregulation 
of E2F is a common occurrence in SCC (Dicker, Popa et al. 2000; Wong, Barnes et al. 2003) 
and overexpression of E2Fs such as E2F1 and E2F7 occurs in the majority of CSCCs and 
HNSCCs (Dicker, Popa et al. 2000; Kwong, Nguyen et al. 2003; Endo-Munoz, Dahler et al. 
2009; Hazar-Rethinam, Merida de Long et al. 2014). E2F1 and E2F7 are known to have 
opposing actions in the regulation of proliferation (Hazar-Rethinam, Endo-Munoz et al. 
2011), differentiation (Endo-Munoz, Dahler et al. 2009) and apoptosis (Panagiotis Zalmas, 
Zhao et al. 2008; Endo-Munoz, Dahler et al. 2009). For example, recent reports have shown 
that treatment of wild-type cells with DNA damaging agents such as doxorubicin or 
etoposide induces E2F7 protein levels and subsequent inhibition of the E2F1-mediated DNA 
damage response (Li, Ran et al. 2008; Panagiotis Zalmas, Zhao et al. 2008). In the context of 
KCs, E2F7 was shown to causally modify responses to conventional chemotherapeutics 
(Hazar-Rethinam, Merida de Long et al. 2014) and UV-responses in vitro (Endo-Munoz, 
Dahler et al. 2009). Thus, sensitivity to common cytotoxic agents and stimuli appear to be 
regulated by the relative ratio of E2F1 to E2F7 in the tissue.  Given that both E2F1 and E2F7 
are known to be overexpressed in SCC (Endo-Munoz, Dahler et al. 2009; Hazar-Rethinam, 
Merida de Long et al. 2014), it is reasonable to speculate that this may also contribute to drug 
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resistance in SCC. In this regard, we recently showed that the sphingosine kinase 1 (Sphk1) 
gene is a direct target of E2F7 in SCC (Hazar-Rethinam, Merida de Long et al. 2014). E2F7-
dependent overexpression of Sphk1 in SCC induces increased production of the anti-
apoptotic phospholipid, sphingosine-1-phosphate (S1P) which in turn invokes anthracycline-
resistance via activation of the PI3K/AKT pathway (Hazar-Rethinam, Merida de Long et al. 
2014). Thus, E2F dysregulation in SCC induced the activation of a Sphk1/S1P-dependent 
drug resistant phenotype (Hazar-Rethinam, Merida de Long et al. 2014). Identification of this 
novel pathway was noteworthy for two reasons. Firstly, anthracyclines such as doxorubicin 
are not in clinical use for the treatment of SCC and thus the ability to sensitise SCCs to an 
existing class of chemotherapeutics would be of clinical value. Secondly, the Sphk1/S1P axis 
is drugable and treatment of mice bearing xenotransplanted SCCs with a Sphk1 inhibitor plus 
an anthracycline resulted in profound tumour regression (Hazar-Rethinam, Merida de Long et 
al. 2014). However, the activation of the Sphk1 pathway was not the entire explanation for 
the anthracycline resistance observed in SCC. Thus, other pathways that control drug 
resistance in SCC were likely to exist.  
 
In the present study, we used transcriptomic profiling to identify a novel drugable 
E2F7/RacGAP1/AKT pathway that selectively induces anthracycline resistance in SCC.  
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6.4 Results 
6.4.1 RacGAP1 is a novel downstream effector of E2F7 
We generated E2F7 knock down (KD) murine KCs via adenovirus mediated Cre deletion of 
floxed sequences in primary KCs isolated from E2F7 floxed mice (Hazar-Rethinam, Merida 
de Long et al. 2014). KD KCs were treated for 48 hours with increasing concentrations of 
doxorubicin (0-1 µM), etoposide (0-100 µM) and cisplatin (0-20 µM). Figure 6.1A-C shows 
that E2F7 deficiency sensitises KCs to doxorubicin, modestly to cisplatin but not at all to 
etoposide. These data suggest that E2F7-mediated doxorubicin resistance is not attributable to 
topoisomerase inhibition since etoposide sensitivity was not modified by E2F7. Moreover, 
pan-caspase inhibition significantly protected E2F7 deficient cells from doxorubicin-induced 
cytotoxicity (Figure 6.1D), indicating that apoptotic pathways are being activated.  
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Figure 6.1 Cytotoxic responses to doxorubicin in E2F7-deficient murine KCs. E2F7-
floxed keratinocytes were incubated with (squares) or without (circles) Ad-Cre-GFP for 48 
hours and then incubated with varying doses of doxorubicin (A), etoposide (B) or cisplatin 
(C). Viability (Absorbance 490 nm) was assessed 48 hours post-treatment and is expressed as 
the mean ± SEM obtained from triplicate determinations of three independent experiments. 
Ad-Cre-GFP-uninfected E2F7 floxed or Ad-Cre-GFP-infected E2F7 deficient proliferative 
keratinocytes were treated with 1 µM doxorubicin in the presence or absence of ZVAD-fmk 
and viability determined 48 hours later (D). Viability is plotted as a percentage of 
doxorubicin treated uninfected E2F7 floxed MEKs and represents the mean ± SEM obtained 
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from triplicate determinations of three independent experiments. HEK, Detroit562, 
KJDSV40, SCC15 and SCC25 cells were treated with doxorubicin for 48 hours and viability 
plotted as percentage of untreated cells (E). The inset includes the estimated IC50 values for 
doxorubicin in HEK, KJDSV40 and SCC25 cells determined by nonlinear regression 
analysis.   
 
We undertook a screen of doxorubicin sensitivity in human epidermal keratinocytes (HEK) 
and 4 SCC cell lines. The KJDSV40 cell line exhibited the highest sensitivity to doxorubicin 
(IC50 of 0.082 µM; Figure 6.1E) whilst SCC25 cells displayed the least sensitivity (IC50 of 
0.55 µM; Figure 6.1E) and HEKs displayed intermediate sensitivity (IC50 of 0.29 M; Figure 
6.1E). We have previously shown that the insensitive SCC25 cell line express high levels of 
E2F7 whilst the sensitive KJDSV40 cell line express low levels of E2F7 (Hazar-Rethinam, 
Merida de Long et al. 2014). Based on these data, we selected the sensitive KJDSV40 cell 
line and the insensitive SCC25 cell line for transcriptomic profiling.  
 
Specifically, we generated a list of genes which were poorly expressed in KJDSV40 cells and 
highly expressed in SCC25 (Figure 6.2A). We also generated a second list of genes that were 
differentially regulated in SCC25 cells in which E2F7 had been silenced with siRNA (Figure 
6.2A). We then used these two lists to identify those transcripts (referred to as List A) that 
displayed E2F7-dependent expression between the SCC25 cell lines (Figure 6.2A). We also 
generated an additional list of transcripts for SCC25 cells or SCC25 cells in which E2F7 is 
silenced by siRNA that have been treated with 1 µM of doxorubicin. The transcripts that 
were found to be E2F7-dependent in the context of doxorubicin-treated SCC25 cells were 
then referred to as List B (Figure 6.2A). By comparing Lists A and B, we identified 
RacGAP1 as the most differentially overexpressed gene with a B value greater than 11.  
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Figure 6.2 RacGAP1 is a downstream effector of E2F7. Summary of the strategy used to 
identify E2F7-dependent transcripts that associate with doxorubicin resistance in SCC cells 
(A). RacGAP1 mRNA and protein levels were determined in KJDSV40 and SCC25 cells by 
qRT-PCR and immunoblotting, respectively (B and C). The expression of RacGAP1 
transcripts and protein were determined by qRT-PCR and immunoblotting, respectively from 
extracts derived from SCC25 and SCC25 cells in which E2F7 was silenced with siRNA for 
48 hours (D and E). RNA was extracted from KJDSV40 and KJDSV40 cells in which E2F7 
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was overexpressed from an expression plasmid. The expression of RacGAP1 transcripts and 
protein were determined 48 hours post-transfection by qRT-PCR and immunoblotting, 
respectively (F and G). To quantitate E2F7 binding to the RacGAP1 promoter, ChIPs were 
performed using an E2F7 antibody or non-immune IgG as control in HEK, KJDSV40 and 
SCC25 cells (H). Each ChIP and qRT-PCR were repeated 3 or 2 times respectively. SDs refer 
to the 3 independent experiments. Data are the mean ± SEM of duplicate determinants 
normalized for expression of the housekeeping gene TBP for (B), (D), (E) and (G); n = 3. β-
Actin is provided as a loading control for (C), (F) and (H). Western blot figure is 
representative of three independent experiments. ****, P < 0.0001.   
 
RacGAP1 (also known as MgcRacGAP and CYK4) is an evolutionarily conserved GTPase 
activating protein (GAP) which displays activity towards the Rho family of GTPases. The 
Rho family of GTPases is a subfamily of the Ras superfamily and consists of small signalling 
G proteins: Rho (A, B and C isoforms), Rac (1,2,3 isoforms and RhoG) and Cdc42 (Cdc42, 
Tc10, TCL, Chp/Wrch-2 and Wrch-1) (Wertheimer, Gutierrez-Uzquiza et al. 2012; 
Pliarchopoulou, Kalogeras et al. 2013) which function as molecular switches between a GTP-
loaded “ON” and a GDP-loaded “OFF” state (Pliarchopoulou, Kalogeras et al. 2013). Thus, 
RacGAP1 has the potential to regulate a diverse array of cellular functions through its central 
role as a regulator of the activation state of the Rho family of GTPases. In particular, 
RacGAP1 is known to play important roles in the completion of cytokinesis (Hirose, 
Kawashima et al. 2001; Zhao and Fang 2005), cell transformation, motility, migration and 
metastasis (Sahai 2005; Sanz-Moreno, Gadea et al. 2008; Vega and Ridley 2008; Yamazaki, 
Kurisu et al. 2009). RacGAP1 is also involved in IL6-induced macrophage differentiation 
(Kawashima, Hirose et al. 2000) and nuclear transport of STAT3/5 transcription factors 
(Tonozuka, Minoshima et al. 2004). The functions of RacGAP1 are governed by complex 
processes including phosphorylation, subcellular localization and control of expression 
(Nishimura, Oki et al. 2013). However, a role for RacGAP1 in SCC or doxorubicin 
sensitivity has not been shown previously.  
 
Quantitative RT-PCR and western blotting were used to confirm that RacGAP1 was more 
highly expressed in SCC25 (doxorubicin insensitive) cells than in KJDSV40 (doxorubicin 
sensitive) cells (Figure 6.2B and C). Similarly, we showed that knockdown of E2F7 by 
siRNA in SCC25 cells caused a reduction in RacGAP1 mRNA (Figure 6.2D) and protein 
level (Figure 6.2E). Conversely, overexpression of E2F7 in KJDSV40 cells resulted in 
elevated levels of RacGAP1 transcript (Figure 6.2F) as well as RacGAP1 protein (Figure 6. 
2G). These data suggest that RacGAP1 is a downstream target of E2F7 in SCC cells.  
167 
 
Supporting this, ChIP analysis of E2F7 binding showed that E2F7 could bind the RacGAP1 
promoter suggesting that RacGAP1 is a direct transcriptional target of E2F7 (Figure 6.2H). 
This is the first report to show that RacGAP1 is a downstream effector of E2F7.  
 
6.4.2 RacGAP1 expression is elevated in SCCs 
We examined RacGAP1 expression levels by immunohistochemistry using a tissue 
microarray (TMA) consisting of 35 paired normal, primary tumour and matched metastasis 
from HNSCC patients treated at the Princess Alexandra Hospital (PAH). The TMAs were 
stained for E2F7 and RacGAP1 protein expression and scored blinded by two Pathologists. 
All matched adjacent “normal” epithelia demonstrated either negative or weak staining for 
RacGAP1 which was predominantly nuclear in location (Figure 6.3A). Conversely, moderate 
to high levels of RacGAP1 expression were consistently recorded for the primary tumour 
(Figure 6.3B) and its matched lymph node metastasis (Figure 6.3C). The tumour epithelial 
cells showed nuclear and cytosolic expression for RacGAP1. RacGAP1 was significantly 
overexpressed in 73 % of primary and metastatic human SCCs compared to matched adjacent 
normal tissue (P < 0.0001; Figure 6.3D). In addition, our analyses showed that E2F7 
expression is significantly upregulated in HNSCC compared to matched adjacent normal 
tissue (P < 0.0001; Figure 6.3D). Kaplan-Meier analysis revealed an inverse relationship 
between RacGAP1 expression levels and progression-free survival (PFS) of HNSCC patients 
studied over a period of 42 months whose samples were arrayed on the TMA  (Figure 6.3E). 
These data show, for the first time, that RacGAP1 is overexpressed in HNSCC and is 
associated with a poorer PFS.    
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Figure 6.3 Expression of RacGAP1 in HNSCC and adjacent normal tissue and its 
association with progression free survival. Representative images of adjacent normal tissue 
(A) and HNSCC specimens stained for RacGAP1 (B and C). Quantitation of E2F7 and 
RacGAP1 staining intensities in matched samples of primary tumour, normal squamous 
epithelium and lymph node metastases (n = 35) (D). Tissue sections were scored using a 
modified quickscore method to determine the percentage of cells stained (0-100%) and the 
intensity of staining (1+ to 3+). Kaplan-Meier analysis of progression free survival stratified 
by RacGAP1 expression in the HNSCC patient cohort (E). ns is not significant, ****, P < 
0.0001.   
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6.4.3 RacGAP1 expression/activity determines sensitivity to doxorubicin 
We examined the effect of shRNA-mediated knockdown or RacGAP1 overexpression on 
sensitivity to doxorubicin. RacGAP1 gene silencing was achieved using 3 different constructs 
of which shRNA.3 displayed the greatest knockdown in RacGAP1 protein level (Figure 
6.4A). For subsequent experiments, the shRNA complex shRNA.3 was employed. Consistent 
with previous reports (Nishimura, Oki et al. 2013), RacGAP1 shRNA transfected SCC25 
cells displayed significant reductions in proliferation (Figure 6.4B), colony-forming 
efficiency in vitro (Figure 6.4C) and induced a modest increase in cleaved PARP1 (Figure 
6.4D) compared to control vector transfected cells. Finally, silencing RacGAP1 significantly 
enhanced the sensitivity of SCC25 cells to doxorubicin (Figure 6.4E). Conversely, 
overexpression of RacGAP1 in insensitive KJDSV40 cells resulted in increases in RacGAP1 
protein level (Figure 6.4F), and reduced sensitivity to doxorubicin compared to vector 
control (Figure 6.4G). Combined, these data indicate that RacGAP1 can promote 
proliferation and inhibit doxorubicin induced cell death in SCCs.   
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Figure 6.4 The sensitivity to doxorubicin is mediated via an E2F7/RacGAP1 axis in 
SCC. SCC25 cells were transfected with 4 different constructs coding for shRNAs directed 
against RacGAP1. After 48 hours, RacGAP1 protein expression was determined by 
immunoblotting (A). β-Actin is provided as a loading control. SCC25 cells were transfected 
with the RacGAP1shRNA.3 or a scrambled shRNA construct. After 48 hours, BrdU 
incorporation (B) and CFE (C) were determined. Data expressed as a percentage of that 
observed for control shRNA. Cleavage of PARP was determined by immunoblotting extracts 
of RacGAP1shRNA and control shRNA transfected SCC25 cells (D). β-Actin is provided as 
a loading control. RacGAP1shRNA and control shRNA transfected SCC25 cells were treated 
with doxorubicin (1µM) for 48 hours and viability estimated by trypan blue exclusion (E). 
Viability is plotted as percentage control (untreated). KJDSV40 cells were transfected with 
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RacGAP1 expression plasmid or a noncoding empty vector. After 48 hours, RacGAP1 
protein expression was determined by immunoblotting (F). β-Actin is a loading control. 
RacGAP1 expression plasmid or empty vector transfected KJDSV40 cells were treated with 
doxorubicin (1µM) for 48 hours and viability estimated by trypan blue exclusion (G). 
Viability was expressed as percentage control (untreated). Western blot figures are 
representative of three independent experiments. All quantitative data presented as mean ± 
SEM. For viability values represent triplicate determinations of three independent 
experiments; for CFE, expression values represent duplicate determinations from at least 
three independent experiments; for BrdU values represent triplicate determinations from 4 
independent experiments. **, P <  0.01, ***, P <  0.001, ****, P < 0.0001.   
 
6.4.4 RacGAP1 differentially regulates the GTP-loaded state of RhoA and Rac1 in 
SCC cells 
We examined whether the overexpression of RacGAP1 in the SCC cell lines was reflected in 
alterations of the GTP-loading (activation status) of the model targets RhoA and Rac1.  
Specifically, RhoA GTP loading was constitutively higher in KJDSV40 cells, which express 
very low levels of E2F7 and RacGAP1, compared to SCC25 cells which express high levels 
of E2F7 and RacGAP1 (Figure 6.5A). In contrast, GTP-loading of Rac1 was higher in 
SCC25 cells when compared with KJDSV40 cells (Figure 6.5B), and the GTP-loading of 
Rac1 was significantly reduced in SCC25 cells following RacGAP1 knockdown (Figure 
6.5B). Finally, knockdown of RacGAP1 in SCC25 cells resulted in an increase in the GTP-
loading of RhoA (Figure 6.5A). These results indicate a number of important points. Firstly, 
RhoA appears to be a preferred substrate for RacGAP1 in SCC25 cells. This is reflected by 
the high level of RhoA-GTP loading compared to Rac1-GTP loading as well as the increase 
in GTP-loading observed following RacGAP1 knockdown in the SCC25 cells. Secondly, 
whilst Rac1-GTP loading behaviour is not indicative of it being a preferred substrate of 
RacGAP1, it is clear that alterations in RacGAP1 activity modify Rac1-GTP loading. Finally, 
the preference for RhoA by RacGAP1, in SCC cells, is consistent with a previous report 
showing that the conventional preference for Rac1 can be switched to RhoA following 
phosphorylation of the Serine 387 site of RacGAP1 by Aurora B kinase (Minoshima, 
Kawashima et al. 2003; Doki, Kawashima et al. 2009). 
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Figure 6.5 GTP-loading state of Rac1 and RhoA in SCC cells. Rhotekin-binding domain 
(RBD) binding and p21 activated kinase I-binding domain (PAK-PBD) assays were 
performed on the extracts from KJDSV40, SCC25 and SCC25 cells in which RacGAP1 had 
been silenced by shRNA, as indicated. The amount of activated or total RhoA and Rac1 were 
detected by immunoblotting the RBD and PAK-PBD samples and the whole cell lysate with 
RhoA or Rac1 antibodies. To confirm equal input, the membrane was re-probed with an actin 
antibody.  
 
6.4.5 RacGAP1 modulates doxorubicin sensitivity via downstream activation of the 
PI3K/AKT pathway 
There is an existing literature showing that the PI3K/AKT pathway is an important 
component of RacGAP1 signalling (Wang, Ooi et al. 2011). However, whether PI3K/AKT 
signalling lies upstream or downstream of the Rho family of GTPases remains less clear and 
appears to be context-specific (Wang, Ooi et al. 2011). Dysregulation of the PI3K/AKT 
pathway is a common event in HNSCC which can be attributed to multiple factors such as 
mutations, amplifications and signal-induced activation of the pathway (Iglesias-Bartolome, 
Martin et al. 2013). For example, we recently showed that E2F7 overexpression or 
knockdown caused an increase and decrease in p-AKT levels in SCC cells respectively 
(Hazar-Rethinam, Merida de Long et al. 2014). Since, RacGAP1 is a downstream effector of 
E2F7 in SCC cells, we examined whether RacGAP1 could modify the PI3K/AKT signalling 
pathway in SCC cells. In the first instance we noted that knockdown of RacGAP1 in SCC25 
cells had no impact on the activation status of the ERK pathway (Figure 6.6A). In contrast, 
RacGAP1 knockdown in SCC25 cells significantly reduced the level of p-AKT (Figure 6.6B) 
whilst RacGAP1 overexpression in KJDSV40 cells increased p-AKT levels (Figure 6.6C). 
We had previously shown that the PI3K/mTOR inhibitor, BGT226, was able to ablate AKT 
signalling and induce apoptosis in SCC cell lines (Erlich, Kherrouche et al. 2012). We 
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compared the sensitivity of SCC25 cells to BGT226 in SCC25 cells or SCC25 cells in which 
RacGAP1 was knocked down. Figure 6.6D indicates that knockdown of RacGAP1 is able to 
reduce SCC25 cell viability to 70% that of control cells. Similarly, inhibition of PI3K activity 
using a dose of BGT226 known to induce maximal inhibition (Erlich, Kherrouche et al. 2012) 
reduced SCC25 cell viability to approximately 50% (Figure 6.6D). Finally, exposure of 
RacGAP1-deficient SCC25 cells to BGT226 resulted in a further decrease in viability to 
below 20% (Figure 6.6D). These data indicate that RacGAP1 participates in AKT-dependent 
and AKT-independent events.   
 
We recently reported that E2F7 is able to directly activate the Sphk1/S1P axis in SCC cells 
which induces doxorubicin resistance (Hazar-Rethinam, Merida de Long et al. 2014). It is 
also interesting to note that both the E2F7/RacGAP1 pathway identified in this study and the 
E2F7/Sphk1/S1P pathway (Hazar-Rethinam, Merida de Long et al. 2014) induced 
doxorubicin resistance and converged on the AKT pathway. Therefore, we examined whether 
the Sphk1 and RacGAP1 pathways may interact with one another. Figure 6.6E shows that 
knockdown of Sphk1 can induce loss of RacGAP1 mRNA whilst knockdown of RacGAP1 
induces loss of Sphk1 mRNA expression. Whilst the mechanism controlling this feedback is 
unknown, it is clear that targeted inhibition of either the RacGAP1 pathway or the Sphk1 
pathway is likely to impact one another. To illustrate this point, knockdown of RacGAP1 or 
Sphk1 in SCC25 cells results in reduced p-AKT levels (Figure 6.6F) and increased 
sensitivity to doxorubicin (Figure 6.6G) which can be reversed by the addition of exogenous 
S1P (Figure 6.6F and G).  
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Figure 6.6 RacGAP1 lies upstream of AKT and regulates its activity. SCC25 cells were 
transfected with the RacGAP1shRNA or a scrambled shRNA construct. After 48 hours, p-
ERK and total ERK protein levels (A) and p-AKT and total AKT protein levels (B) were 
determined by immunblotting. p-AKT and total AKT protein levels are shown for KJDSV40 
cells in which RacGAP1 was overexpressed (C). RacGAP1shRNA and control shRNA 
transfected SCC25 cells were treated with doxorubicin (1µM) for 48 hours and viability 
estimated by trypan blue exclusion and plotted as percentage control shRNA (D). SCC25 
cells were transfected with Sphk1shRNA and RacGAP1shRNA as well as control shRNA. 
After 48 hours, RacGAP1 (left) and Sphk1 (right) mRNA levels were determined by qRT-
PCR (E). SCC25 cells were transfected with RacGAP1 or Sphk1 shRNAs. 48 hours after 
transfection, cells were treated with 1 µM S1P for 24 hours. p-AKT and total AKT protein 
levels were then determined by immunoblotting (F). SCC25, SCC25 in which RacGAP1 or 
Sphk1 had been silenced were treated with 1 µM doxorubicin and 1 µM S1P for 24 hours. 
Viability was then assessed and plotted as percentage doxorubicin only treated (G). Western 
blot figures are representative of three independent experiments. All quantitative data 
presented as mean ± SEM obtained from triplicate determinations of three independent 
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experiments for (D) and (G). Data are the mean ± SEM of duplicate determinants normalized 
for expression of the housekeeping gene TBP for (e); n = 3. **, P <  0.01, ***, P <  0.001, 
****, P < 0.0001.    
 
6.4.6 RacGAP1 suppression enhances sensitivity of SCC25 to doxorubicin in vivo 
SCC25 cells were generated to stably express either vector control or RacGAP1 shRNA and 
inoculated into NOD/SCID mice. When tumours were around 4 mm in diameter, mice were 
randomized into four groups and treated with vehicle, dimethyl sulfoxide (DMSO), or 0.5 
mg/kg doxorubicin by intraperitoneal (i.p.) injections twice per week. RacGAP1 knockdown 
was confirmed by western blotting immediately before the inoculation of SCC25 cells 
(Figure 6.7A). Treatment with doxorubicin was well tolerated by the NOD/SCID mice and 
the body weights remained stable throughout the study (Figure 6.7A). RacGAP1-deficient 
cells showed reduced tumour growth rate (Figure 6.7B). Treatment of mice bearing vector 
control SCC25 tumours with/without 0.5 mg/kg doxorubicin had minimal effect on tumour 
growth rates (Figure 6.7B). However, RacGAP1 deficient SCC25 tumours treated with 
doxorubicin started to regress by day 4 post-treatment which continued for a further 7 days at 
which time all mice were sacrificed due to the tumour burden in control mice. The 
subcutaneous tumours were excised, photographed and examined histologically (Figure 
6.7C). 
 
Immunohistochemical examination of the excised tumours showed that knockdown of 
RacGAP1 was maintained throughout the study (Figure 6.7D). Tumours from vehicle and 
doxorubicin treated control mice stained strongly for PCNA, indicating a higher proportion of 
proliferating cells in control tumours compared to RacGAP1 deficient tumours (treated or 
untreated; Figure 6.7D). In contrast, doxorubicin induced higher apoptosis indices in tumours 
derived from SCC25/RacGAP1shRNA than in the SCC25/vector control as estimated by 
immunostaining for cleaved caspase-3 (Figure 6.7D). Ser473 p-AKT levels in RacGAP1-
deficient cells were also decreased (Figure 6.7D). Collectively, these results suggest that 
RacGAP1 contributes to the growth of HNSCC in vivo and that targeted inhibition of 
RacGAP1-overexpressing tumours may sensitise them to the cytotoxic actions of 
doxorubicin.    
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Figure 6.7 RacGAP1 suppression enhanced sensitivity of SCC25 to the cytotoxic actions 
of doxorubicin in vivo. On the day of subcutaneous injections, RacGAP1 deficiency was 
confirmed by immunoblotting using protein extracts from SCC25 cells in which RacGAP1 
had stably silenced with shRNA (A). β-Actin is provided as a loading control. All animals 
were inoculated subcutaneously with 2x10
6
 SCC25 cells expressing vector alone (scrambled 
shRNA) or Sphk1 shRNA and tumours allowed to establish till they reached the indicated 
sizes. Established tumours were treated with vehicle or 0.5 mg /kg doxorubicin twice per 
week. Animal weight was determined twice per week (A). Tumour volumes were monitored 
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twice weekly (B). The inset includes vehicle or 0.5 mg /kg doxorubicin treated SCC tumours 
harbouring RacGAP1shRNA (B). After 13 days of treatment, animals were sacrificed and 
tumours excised. Representative results from distinct groups are shown (C). + indicates 
tumours formed from control shRNA transfected SCC25 cells; - indicates tumours formed 
from RacGAP1shRNA transfected SCC25 cells. Immunostaining for RacGAP1, PCNA, 
cleaved caspase-3 and p-AKT or normal Rabbit IgG as a negative control (D). Representative 
images of at least three independent tumours are shown for each group (Bar = 100µm). Data 
presented as mean ± SEM of individual measurements from six mice per group.    
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6.5 Discussion 
This is the first study to identify an E2F7/RacGAP1/AKT axis through which SCC cells 
acquire resistance to doxorubicin. Specifically, we show that (i) RacGAP1 is a novel 
downstream effector of E2F7, (ii) RacGAP1 is overexpressed in patient SCC and is 
associated with poor progression-free survival, (iii) RacGAP1 overexpression is associated 
with inactivation of the RhoGTPases and activation of the RacGTPases and iv) E2F7-
dependent doxorubicin resistance is mediated via induction of RacGAP1 and Sphk1 which in 
turn activates AKT-dependent and AKT-independent pathways in vitro and in vivo.  
 
The E2F transcription factor family are involved in a diverse array of cellular functions that 
are controlled by the relative ratio of atypical E2F (e.g. E2F7) to activating E2F (e.g. E2F1). 
For example, the apoptotic actions of E2F1, in SCC cells, can be antagonised by E2F7 
overexpression (Endo-Munoz, Dahler et al. 2009). Similarly, E2F7 inhibits doxorubicin-
induced cytotoxicity by inducing the expression of Sphk1 resulting in increased levels of S1P 
which enhance the Ser473 p-AKT-dependent pro-survival response (Hazar-Rethinam, Merida 
de Long et al. 2014). These data are of particular relevance since we know that the majority 
of human SCCs express high levels of both E2F1 and E2F7. In the present study, we found 
that high levels of RacGAP1 in advanced SCC patients were associated with a poor 
progression free survival. Moreover, we demonstrated that forced overexpression of E2F7 
was able to induce RacGAP1 overexpression and doxorubicin resistance whilst knockdown 
of E2F7 reduced RacGAP1 expression and induced sensitivity to doxorubicin in vitro and in 
vivo. These data indicate that RacGAP1 is a direct downstream transcriptional target of E2F7. 
The RacGAP1 promoter contains E2F binding sites and E2F activation has been reported to 
be required for the initiation of transcription at the RacGAP1 promoter in human lymphocyte 
cell line (Seguin, Liot et al. 2009). Consistent with this, we showed that elevated E2F7 levels 
in SCC are associated with increased binding of E2F7 to the RacGAP1 promoter and 
increased expression of RacGAP1 in SCCs. E2F7 is traditionally considered to be a 
transcriptional repressor, however, it has also been shown that E2F7 can function as a direct 
transcriptional activator of the VEGFA promoter via the formation of an E2F7-HIF1α 
transcriptional complex to regulate primary angiogenesis (Weijts, Bakker et al. 2012). 
Similarly, E2F7 has been shown to bind the Sphk1 promoter in SCC cells and is associated 
with increased Sphk1 transcription (Hazar-Rethinam, Merida de Long et al. 2014). The 
precise mechanism by which E2F7 regulates the transcription of RacGAP1 and Sphk1 is 
179 
 
currently under examination. Regardless of the mechanism, our functional data shows that 
E2F7 regulates doxorubicin-induced cytotoxicity via transcriptional induction of RacGAP1.  
 
To our knowledge, this is the first report showing overexpression of RacGAP1 in HNSCC 
tumour samples. This is also the first report to show that overexpression of tumour-associated 
RacGAP1 is directly controlled by E2F7, which itself is known to be overexpressed in SCC 
and to induce drug resistance (Hazar-Rethinam, Merida de Long et al. 2014). Overexpression 
of RacGAP1 has been reported in high grade meningiomas, nonsmall-cell lung cancer, gastric 
cancer, hepatocellular carcinoma, breast cancer (Wang, Ooi et al. 2011; Ke, Ke et al. 2013; 
Liang, Liu et al. 2013; Pliarchopoulou, Kalogeras et al. 2013; Saigusa, Tanaka et al. 2014) as 
well as in the more aggressive tumour phenotypes of epithelial ovarian cancer, high-grade 
breast cancer and invasive cervical cancer (Ma, Salunga et al. 2003; Lu, Patterson et al. 2004; 
Rosty, Sheffer et al. 2005). However, it is unknown whether the overexpression of RacGAP1 
in these tumours is linked to overexpression of E2F7. Whilst the overexpression of RacGAP1 
is not considered to be simply a “passenger” in other cancer types, (Sahai 2005; Sanz-
Moreno, Gadea et al. 2008; Vega and Ridley 2008; Yamazaki, Kurisu et al. 2009), its 
contribution to HNSCC is unknown. Our data shows that loss of RacGAP1 expression is able 
to reduce SCC growth in a xenotransplant model via inhibition of proliferation and increased 
basal apoptosis. In addition, we show that high levels of expression are associated with poor 
PFS of HNSCC patients. Thus, our clinical and preclinical data would suggest that E2F7-
dependent overexpression of RacGAP1 is likely to be a driver of tumour growth and drug 
resistance in HNSCC.  
 
The functional consequences of RacGAP1 overexpression are not reflective of a generalised 
loss of GTP loading of the Rho/Rac family of GTPases. Our data indicated that RacGAP1 
favoured the conversion of RhoGTP to RhoGDP in HNSCC cells. However, it was clear that 
the GTP-loading status of Rac1 was also responsive to changes in RacGAP1 expression. For 
example, RacGAP1 appeared to negatively regulate the GTP-loading status of Rac1 such that 
knockdown of RacGAP1 resulted in a reduction in the GTP-loading state of Rac1. Whilst this 
seemed counterintuitive, it has been shown that phosphorylation of RacGAP1 by Aurora B 
kinase, on Serine 387 shifts its GAP activity from Rac to Rho, resulting in increased GTP-
loading (activation) of Rac1 and reduced GTP loading of Rho (inactivation) (Doki, 
Kawashima et al. 2009).  We were unable to determine whether the reduced proliferation, or 
increased doxorubicin-sensitivity, in SCC cells following RacGAP1 knockdown was due to 
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the reduced GTP loading state of Rac or the increased GTP-loading state of Rho members or 
the relative ratio of GTP-loaded Rho/GTP-loaded Rac. However, it should be noted that the 
antiapoptotic protein Bcl-2 has been shown to interact with Rac1, and it was suggested that 
this interaction could protect tumour cells from the cytotoxic actions of etoposide and 
daunorubicin (Velaithan, Kang et al. 2011). Moreover, it was recently suggested that Rac1 
was a potential therapeutic target in chemo-radioresistant HNSCC (Skvortsov, Dudas et al. 
2014). Thus, the E2F7-dependent drug resistant phenotype we observed in SCC cells is likely 
due to GTP-loaded Rac1. 
 
There is an existing literature on the role of PI3K/AKT in controlling RacGAP1 activity and 
the GTP-loading of the Rho family of GTPases. In particular, it has been shown that AKT 
directly binds to and activates RacGAP1 activity via phosphorylation of T249 (Jacquemet, 
Green et al. 2013). In the present study we show that E2F7 induces RacGAP1 expression 
which is associated with i) an increase in activated Rac1, ii) a decrease in RhoA activity, iii) 
an increase in Ser473 p-AKT and iv) resistance to doxorubicin. These findings are consistent 
with the observation that PI3K/AKT signalling are among the most significantly altered 
canonical pathways following RacGAP1 silencing in HCC (Wang, Ooi et al. 2011). Our 
observations also suggest that the overexpression of RacGAP1 in SCC may contribute to the 
activation of the AKT pathway that is seen in more than 40% of all HNSCCs. However, how 
RacGAP1 contributes to AKT activation remains unclear. We certainly know that 
overexpressing or knocking down E2F7 or RacGAP1 modifies Ser473 phosphorylation of 
AKT. However, we also know that E2F7 directly induces Sphk1 expression and S1P levels in 
SCC leading to increased Ser473 phosphorylation of AKT (Hazar-Rethinam, Merida de Long 
et al. 2014). Finally, we now show that Sphk1 and RacGAP1 indirectly modify one another’s 
expression. Thus, it is difficult to determine whether RacGAP1-dependent effects on AKT 
phosphorylation status are modified by RacGAP1 or indirectly via changes in Sphk1/S1P. 
Regardless of the mechanism, our results demonstrate the existence of a novel, complex and 
interdependent network between E2F7, RacGAP1 and Sphk1/S1P, and the importance of 
such a network in chemosensitivity.   
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6.6 Materials and Methods 
6.6.1 Chemicals and viability assays 
The following drugs were purchased: doxorubicin (Sigma Aldrich, Castle Hill, Australia), 
S1P (Cayman Chemicals, Sapphire Bioscience, Waterloo, Australia), ZVAD-fmk (Alexis 
Biochemicals, Sapphire Bioscience, Waterloo, Australia). BGT26 was provided by Novartis 
(Basel, Switzerland) and stocks of BGT226 were prepared as described (Erlich, Kherrouche 
et al. 2012). ZVAD-fmk was added 30 minutes before other treatments. Cell viability was 
performed by trypan blue exclusion or using Cell Titer 96 Aqueous One Solution Cell 
Proliferation Assay (Promega, Alexandra, Australia).  
 
6.6.2 Tissue culture, adenovirus infection and transfection 
Murine epidermal keratinocytes and human epidermal keratinocytes were isolated and 
cultured as described (Jones, Dicker et al. 1997; Zhao, Gu et al. 2005). E2F7 KD 
keratinocytes generated by ready-to-use adenovirus harbouring Cre recombinase infection of 
MEKs as per manufacturer’s recommendations (MOI of 50) (Vector Biolabs, Philadelphia, 
PA, USA). Detroit562 and SCC25 cells were obtained from the American Type Culture 
Collection. SCC15 was a kind gift from Dr. Elizabeth Musgrove (Garvan Institute, New 
South Wales, Australia) and were verified by short tandem repeat genotyping (Dicker, Popa 
et al. 2000). KJDSV40 cells were maintained as described previously (Dicker, Popa et al. 
2000). Control and overexpression plasmids used for manipulating E2F7, and the siRNA 
used for targeting E2F7 have been described previously (Panagiotis Zalmas, Zhao et al. 2008; 
Endo-Munoz, Dahler et al. 2009). SureSilencing shRNA plasmids directed against RacGAP1 
or Sphk1 were purchased from SuperArray Bioscience Corp (SA Biosciences, Qiagen, 
Chadstone Centre, Australia). A RacGAP1 expression (TrueORF Gold Clones) and control 
plasmids were purchased from OriGene Technologies (Australian Biosearch, Karrinyup, 
Australia).  
 
6.6.3 RNA isolation and quantitative RT-PCR  
Total RNA was isolated, cDNA prepared and quantitative reverse transcriptase PCR (qRT-
PCR) performed as described (Endo-Munoz, Dahler et al. 2009; Endo-Munoz, Cumming et 
al. 2010). Primer sequences were E2F7 Forward: GTCAGCCCTCACTAAACCTAAG, E2F7 
Reverse: TGCGTTGGATGCTCTTGG; RacGAP1 Forward: 
GACGTTGAATAGGATGAGTCATGG, RacGAP1 Reverse: 
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GCTCAAACAGATTCCGCACA; Sphk1 Forward: AAGACCTCCTGACCAACTGC, 
Sphk1 Reverse: GGCTGAGCACAGAGAAGAGG.  
 
6.6.4 Gene expression analysis 
Each sample was analysed in duplicate. Complementary RNA was generated from samples 
using the Illumina TotalPrep RNA Amplification Kit and hybridised with Illumina 
HumanHT-12 v4 Expression BeadChips (Illumina, Scoresby, Austalia) as per manufacturer’s 
protocol. Expression data from the microarrays was analysed as previously described (Endo-
Munoz, Cumming et al. 2010). Only genes with a fold change of 1 (in either direction) or 
greater and a B-value of greater than 3 (exceeding the 95% probability of differential 
expression) were considered to be differentially expressed and further analysed. 
Differentially expressed probe sets were analysed as pair-wise contrasts. Microarray data has 
been uploaded to Gene Expression Omnibus under the reference: GSE58074.  
 
6.6.5 Colony forming assay 
Known number of SCC cells were plated and allowed to grow for 15 days. Plates were fixed 
and stained with Coomassie Blue and counted as previously described (Dicker, Serewko et al. 
2000). Colony forming efficiency was expressed as the total number of colonies/total number 
of cells plated x 100.  
 
6.6.6 DNA synthesis 
DNA synthesis was measured using a colorimetric ELISA 5-bromo-2-deoxyuridine (BrdU) 
incorporation assay (Roche Diagnostics, Castle Hill, Australia) in accordance with the 
manufacturer’s instructions.  
 
6.6.7 Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) was performed using the SimpleChIP Enzymatic 
Chromatin IP Kit (Magnetic Beads) (Cell Signaling, Genesearch, Arundel, Australia) in 
accordance with the manufacturer’s instructions. ChIP enrichment was determined by 
conducting qRT-PCR as described above. The primers used were as follows:  
5'-GAAGTGAGTAGTGGGGGTGC-3' (RacGAP1 Forward);  
5'-TCCATCTTTCACACGAACACTCT-3' (RacGAP1 Reverse). 
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6.6.8 Immunoblot 
Immunoblotting was carried out according to previously published procedures (Erlich, 
Rickwood et al. 2009) using the following primary antibodies: Anti-RacGAP1 [EPR9018] 
1:2,000 (Abcam, Sapphire Bioscience, Waterloo, Australia), Anti-Sphk1 1:1,000 (Sigma 
Aldrich), PARP 1:1,000 (Cell Signaling), phospho-Akt (Ser473) (D9E) XP 1:2,000 (Cell 
Signaling), Akt 1:2,000 (Cell Signaling), phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 
(E10) 1:2 000 (Cell Signaling), ERK 1 (C-16) 1:2,000 (Santa Cruz, ThermoFisher Scientific, 
Scoresby, Australia) and β-actin 1:10,000 (Sigma Aldrich).  
 
6.6.9 Immunohistochemistry 
Immunohistochemistry was carried out according to previously published procedures (Erlich, 
Rickwood et al. 2009; Cameron, Dahler et al. 2010) using the following primary antibodies 
were used: Anti-PCNA 1:3,000 (Sigma Aldrich), Anti-RacGAP1 [EPR9018] 1:100 (Abcam), 
cleaved caspase-3 (Asp 175) 1:50 (Cell Signaling), phospho-Akt (Ser473) (D9E) XP 1:50 
(Cell Signaling). Secondary antibody was Starr Trek Universal HRP Detection System 
(Biocare Medical, Applied medical, Stafford, Australia) followed by colorimetric 
immunohistochemical staining with Cardassian DAB Chromogen as per manufacturer’s 
instructions (Biocare Medical).  
 
6.6.10 Tissue microarrays (TMA) 
Generation and composition of the patient TMAs has been previously described (Hazar-
Rethinam, Merida de Long et al. 2014). Immunohistochemistry was conducted using Dako 
EnVision + System-HRP (DAB) Kit in accordance with the manufacturer’s instructions 
(DAKO, Botany, Australia). Sections were incubated with Anti-E2F7 1:250 (Abcam) and 
Anti-RacGAP1 [EPR9018] 1:100 (Abcam) antibodies. Staining intensity was evaluated by 
two Pathologists in a blinded fashion using a modified quickscore method as described 
(Detre, Saclani Jotti et al. 1995).  
 
6.6.11 Determination of RhoA and Rac1 activity 
RhoA and Rac1 activities were measured with RhoA/Rac1/Cdc42 Activation Assay Combo 
Biochem Kit (Cytoskeleton, Jomar Bioscience, Kensington, Australia) in accordance with the 
manufacturer’s instructions.   
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6.6.12 Animal studies 
All animal experiments were approved by the Institutional Animal Ethics Committee. In vivo 
tumour studies used six-week-old female nonobese diabetic/severe combined 
immunodeficient mice. Mice were injected subcutaneously on the flank with 2 x 10
6
 cells. 
Groups of 6 mice received treatments (intraperitoneal injections twice/week) when tumours 
were around 4 mm in diameter. Animal weight and tumour growth were monitored for a 
period of up to 3 weeks and animals were sacrificed when tumours reached 10 mm in 
diameter.    
 
6.6.13 Statistical analysis 
Statistical significance was calculated by a Student’s t test with a 95% confidence level using 
GraphPad Prism v5 (GraphPad software, LA Jolla, USA).  
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7 General discussion and conclusions 
This thesis has presented data which provides new avenues towards improving our 
understanding of KCs differentiation, KC neoplasia and chemotherapeutic sensitivity in SCC. 
The key findings are discussed and summarised below. This study was undertaken to 
understand the molecular basis for E2F7 and E2F8 action, in the hope that novel factors that 
regulate E2F7 and E2F8 activity may lead to a better understanding of SCC genesis and new 
therapeutic strategies to treat SCC patients.  
 
7.1 Isoform specific functions of atypical E2Fs 
Evidence that has emerged over the past 2 decades is that the E2F transcription factor family 
are pleiotropic factors that exhibit isoform-specific and context-specific functions. Thus, it is 
important to consider the results of E2F studies in the specific context in which they were 
reported. The most obvious example of this is that E2F7 and E2F8 have both been shown to 
be important to the control of stress and apoptotic responses in developing embryos whereas 
in keratinocytes it would appear that E2F8 does not contribute to these functions.   
 
In Chapter 3, we showed that E2F7 deficiency selectively enhanced the cytotoxic responses 
of KCs to UVB and doxorubicin (Figure 3.8 and Figure 3.9). In contrast, E2F1 deficiency 
protected KCs from UV- and doxorubicin-induced cytotoxicity, and this is more obvious if 
one compares the E2F1KO dose response curve to that of the E2F7KD data (Figure 3.8 and 
Figure 3.9). These data indicate that UV- and doxorubicin-induced cytotoxic responses may 
involve E2F1 and E2F7-dependent processes and that E2F1 and E2F7 appear to play 
opposing roles in the modulation of cytotoxic responses. Our findings are in line with 
previously published work in which E2F1 was shown to be a physiological target for stress-
induced apoptosis, because such apoptosis could be rescued by depletion of E2F1 in vitro as 
well as in vivo (Li, Ran et al. 2008). In addition, our findings shed light onto some noticeable 
contradictions relating to the role of E2F1 in UV-induced cytotoxic responses in mouse skin. 
Previously, it was reported that the role of E2F1 in survival and death is context dependent 
(Meng and Ghosh 2014). In the context of keratinocytes, studies in which E2F1 was knocked 
out or overexpressed suggested that E2F1 protected against UV-induced apoptosis 
(Wikonkal, Remenyik et al. 2003; Knezevic and Brash 2004; Berton, Mitchell et al. 2005; 
Knezevic, Zhang et al. 2007). In contrast, studies from Pierce and colleagues in which E2F1 
was overexpressed in the mouse epidermis resulted in increased constitutive apoptosis 
187 
 
(Pierce, Fisher et al. 1998; Pierce, Gimenez-Conti et al. 1998). Based on our data, we would 
suggest that the anti-apoptotic actions of E2F1 may be mediated via E2F1-dependent 
transcriptional induction of E2F7. However, high transient levels of E2F1 may induce 
apoptosis before E2F7 is transcribed and active.    
 
7.2 Doxorubicin selectivity 
A major finding of my thesis was the sensitivity of E2F7 deficient KCs to doxorubicin. Of 
particular interest, these effects are likely to be keratinocyte-specific since E2F7 expression 
in primary osteosarcoma is not altered compared to non-malignant bone (Endo-Munoz, 
Dahler et al. 2009) and osteosarcoma is sensitive to doxorubicin. 
 
Although several possibilities might be proposed for specific interactions between a 
transcription regulator and a Topoisomerase II inhibitor, a transcription-independent 
contribution of E2F7 to these effects seems reasonable. Supporting this, La Thangue’s group 
recently showed that E2F7 makes a contribution to DNA repair processes by physically 
binding to the damaged DNA and subsequently altering the local chromatin environment of 
the DNA lesion (Zalmas, Coutts et al. 2013). Regardless of the underlying mechanism, it 
seems clear that E2F7 is a multi-functional transcription factor. Furthermore, the differential 
effects of E2F7 knockdown on doxorubicin, etoposide and cisplatin treatments suggest that 
E2F7-mediated resistance to doxorubicin in SCC cells may not represent a general 
modulation of the survival machinery of the cells and perhaps may function outside the 
canonical DNA repair pathways. Therefore, we embarked on an unbiased systems-based 
screen in order to investigate the mechanisms that lead to enhanced resistance to doxorubicin 
and to identify the downstream targets of E2F7 in the modulation of doxorubicin selective 
sensitivity.   
 
The physiological validity of our microarray results was confirmed by several observations. 
Firstly, the –omics study resulted in a very select list of candidates. Notably, one of the well 
known genes which is frequently dysregulated and contributes to SCCgenesis, CD44, was 
listed in this list. Significantly, there is literature suggesting that CD44 gene expression is 
regulated by the Sphk1/S1P receptor signalling pathway in colon cancer cells (Kawahara, 
Otsuji et al. 2013). Furthermore, Abdraboh and his colleagues reported that CD44 operates 
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through PI3K/AKT and E2F1 signal transduction cascade which leads to breast tumour 
invasion (Abdraboh, Gaur et al.).  
 
Another important observation I made during this thesis is that E2F7 (primarily known as a 
transcriptional repressor) appeared to directly activate the transcription of RacGAP1 and 
Sphk1. This is conceptually new and intriguing and is supported by recently published papers 
as discussed in Section 1.9.3 Regulation of transcription by atypical E2Fs. It is a formal 
possibility that in the regulation of chemosensitivity, E2F7 could execute its role as a 
transcriptional regulator on non-canonical E2F7-binding sequence/sites when associated with 
a transcriptional activator. This is consistent with the lack of consensus E2F-binding sites 
within the Sphk1 promoter. Interestingly, E2F7-responsive region within the Sp1 promoter 
has been shown to be different than the published E2F consensus sequence (Hazar-Rethinam, 
Cameron et al. 2011). Alternatively, the relative ratio of E2F7 and its direct target, the 
transcriptional activator E2F1, may affect Sphk1 expression directly. Hence, the regulation of 
Sphk1 may be highly sensitive to changes in the E2F1:E2F7 ratio which in turn regulates 
sensitivity to doxorubicin.  
  
In spite of not showing the precise mechanism of E2F7 action as an activator on the two 
novel target genes, Sphk1 and RacGAP1, our data clearly demonstrate that E2F7 regulates 
these genes via direct effects at the gene promoters. Our functional in vitro data confirmed 
that the binding of E2F7 correlates with changes in Sphk1 and RacGAP1 gene expression 
shortly after changes in the levels of the transcriptional regulator. Specifically, we show that 
i) E2F7 overexpression induces Sphk1 and RacGAP1 expressions (Chapter 5 and Figure 
6.2), ii) E2F7 knockdown reduces Sphk1 and RacGAP1 expressions (Chapter 5 and Figure 
6.2) and iii) E2F7 directly binds to the Sphk1 and RacGAP1 promoters (Chapter 5 and 
Figure 6.2). It is an important fact to consider since the binding of a transcription factor to the 
promoter region of a gene does not always result in functional changes in the activity of the 
gene product so it remains a formal possibility that the binding of the factor contributes to 
minimal or even no control of the gene. 
 
Sphk1-generated S1P has been implicated in several pathological and physiological 
processes, including carcinogenesis. Consistent with these roles as the major enzyme 
responsible for S1P synthesis, expression of Sphk1 is tightly regulated at all stages through 
epigenetic, transcriptional and post-transcriptional mechanisms (Fyrst and Saba 2010). Its 
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stable upregulation in cancer has been shown to occur at the transcriptional level by several 
transcriptional regulators (EGF, 17β-estradiol, PMA, histamine, prolactin) and in response to 
several growth factors. Notably, cancer cells are also able to maintain high levels of Sphk1 in 
response to HIF1α (Fyrst and Saba 2010) which is a novel binding partner of E2F7.  
 
With respect to E2F7 and its downstream effector RacGAP1, as discussed in Chapter 6, the 
promoter of RacGAP1 contains E2F binding sites and E2F activation is absolutely required 
for the initiation of transcription at RacGAP1 promoter (Seguin, Liot et al. 2009). 
Furthermore, supporting our observation from this project is the work from Weijts et al 
(Weijts, Bakker et al. 2012) demonstrating that E2F7 directly binds and stimulates the 
VEGFA promoter following the formation of an E2F7-HIF1α transcriptional complex to 
regulate primary angiogenesis. Curiously, RacGAP1 has been shown to interact physically 
with HIF1α and regulates its transcriptional activity (Lyberopoulou, Venieris et al. 2007). 
 
7.3 Novel combination of Sphk1 inhibitors/RacGAP1 inhibition and 
doxorubicin as a potential therapeutic for advanced SCC 
An important conclusion we made in this study is that Sphk1 and RacGAP1 are downstream 
effectors of E2F7 and are responsible for E2F7-mediated effects on sensitivity to 
doxorubicin.  
 
Two Sphk isoenzymes exist and it could be argued that the rheostat theory cannot be 
conclusively addressed unless both the isoforms are targeted. However, in vivo studies of 
Sphk1 or Sphk2 knockout mice suggested that these kinases may have compensatory roles as 
Sphk1 and Sphk2 double knockout mice die at an embryonic stage of development (Allende, 
Sasaki et al. 2004; Mizugishi, Yamashita et al. 2005), indicating that pan-Sphk1 inhibitors 
may not be ideal therapeutics and instead specific targeting of Sphk isoenzymes would be 
reasonable therapeutic option. SK1-I has been defined as a Sphk1 specific inhibitor: inhibits 
selectively Sphk1 activity, but not Sphk2. In vitro studies (with human histiocytic leukemia 
and Jurkat acute T-cell leukemia cells) and in vivo studies (with leukemic blasts) reported that 
SK1-I has significant cytotoxic and apoptotic effects as a single agent (Paugh, Paugh et al. 
2008), and, moreover, SK1-I inhibits growth human glioblastoma cells in a dose dependent 
manner (Kapitonov, Allegood et al. 2009). Notably, we observed no cytotoxic effect after 
treatment of resistant SCC cells with SK1-I alone in vitro and no alteration in tumour growth 
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after treatment of SCC25 xenografts with SK1-I alone. In contrast, combination treatment of 
SK1-I with doxorubicin induced chemosensitivity, allowing for doses of doxorubicin that 
normally do not cause cell death to cause much greater cell killing, but did not potentiate the 
cytotoxic action of doxorubicin in normal HEKs nor in sensitive SCC cells, highlighting the 
selectivity of combination therapy for resistant SCC cells. 
 
With regard to RacGAP1, in retrospect, it seems likely that its pleiotropic effects on 
cytokinesis have obscured their role in SCC tumourigenesis till now. There is an extensive 
literature indicating that RacGAP1 play key roles in important biological functions through 
mechanisms other than regulating Rac GTPase activity. Significantly, RacGAP1-mediated 
drug resistance in SCC has not been described before and has significant pathological and 
clinical implications in SCC.   
 
7.4 Future directions 
Future directions which may be considered with respect to isoform-specific activities of E2F8 
would provide new avenues towards improving our understanding of keratinocyte 
differentiation and keratinocyte neoplasia. The findings from this study showed that E2F8 
expression is modestly reduced during squamous differentiation and that loss of E2F8 (as 
observed in SCC) in murine keratinocytes inhibits the induction of differentiation. Firstly, our 
preliminary findings should be confirmed by growth as an organotypic culture. Other 
valuable information could be gained from doing organotypic culture is to be able to monitor 
time to reach maximal stratification as well as epithermal thickness. Transcriptomic profiling 
approach could next be taken to identify gene targets that are unique to E2F8 or shared with 
E2F1 and E2F7. The genes identified in the transcriptomic profiles could be followed up by 
the ChIP-Seq analysis which would also add additional information by identifying the genes 
modified by E2F8 that are direct targets of E2F8. Analysis of the data sets would be 
performed to identify potential E2F8 specific pathways associated with differentiation in 
normal keratinocytes and dysregulation in SCC cells. The identified specific pathway(s) 
would then be pursued at a functional level in our models of keratinocytes and SCC in vitro 
and in vivo.      
  
As we discussed in Chapter 4 and Chapter 5, our functional data clearly shows that E2F7 
regulates Sphk1 and RacGAP1 expression even though we did not demonstrate the exact 
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mechanisms at the molecular level. There are several possible mechanisms to explain this. 
Firstly, it is a formal possibility that E2F7 may be a direct activator of Sphk1 and RacGAP1 
transcriptions. Alternatively, E2F7 could act in a dominant-negative manner by blocking the 
binding of other E2F repressor complexes. One other possibility could be that the biological 
functions of E2F7 may be different in normal versus cancer cells. It is consistent with 
previously published work demonstrating that some of the E2F family of transcription factors 
members such as E2F4 is able to shuttle within the cells in a CRM-1 dependent manner 
(Gaubatz, Lees et al. 2001). Indeed, during the course of this study, it was noted that in 
primary SCCs and in the SCC25 cell line E2F7 was localised to the cytosol whereas in 
normal keratinocytes and stratified epithelium it was localised to the nucleus. So far we have 
demonstrated that this shift in localisation is of functional significance since ChIP analysis of 
the Sphk1 promoter in HEKs and SCC25 cells showed that E2F1 and E2F7 could both bind 
the Sphk1 promoter but there was a clear preference for E2F1 binding the Sphk1 promoter in 
SCC25 cells in which E2F7 is localised to the cytosol. This is ongoing work in the laboratory 
at present and the possibility that the functions of E2F7 described in this study could be a 
consequence of its cellular location will be the subject of future investigations.     
 
As discussed in Chapter 6, our data demonstrated that RacGAP1 favoured the conversion of 
RhoGTP to RhoGDP in SCC cells. Whilst this seems counterintuitive, it has been shown that 
phosphorylation of RacGAP1, by Aurora B kinase, on Serine 387 shifts its GAP activity from 
Rac to Rho, resulting in increased GTP-loading (activation) of Rac1 and reduced GTP-
loading of Rho (inactivation) (Doki, Kawashima et al. 2009). In this respect, future 
experiments would be first of all confirming the phosphorylation-dependent shift in 
RacGAP1’s GAP activity using Anti-RacGAP1 phospho S387 antibody which detects 
endogenous levels of RacGAP1 only when phosphorylated at Serine 387. If RhoA is a 
preferred substrate for RacGAP1 in SCC cells due to phosphorylation on Serine 387, then 
one would expect to observe high levels of RacGAP1 in SCC25 when compared with 
KJDSV40 cells. These experiments would certainly provide unequivocal evidence that the 
conventional preference of RacGAP1 for Rac1 can be switched to RhoA following 
phosphorylation of the Serine 387 site of RacGAP1 and that the E2F7-dependent drug 
resistant phenotype we observed in SCC cells is likely due to GTP-loaded Rac1. It may also 
be considered to reiterate experiments where we were unable to show during the course of 
this study that the reduced proliferation or increased doxorubicin-sensitivity in SCC cells 
following RacGAP1 knockdown was due to the reduced GTP loading state of Rac or the 
192 
 
increased GTP-loading state of Rho members or the relative ratio of GTP-loaded Rho/GTP-
loaded Rac.   
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7.5 Conclusions 
My thesis addressed the following aims:  
 Characterise the biological activity of E2F1, 7 and 8 in murine keratinocyte models of 
squamous differentiation, with particular emphasis on E2F8. 
 Define the molecular basis for E2F1- and E2F7-dependent modulation of sensitivity 
to cytotoxic stimuli in SCC in vitro and in vivo. 
 
In addressing these aims, I generated compelling data highlighting novel isoform-specific 
actions of E2F8 and E2F7 in controlling squamous differentiation and stress responses in 
keratinocytes, respectively, and subsequently identified the associated E2F7-dependent 
effectors that regulate cytotoxic responses to chemotherapy. Specifically, I identified a 
previously unknown and potentially significant role for E2F8 in regulating squamous 
differentiation which advanced our understanding of keratinocyte differentiation and 
keratinocyte neoplasia. Moreover, I also identified a unique and non-redundant role for E2F7 
in regulating sensitivity to cytotoxic stimuli. Considering the fact that dysregulation of 
responses to chemotherapy–induced cytotoxicy is one of the major reasons for treatment 
failure in SCC, it is clear that identifying the downstream effectors that regulate E2F7-
dependent sensitivity to chemotherapeutic agents may have direct clinical impact. Sphk1 and 
RacGAP1 were identified as mediators of E2F7-dependent cytotoxic responses in SCC, and 
Sphk1 or RacGAP1 inhibition unequivocally enhanced the cytotoxic activity of doxorubicin. 
Thus, the results of my thesis have identified a potential drug combination that is being 
pursued by my supervisor for translation into a human clinical trial of idarubicin + buparsilib 
in advanced SCC patients. 
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9 Appendix  
9.1 Appendix I General buffers and media 
 
9.1.1 Phosphate-buffered saline (PBS) 
136.9 mM NaCI 
2.7 mM KCI 
1.5 mM KH2PO4 
2.5 mM Na2HPO4.2H2O 
pH 7.4 
 
9.1.2 1x Tris-Borate EDTA buffer 
45 mM Tris 
45 mM boric acid  
1 mM EDTA  
 
9.1.3 SCC media (for SCC cells) 
1:1 volume:volume of DMEM:Ham’s F12 nutrient mix pH 7.1 
5% FBS 
0.43 µg/mL hydrocortisone 
1% v/v penicillin/streptomycin/glutamine 
10 µg/mL gentamycin 
 
9.1.4 RIPA buffer 
50 mM Tris-HCI pH 7.4 
150 mM NaCI 
1% v/v NP-40 
0.5% w/v sodium deoxycholate 
0.1% SDS 
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9.1.5 1x Sample buffer 
10% glycerol 
2% SDS 
50 mM Tris-HCI pH 6.8 
100 mM DTT 
0.005% w/v bromophenol blue 
 
9.1.6 4x sample buffer 
40% glycerol 
8% SDS 
200 mM Tris-HCI pH 6.8 
400 mM DTT 
0.02% bromophenol blue 
 
9.1.7 Electrophoresis running buffer 
25 mM Tris 
191 mM Glycine 
0.1% v/v SDS 
 
9.1.8 Transfer buffer 
25 mM Tris 
191 mM Glycine 
20% v/v methanol 
 
9.1.9 TBS-T 
20 mM Tris pH 7.6 
137 mM NaCI 
0.1% v/v Tween 20 
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9.1.10 Acrylamide gels for SDS-PAGE 
Resolving layer   
Gel Components per 10 mL final volume 
10% H2O 
30% acrylamide mix 
1.5 M Tris pH 8.8 
10% SDS 
10% ammonium persulfate 
TEMED 
5.3 mL 
3.3 mL 
2.5 mL 
0.1 mL 
0.1 mL 
0.004 mL 
12% H2O 
30% acrylamide mix 
1.5 M Tris pH 8.8 
10% SDS 
10% ammonium persulfate 
TEMED 
3.3 mL 
4.0 mL 
2.5 mL 
0.1 mL 
0.1 mL 
0.004 mL 
 
Stacking layer  
Components per 10 mL final volume  
H2O 
30% acrylamide mix 
1.0 M Tris pH 6.8 
10% SDS 
10% ammonium persulfate 
TEMED 
6.8 mL 
1.7 mL 
1.25 mL 
0.1 mL 
0.1 mL 
0.01 mL 
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Abstract: The E2F transcription factor family is traditionally associated with cell cycle 
control. However, recent data has shown that activating E2Fs (E2F1-3a) are potent 
activators of apoptosis. In contrast, the recently cloned inhibitory E2Fs (E2F7 and 8) 
appear to antagonize E2F-induced cell death. In this review we will discuss (i) the potential 
role of E2Fs in UV-induced cell death and (ii) the implications of this to the development 
of UV-induced cutaneous malignancies. 
Keywords: UV; sunburn cells; E2F; apoptosis 
 
1. What is UV? 
Life on earth is dependent upon UV radiation as an energy source. Ironically, whilst humans are 
dependent upon UV radiation for their existence, UV radiation is a common and potent carcinogen for 
people of Caucasian descent [1].  
Ultraviolet (beyond violet) refers to wavelengths shorter than visible violet light and longer than  
X-rays [2]. The UV radiation spectrum is grouped into three categories based on wavelength. UVC 
(200–280 nm) is the most potent carcinogenic band of UV but poses little threat to terrestrial 
organisms since it is almost completely absorbed by the earth’s atmosphere. Only 10% of incident 
UVB (280–320 nm) radiation penetrates the atmosphere. The vast majority of incident UV (greater 
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than 90%) radiation comes from UVA (320–400 nm). Although UVA radiation predominates at sea 
level, UVB has the highest energy and is 1,000 times more erythematogenic than UVA [2]. Thus, the 
carcinogenic potential of the UV spectrum reaching the earth’s surface is a composite of a small 
amount of high energy UVB and a large amount of low energy UVA. Combined, UVA and UVB 
radiation damage DNA, disrupt pro-apoptotic signaling pathways and suppress immune responses 
ultimately contributing to the carcinogenic action of sunlight [3]. Despite the more potent carcinogenic 
activity of UVB it is only capable of penetrating the more superficial epidermal layers whereas UVA 
can penetrate deeper into the dermis [2].  
2. Mutagenic Effects of UV Radiation 
UV light is a physical mutagen and can ionize molecules resulting in the conversion of absorbed 
light energy into biochemical reactions. DNA is one of the major molecules capable of absorbing UV 
radiation. Absorbed UV radiation causes DNA damage via the formation of DNA lesions often 
referred to as photolesions [4]. DNA damage caused by UVA and UVB can be direct or indirect. 
Direct absorption of UVB by DNA results in the formation of photolesions such as cyclo-butane-
pyrimidine dimers (CPDs) and pyrimidine (6–4) pyrimidone dimers [5] (Table 1). If these pyrimidine 
dimers are not repaired by DNA repair mechanisms, it may result in heritable base transitions. 
Formation of these, C→T single or CC→TT double, transitions at dipyrimidine sites is mutagenic and 
the nature and the presence of these lesions are frequently referred to as the UVB signature [6]. On the 
other hand, UVA is not absorbed by DNA and causes DNA damage via an indirect mechanism 
involving the generation of reactive oxygen species (ROS) generated by UVA-mediated activation of 
photosensitizers (e.g., riboflavin, porphyrins, quinines) resulting in the accumulation of CPDs [7]. 
UVB may also cause the accumulation of ROS and hence can also facilitate indirect DNA damage, 
albeit to a lesser extent than observed with UVA [8] (Table 1).  
Table 1. Summary of mutagenic effects of UVA and UVB. 
 UVA UVB 
Wavelength (nm) 320–400 280–320 
Chromophores Photosensitizers DNA 
Site of damage ROS Pyrimidine dimers (CDP) 6–4 photoproducts 
Mechanism Indirect Direct 
3. Sunburn Cells (UV-Induced Cell Death) 
Following UV exposure keratinocytes will follow one of two fates. If the damage to DNA is 
perceived to be reparable, the keratinocytes will undergo a reversible growth arrest accompanied by 
the mobilisation and activation of the nucleotide excision repair system (NER). This leads to the repair 
of damaged DNA (mutations/DNA lesions) and is facilitated by secreted cytokines, IL12 and IL18, 
which can restore immune responses and prevent from UV-induced immunosuppression [9–11]. 
Alternatively, if the DNA damage is perceived to be too great and the cells lack the capacity to repair 
the damage then the cells will be induced to apoptose [12,13]. Apoptosis, or programmed cell death, is 
a mechanism that prevents cells from passing on mutated DNA to their progeny. Thus, the apoptotic 
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machinery provides a means by which mutated, potentially premalignant cells are able to be  
eliminated [14]. UV-induced apoptosis results in the formation of so-called “sunburn cells” or 
apoptotic keratinocytes. Sunburn cells are easily identified by the presence of photo lesions, pyknotic 
nuclei and cytoplasmic shrinkage characteristic of apoptotic cells [15]. UV-induced apoptotic 
responses are mediated via extrinsic/death receptor signaling and intrinsic/mitochondrial death 
pathways [11,16]. The extrinsic death pathway is initiated by the binding of membrane death receptors 
TNF-R1, CD95, TRAIL-R1 and TRAIL-R2 to their cognate ligands, TNF-α, CD95L/FASL or TRAIL 
(TNF-related apoptosis-inducing ligand). UV can also activate CD95 death receptor signaling 
pathways independent of its natural ligand CD95L [17]. The subsequent formation of a death-inducing 
signaling complex (DISC) is characteristic of death receptor-mediated apoptosis in response to UV 
radiation [18,19]. Activation of death receptor signaling ultimately activates the initiator pro-caspases-
8/-10 leading to the eventual activation of downstream effector procaspases-3,-6,-7 [12]. Activation of 
the intrinsic apoptotic pathway is stimulated by the release of cytochrome c from outer mitochondrial 
membrane [20]. Activation of the intrinsic apoptotic pathway is controlled by the balance between  
pro-apoptotic (Bax, Bak, Bad, Bid, Bim) and anti-apoptotic (Bcl-2, Bcl-Xl, Mcl-Xl) Bcl-2 family 
proteins. When pro-apoptotic stimuli predominate, it leads to the permeabilisation of the mitochondrial 
outer membrane potential leading to cytochrome C release and eventual procaspase-9 activation [21,22] 
(Figure 1).  
Figure 1. UV-mediated keratinocyte apoptosis can be initiated by extrinsic or intrinsic 
pathways. Extrinsic pathways include death receptor activation via death ligand binding, 
DISC formation, activation of pro-caspases and activation of effector caspase-3 leading to 
apoptosis. Activation of intrinsic pathways induces cytochrome c release from mitochondria 
and activation of pro-apoptotic Bcl-2 proteins and inhibition of anti-apoptotic Bcl-2 proteins, 
activation of pro-caspase-9 and activation of effector caspase-3 leading to apoptosis. 
 
4. Role of UV in Skin Carcinogenesis 
Skin cancers are frequently divided into melanoma and non-melanoma skin cancers (NMSC). 
Regardless of classification, the main contributory factor in the development of cutaneous malignancies, 
in humans, is UV exposure [23]. Melanoma is a common and aggressive tumour type derived from 
melanocytes. The major forms of non-melanoma skin cancer are basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC) [24]. In a recent study, Trakatelli et al. [25] showed that NMSC had 
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significantly increased in incidence in Caucasians in the last decade. NMSC skin cancers are the most 
common malignancy in Caucasians and their incidence reflects the potent carcinogenic activity of UV 
radiation [26]. There are a number of reviews on the molecular mechanisms associated with  
UV-induced skin cancer and in particular we refer the reader to other articles within this issue of the 
journal. Of relevance to the current review are reports that UV-induced SCC formation is associated 
with dysregulation of the control of proliferation, differentiation and apoptosis [27–31]. Amongst these 
known changes it is notable that disruption of the Rb/E2F axis is over-represented. In particular, there 
is considerable data relating to the expression, activity and role of dysregulated E2F1 in SCC 
formation [26,32–35]. For example, disruption of the Rb/E2F axis is common in almost all human 
cancers including SCC [36]. Loss of function mutations of p53, Rb, or upstream regulators of the 
Rb/E2F axis such as INK4A (p16) are frequently associated with SCC and may result from mutation, 
deletion or promoter hypermethylation [37–39]. Moreover, SCCs are frequently associated with 
amplification/activation of mitogenic pathways controlled by cyclin D1, cdk4 or EGFR [31,40]. All 
these events are known to contribute to the dysregulation of proliferation and differentiation [31,40,41]. 
In addition, dysregulation of enzymes regulating oxidative stress such as GPX2 have also been shown 
to contribute casually to UV-induced SCC formation [25]. Dysregulation of antioxidant enzymes is 
known to disturb the apoptotic axis. Indeed, apoptotic regulators related to sensitivity and response to 
UV-induced damage are invariably targeted during keratinocyte transformation [13]. Consequently, 
the major safeguard that keratinocytes use to protect themselves against UV-induced mutations, 
namely sunburn cell formation, is compromised in keratinocytes following exposure to carcinogenic 
doses of UV [41]. However, the exact mechanisms by which UV-induced mutational damage contributes 
to the biological events controlling keratinocyte transformation and SCC progression remain unclear.  
5. The E2F Family 
The squamous differentiation program of the epidermis involves co-ordinate regulation of 
proliferation, differentiation and apoptosis. The barrier functions of the epidermis depend upon the 
integrity of this program and its ability to respond to environmental insults such as UV radiation [7,42]. 
The process of squamous differentiation is a tightly regulated process in which transcription factors 
control the differentiation program and its barrier functions [36]. Thus, it is not surprising that 
disruption to transcriptional control is a frequent target in oncogenesis [43]. Many transcription factors 
have been implicated in the control of squamous differentiation and carcinogenesis. However, the E2F 
family of transcription factors have emerged as pleiotropic regulators, directly controlling (i) cell 
proliferation, (ii) apoptosis, (iii) differentiation, (iv) DNA-damage response and DNA repair,  
(v) development, (vi) senescence and (vii) autophagy [28,29,44–49]. Moreover, E2Fs are also 
indirectly involved in modulating the activity of important cellular signaling pathways such as MAPK, 
p38 and PI3-K/AKT through transcriptional regulation of upstream pathway components [50,51]. 
E2F was first discovered as a cellular factor required for the activation of the E2 viral  
promoter [29,52]. This factor was later cloned and named E2F1 [43]. However, it was quickly 
recognised that E2F1 was just one member of, what is now, a family of 8 members, E2Fs 1–8, coding 
for 10 different E2F forms [53]. The role of the E2Fs is complex. Individual E2F family members can 
be involved in multiple cellular activities. For example, E2F1 is directly involved in the G1/S transition 
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(E2F3b-5) and inhibitory E2Fs (E2F6-E2F8). The expression of activator E2Fs varies during the cell 
cycle reaching a peak of activity, bound to target gene promoters via E2F response elements, during 
late G1/S phase. In this context, they control the expression of genes and activities required for DNA 
synthesis [53,67,68]. The expression and activity of the repressor E2Fs (E2F3b, E2F4, E2F5, E2F6) 
remain relatively constant throughout the cell cycle [53]. They bind target gene promoters during G0 
with E2F inhibitory pocket proteins coupled with repressive histone deacetylases [39,69] and prevent 
promiscuous transcription of proliferation genes [53,57,70]. The so-called repressor E2Fs get their 
name due to their ability to actively recruit transcriptional inhibitors such as histone deacetylase 1 (e.g., 
E2F4 and 5) or PRC2 (E2F6) to the E2F sites resulting in transcriptional repression [57,58].  
In contrast, inhibitory E2Fs (E2F 7 and 8) compete for binding sites with other E2Fs and mediate their 
inhibition by excluding active or repressive E2Fs from binding [55]. The expression of E2F7 and E2F8 
is cell-cycle regulated. Transcription of E2F7 and E2F8 increases towards G1-to-S transition reaching 
its peak during S-to-G2 transition [28,57,59,60,71]. Thus, the role of E2F7/8 in cell cycle control 
appears to tie in with the direct inhibition of the E2F1 activities related to cell cycle traverse [42,63].  
In contrast, the role of the inhibitory E2Fs in the control of differentiation appears to be isoform-specific 
and is mediated via isoform-specific DNA response elements [26,54]. Finally, the anti-apoptotic action 
of the inhibitory E2Fs appears to be mediated via direct inhibition of E2F1-mediated apoptosis [42,63]. 
The interplay between E2F1-stimulated apoptosis and E2F7/8-mediated inhibition of apoptosis is 
critical to understanding the role of E2Fs in UV-induced skin cancer formation and their potential as 
drugable targets for treating squamous cell carcinomas or enhancing chemotherapeutic responses. 
6. E2F-Induced Apoptosis and Skin Cancer Formation 
The ability of the different E2Fs to contribute to apoptosis especially to UV-mediated apoptosis is 
contentious. Much of this controversy arises from some seemingly paradoxical data relating to  
the action of E2F1. Earlier studies with E2F1 reported that overexpression of E2F1 in tissue culture 
cells and in transgenic mice caused a stimulation of apoptosis and an enhancement of tumour 
formation [33,34,72,73]. In particular, overexpression of E2F1 in the epidermis of transgenic mice 
caused elevated apoptotic indices in keratinocytes of the basal layer and an increase in skin tumour 
formation in mice that overexpressed E2F1 and cyclin D1 [34]. In contrast, mice transgenic for E2F4 
expression in skin did not have increased apoptotic indices [74]. Similarly, mice deficient for  
E2F1 were predisposed to thymomas due to their inability to delete t cells via E2F1-mediated 
apoptosis [75,76]. These earlier studies clearly supported the concept that the pro-proliferative actions 
of E2F1 were oncogenic whilst the pro-apoptotic actions of E2F1 were tumour suppressive [77].  
E2F1-stimulated apoptosis can be mediated by p53-dependent and p53-independent pathways. The 
p53-dependent pathway involves the stabilization of p53 via p14/p19ARF [78] whilst activation of 
APAF1 and p73 or CHK2 is required for p53-independent apoptosis [79–81]. In response to UV, E2F1 
transcript and protein levels increase in an ATM/ATR dependent manner and leads to accumulation of 
events required for apoptosis [82]. This suggested that UV-induced E2F1 mediated apoptosis in skin 
may have tumour suppressive effects. However, studies by Dimova and Dyson reported that the 
ectopic expression of E2F1 may result in the expression of survival genes suggesting that E2F1 may be 
anti-apoptotic under certain conditions [48]. This suggests that the role of E2F1 in regulating apoptosis 
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may be context-specific. Consistent with this, it has been reported that E2F1 is anti-apoptotic in 
keratinocytes in the context of UVB irradiation [52,83]. Specifically, E2F1 deficient mice and mice 
transgenic for E2F1 in skin displayed increased and reduced apoptotic indices in response to UVB 
irradiation respectively [52,78]. Wikonkal et al. [52] also showed that the pro-survival effect of E2F1, 
in response to UVB, was p53-independent. Finally, it was shown that the pro-survival effect of E2F1, 
in response to UVB irradiation of keratinocytes/epidermis could be attributed to the ability of E2F1 to 
sense DNA damage and co-ordinate the DNA damage repair [52]. In this regard, E2F1 has been 
reported to function directly at sites of DNA repair to eliminate DNA photoproducts [84,85] or 
indirectly by controlling the transcription of genes required for DNA repair machinery [86,87].  
Whilst these data appear to definitively show that E2F1 is oncogenic in skin due to its anti-apoptotic 
effects, there still remain some unresolved issues. For example, studies have shown that E2F1-mediated 
responses to UVB irradiation may be dose-dependent such that low doses of UVB activate DNA repair 
mechanisms whilst high doses induce apoptosis in cells in which the cellular DNA repair machinery is 
unable to repair the damage [88]. Moreover, another important consideration is the level of E2F1. For 
example, it is easy to see the benefit of a pro-survival signal being generated in response to the 
relatively low levels of E2F1 that may be experienced during cell cycle traverse. It is also easy to see 
biological justification that elevation of E2F1, in response to stressors such as UVB, could invoke 
apoptotic responses [89,90]. Earlier studies by Yang and his colleagues have shown that E2F6 is able 
to repress UV-induced apoptosis in human embryonic kidney cells via direct interaction with  
BRCA1 [91]. Intriguingly, the expression of E2F6 is influenced by E2F1 [92]. However, it is 
noteworthy that keratinocytes do not appear to express detectable levels of E2F6 [51] suggesting this 
situation may not apply in skin. The same cannot be said for recent studies with E2F7 and E2F8. E2F7 
and 8 are inhibitory E2Fs that bind to, and repress, E2F1 transcription and E2F1-induced  
apoptosis [63]. Both E2F7 and E2F8 are expressed in skin [57,61] and are able to influence the cellular 
DNA damage response [41]. Zalmas et al. [41] demonstrated that DNA damage induced by etoposide 
treatment induced E2F7 and E2F8 expression. Moreover, they demonstrated that DNA damage 
invoked an increase in E2F7 and E2F8 binding to E2F-responsive genes such as E2F1 resulting in an 
inhibition of E2F1-mediated apoptosis [41]. In fact, microarray analysis of cells subjected to DNA 
damage revealed that E2F7 and E2F8 could be considered bona fide DNA damage response  
genes [58,63] (Figure 3). These studies seem to be relevant to skin UV responses since we recently 
reported that E2F7 plays a role in regulating proliferation, differentiation and UV-induced cytotoxicity 
in human keratinocytes in vitro [26]. Moreover, we reported that E2F1 and E2F7 were overexpressed 
in human squamous cell carcinomas approximately 50 fold and 200 fold respectively [26]. Such 
elevations in E2F1 and E2F7 are clearly pathologic and the consequences on UV-induced tumour 
development and progression remain unknown. However, given that E2F1 and E2F7 are said to 
autoregulate the expression of one another and given that E2F7 antagonises E2F1-induced apoptosis 
and UV-induced apoptosis in human keratinocytes [26], it would seem reasonable to speculate that 
E2F7 may also play a role in UV responses in human epidermis (Figure 4). Thus, apoptotic responses 
of keratinocytes, to UV, or chemotherapeutics, are likely to be dictated by the relative levels of E2F1 
and E2F7. 
  
Int. J. Mol. Sci. 2011, 12  
 
Figure 3. Regulatory network on 
(growth-dependant and/or DNA
Figure 4. Schematic showing how 
malignancies due to dysregulated apoptotic control.
       
E2F1 and E2F7/8 activity representing upstream events 
 damage mediated activation) and downstream targets.
E2F1 and E2F7 contribute to formation of cutaneous 
  
    
 
8954 
 
  
  
Int. J. Mol. Sci. 2011, 12             
 
 
8955 
In conclusion, the carcinogenic components of sunlight, relevant to humans, are UVA and UVB. 
UV radiation induces either a cell cycle arrest or an apoptotic response in human keratinocytes. Both 
the cell cycle arrest and the apoptotic response appear to be mediated by E2F1. More recently, an 
antagonistic form of E2F, E2F7, has been reported that antagonizes the pro-proliferative and apoptotic 
effects of E2F1. Both E2F1 and E2F7 are significantly overexpressed in transformed keratinocytes and 
there is evidence that the dysregulation of expression of the E2F1 and E2F7 isoforms may contribute 
to skin cancer formation. 
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